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ABSTRACT 
 
Hypericum perforatum (Hp) is commonly known for its anti-viral, anti-depressant, 
and anti-proliferative properties, but traditionally Hp was also used to treat inflammation.  
Studies on the anti-inflammatory activity of Hp are far less advanced than studies on other 
bioactivities.  In fact until recently, there was still debate as to which constituents present in 
Hp may be responsible for the anti-inflammatory properties. 
In this study, the anti-inflammatory activity and cytotoxicity of different Hp 
extractions and accessions and constituents present within Hp extracts were characterized in 
RAW 264.7 mouse macrophage cells.  In contrast to the light-dependent anti-viral activity of 
Hp, the anti-inflammatory activity observed with all Hp extracts was light-independent.  
Extracts made from Hp Elixir™ plant material using Soxhlet ethanol or chloroform for 
extraction displayed superior activity to extracts made from other accessions.  When pure 
constituents were tested, the flavonoids quercetin, quercitrin, isoquercitrin, and hyperoside, 
the bi-flavonoid amentoflavone, the phloroglucinol hyperforin, and light-activated 
naphthodianthrone pseudohypericin displayed significant reduction in lipopolysaccharide 
(LPS)- induced prostaglandin E2 (PGE2) production, albeit at concentrations generally higher 
than the amount present in the Hp extracts. Constituents that were present in the Hp extracts 
at concentrations close to those that inhibited the production of PGE2 were pseudohypericin 
and hyperforin, suggesting that they are the primary anti-inflammatory constituents along 
with the flavonoids, and perhaps the interactions of these constituents and other unidentified 
compounds are important for the anti-inflammatory activity of the Hp extracts.  
To further delineate the constituents that may be important for anti-inflammatory 
activity, an ethanol extract of Hp was fractionated with the guidance of an anti-inflammatory 
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bioassay, LPS-induced PGE2 production, through 4 rounds of fractionation.  Four 
constituents were identified as putative bioactive constituents for the reduction in PGE2.  
When combined together at concentrations detected in the third round Hp fraction to make a 
4 component system, these constituents (0.2 µM chlorogenic acid, 0.08 µM amentoflavone, 
0.07 µM quercetin, and 0.03 µM pseudohypericin) explained the majority of the activity of 
the fraction when activated by light, but only partially explained the activity of this Hp 
fraction in dark conditions.  One of the constituents, light-activated pseudohypericin, was 
necessary, but not sufficient to explain the reduction in LPS-induced PGE2 of the 4 
component system.  The Hp fraction and the 4 component system inhibited cyclooxygenase 
(COX-2) and cytosolic phospholipase A2 (cPLA2), two enzymes in the PGE2-mediated 
inflammatory response, in a similar way.    
To further explore the potential of the four putative bioactive constituents combined 
into a 4 component system, we used microarray gene expression analysis to identify key gene 
targets of the 4 component system and the Hp fraction, a third round subfraction from an Hp 
ethanol extract.  Twelve genes were implicated in the activity of the 4 component system 
+LPS and the fraction +LPS and 8 of the 12 were part of either the janus kinase and signal 
transducer and activator of transcription (JAK-STAT) or eicosanoid biosynthesis pathways.  
Additionally, these two pathways, which are important in inflammation, could be linked via 
the mitogen-activated protein kinase (MAPK) pathways.   The 4 component system 
explained some of the activity of the fraction through inflammatory pathways, however; the 
fraction also affected genes that the 4 component system did not affect.  Thus, other known 
or unknown compounds in the fraction may be responsible for activities that were identified 
in the microarray analysis, such as effects on cell cycle. 
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CHAPTER 1: INTRODUCTION 
 
General Introduction 
 
 Hypericum perforatum (Hp), also known as St. John‟s wort or Klamath weed, has 
been used for decades to treat ailments ranging from nervous disorders to snake bites (1).  
Consumers today use preparations of Hp to treat mild-to-moderate depression, and a wide 
variety of conditions, and it is one of the most popular herbal supplements in the United 
States as measured by total botanical supplement sales per year (2).   While extensive 
research suggests that Hp is effective for the treatment of mild-to-moderate depression and 
ongoing research highlights the role of Hp extracts in anti-proliferative and anti-viral 
therapies, relatively little research supports the use of Hp preparations for the treatment of 
inflammation (3-6).  Therefore, research on the anti-inflammatory activity of Hp is 
desperately needed because there is documented consumer usage of Hp preparations to treat 
general inflammatory conditions (2). 
 Hypericin and pseudohypericin, compounds unique in select species of Hypericum, 
were originally thought to be responsible for the anti-depressant activities of Hp extracts (1, 
7).  Recent research supports that the phloroglucinol hyperforin, which is also present in only 
select species of Hypericum, is at least partially responsible for the activity (1, 7).  
Additionally, interactions of constituents in Hp preparations may enhance the anti-depressant 
bioactivities of Hp (8).  A study by Noldner and Schotz (2002) showed that Hp extracts and 
pure flavonoids alone were inactive in the forced swimming test model for depression but 
when they were combined, there was a strong anti-depressant effect (9).  Interactions of 
constituents have also been shown to be responsible for reducing toxicity of Hp.  A study by 
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Wilhem et al. (2001) showed the flavonoid quercetrin was able to attenuate phototoxicity 
associated with Hp extracts in HaCat skin cancer cells (10).     
 Flavonoid and bi-flavonoid compounds present in Hp extracts possess considerable 
anti-inflammatory activities (11-19).  However, many of the compounds unique to the 
Hypericum genus do not have well-documented anti-inflammatory activity.   Additionally, 
naphthodianthrone compounds must be light-activated for the greatest efficacy in anti-viral 
and anti-proliferative assays, but it is unclear if light-activation is necessary for the anti-
inflammatory properties of Hp extracts (20, 21).  Most research supports the pro-
inflammatory activity of hypericin (22, 23).  Additionally, hyperforin appears to possess 
some anti-inflammatory activity (24). 
The objective of this study was to assess the anti-inflammatory activity of Hp 
preparations in RAW 264.7 mouse macrophages to identify key constituents responsible for 
the activity and to elucidate genes and pathways that are responsible for the bioactivities seen 
with the Hp extracts.  Additionally, since some constituents in Hp are light-activated, studies 
assessed whether the anti-inflammatory activity of these extracts and fractions was dependent 
on light-activation. 
The Hp extracts exhibited light-independent anti-inflammatory activity, characterized 
as a reduction in lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2),  and the light-
independence was contrary to previously reported anti-viral and anti-proliferative activities 
of Hp extracts that were light-dependent (20, 6).  Constituents in Hp extracts such as 
flavonoids, bi-flavonoids, and phloroglucinols also exhibited light-independent anti-
inflammatory activity.  However, the naphthodianthrone pseudohypericin reduced LPS-
induced PGE2 levels only in light-activated conditions and the naphthodianthrone hypericin 
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increased LPS-induced PGE2 levels only in light-activated conditions.  Thus, the role of 
individual constituents in the chemical mixture appeared to be complex.   Since Hp extracts 
possessed light-independent anti-inflammatory activity but some constituents were dependent 
on light-activation, it appeared that interactions of constituents may be altering the properties 
of the constituents present in Hp extracts.    Additionally, the levels of constituents in Hp 
extracts and fractions did not account for the reductions in PGE2 associated with the extracts.   
A bioactivity-guided fractionation of an Hp Soxhlet ethanol extract was used to identify 
constituents that may be contributing to the anti-inflammatory activity of fractions.  Four 
constituents (amentoflavone, quercetin, chlorogenic acid, and pseudohypericin) were 
identified that explained the light-activated reduction in LPS-induced PGE2 production of an 
Hp third round sub-fraction.  However, unknown or unidentified compounds appeared to be 
responsible for the activity of the fraction in dark conditions.  This was the first report of 
interactions in Hp responsible for anti-inflammatory activity.  Furthermore one constituent, 
pseudohypericin, was necessary but not sufficient for the reduction in PGE2.   
Microarray analysis of the Hp subfraction and 4 component system composed of the 
putative bioactive constituents at concentrations detected in the fraction revealed that in LPS-
stimulated macrophages, pathways important for the activity of both treatments were janus 
kinase- signal transducer and activator of transcription (JAK-STAT) and eicosanoid 
biosynthesis pathways and that the mitogen-activated protein kinase (MAPK) pathways may 
play a pivotal role in connecting the two pathways. Interestingly, there were 12 genes 
identified that may be particularly important targets for both the fraction and identified 
compounds, and 8 of those genes correlated with prostaglandin biosynthesis and JAK-STAT 
pathways.  The fraction affected far more genes than the combined putative bioactive 
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constituents, suggesting that while the constituents may explain some of the activity; they 
cannot explain all the activity of the fraction.  Therefore, it is likely that unknown or 
unidentified compounds in the fraction may provide some activity as well.  Activities 
significantly affected by the fraction, but not the 4 component system included cell cycle and 
cell death as well as effects on biological classes such as steroid, pyrimidine, and cholesterol 
biosynthesis. Finally, quantitative real-time polymerase chain reaction (PCR) analysis was 
used to confirm the results of the microarray and highlight the role of the identified genes 
through the course of an inflammatory response. 
Thesis Organization 
The contents of this thesis includes an introduction, which is comprised of a general 
introduction and a literature review, one manuscript published in the Journal of Agricultural 
and Food Chemistry, one manuscript published in Phytochemistry, and one manuscript that 
will be submitted to a scientific journal, a general conclusion, and an appendix. 
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CHAPTER 2:  LITERATURE REVIEW 
Origin 
Hypericum perforatum (Hp) (Clusiaciae family, alternative name Guttiferae) has 
been used as a treatment for centuries to combat a wide variety of internal and external 
conditions including depressive disorders (1). There are several explanations for the origins 
of the name Hypericum perforatum.  Hypericum is thought to have come from hypo- or 
hyper-eikon which in Greek means “over an apparition.”  Perforatum is derived from Latin 
for “perforated”, which described the perforated leaves of the Hp plant.  Hp is also known as 
St. John‟s wort (1).  St. John‟s refers to the collection of yellow flowers of the Hp plant at the 
feast of St. John the Baptist on June 24th and wort means “plant” in Old English (2).   
Hypericum perforatum is the most well-known species of the Hypericum genus. Hp 
was indigenous to Europe, western Asia, and northern Africa and is now found throughout 
the world, including in the United States (1).   As a perennial, the plant grows in the wild to 
approximately 60 centimeters tall and generally the aerial portions (plant parts above 12 
inches from the ground) of the plant are used for supplements (2).   
The earliest medicinal use of Hp was documented in the second century BC by the 
Greek botanist and physician Nikander (2).  Hp was also used by Paracelsus as an “arnica of 
nerves” to treat nervous disorders, and since that time, it has been used to treat many 
conditions. In 1984, the German Federal Health Agency published the Commission E 
monograph, which recommended Hp to treat depressed moods, nervousness, and anxiety (3).  
Since that time, Hp extracts have been available by prescription in Germany, with greater 
than 100 million defined daily doses prescribed in 2003 alone (4).  In the United States, Hp 
preparations are available commercially as an over-the-counter product.  The popularity of 
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Hp has been rising steadily throughout the last decades.  According to a 2005 figure, annual 
sales of Hp supplements were approximately $9 million in the United States (5). 
Medicinal use and types of preparations 
Traditional uses for Hp preparations include the treatment of both internal and 
external conditions such as wounds, inflammation, neuralgia, malaria, headache, bedwetting, 
and mild-to-moderate depression (6).  Although the anti-depressant activity of Hp extracts 
has been studied most extensively, the extracts possess other bioactivities as well.  These 
activities include anti-viral, anti-proliferative, anti-oxidant, and anti-inflammatory properties 
(6).   
Hp supplements can be prepared in a variety of ways and many of these preparations 
are commercially available.  In the United States, preparations of Hp may include extracts, 
tablets, teas, tinctures, infusions, sprays, lotions, pills, oil macerates, and creams (6).  The 
identification of constituents responsible for specific bioactivities has not been fully 
elucidated, despite the use of Hp preparations to treat a variety of conditions. 
One problem that exists with supplements such as Hp preparations is that the 
variability among the level of constituents in commercial preparations is high, despite recent 
efforts for standardization of the supplements.  The US Pharmacopoeia/National Formulary 
monograph (1999) states that the minimum content of unique compounds in a standardized 
Hp extract must be 0.2% dry weight of total hypericin (including hypericin and 
pseudohypericin) and 3% dry weight of hyperforin (3).  Germany requires that any 
supplement bearing the name Hp must contain at least 0.04% hypericin, which is still less 
than the 0.2% minimum content stated by the US Pharmacopoeia (3).   
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Mohmaney et al. (1998) analyzed several commercial extracts available in the United 
States by high performance liquid chromatography (HPLC) for detection of common 
constituents present in Hp (7).  They found that 5 of 10 products tested contained less than 
80% and 3 of 10 products tested contained less than 50% of the hypericin content stated on 
the label.  There was also considerable variability in the content of hyperforin and flavonoids 
in these products.  In the United States, Hp is regulated as a dietary supplement under the 
Dietary Supplement Health & Education Act of 1994 which holds the manufacturer 
responsible for ensuring the supplements are safe (8).  The Food and Drug Administration 
(FDA) is responsible for three main areas concerning supplements.  First, they may take 
action against the manufacturers who are producing unsafe supplements, and second, they 
assume post-marketing responsibilities such as adverse reporting (8).  Finally, the FDA is 
responsible for identifying adverse labeling or false inserts accompanying the dietary 
supplement (8).   
The effective therapeutic dose for many of the bioactivities associated with Hp is not 
currently known and this data, in addition to safety data and standardization of preparations, 
may lead to improved Hp supplements.  Meier et al. (2003) reported the minimal dose of Hp 
guaranteeing a therapeutic effect is unknown; however, Hp used by humans for anti-
depressant studies generally ranged from 500-650 mg/day orally and varied depending on 
study design (9).  Additionally, the dosage for a fluid or powder extract used in studies for 
anti-depressant activity would be the amount of extract equivalent to 0.5-3.0 mg hypericin 
and pseudohypericin daily (6).   
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Constituents 
There are many classes of constituents present in Hp: naphthodianthrones, 
phloroglucinols, flavonoids and biflavonoids, caffeic acid derivatives, and others.  The 
flavonoids and biflavonoids are present in many species of the plant kingdom and are plant 
secondary metabolites.  The predominant flavonoids in Hp are quercetin (3, 5, 7, 34- 
pentahydroxyflavone) and its glycosylated derivatives quercitrin (quercetin-3-O-
rhamnoside), isoquercitrin (quercetin-3-O-glucoside), hyperoside (quercetin-3-O-
galactoside), and rutin (quercetin-3-O-rutinoside), and the bi-flavonoid amentoflavone (I3‟, 
II8 bi-apigenin) (6).  Other flavonoids that have been identified in Hp include: kaempferol, 
luteolin, and myricetin (6).  Caffeic acid and derivatives of caffeic acid are also abundant in 
Hypericum and include caffeic, chlorogenic, p-coumaric, ferulic, isoferulic, and gentistic 
acids (6).  Chlorogenic acid is one of the most abundant polyphenols in the human diet (10).  
The naphthodianthrones, hypericin and pseudohypericin, and the phloroglucinol, hyperforin, 
are unique to certain species of the Hypericum genus, although other related compounds may 
be present in other plant species (11).  Other compounds that have been identified in Hp are: 
choline, carotenoids, amino acids, xanthones, tannins, γ-mangostin, garcinone B, and 
proanthocyanidins (12, 13, 14).   In addition to these compounds that have been detected, 
there are also unknown and unidentified compounds present in the Hp preparations. 
The concentration of constituents present in the plant varies among individual plants 
due to growing condition, time of harvest, time of preparation, processing of material, 
exposure to light, plant part, and overall variation within species (15).  Naphthodianthrones 
(0.03-3%) were present in Hp flowers and buds of the fresh Hp plant (13).  Phloroglucinols 
(2-5%) were present in flowers and buds, while flavonoids (2-12%) were present in leaves, 
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stalks, and buds of fresh Hp plants (13).  Flowering tops contained the highest concentrations 
of naphthodianthrones and flavonoids, buds and flowers contained the highest amounts of 
amentoflavone, and in leaves rutin was the predominant flavonoid but in flowers quercetin 
tended to be higher than the other flavonoids (6).  Furthermore, flavonoid concentrations 
were highest in plants growing in higher altitudes (6).   
Since the flavonoids are present in many plant species, their bioactivities have been 
studied to a great extent.  Individual flavonoids possess many bioactivities including anti-
inflammatory, anti-allergic, anti-tumor, and hypocholesterolemic activities, and platelet 
stabilizing properties (16).  Despite intensive efforts to identify bioactivities of individual 
flavonoids, it is also important to assess the contribution of flavonoids when present in the 
complex Hp mixtures as the constituents may display a different role in an Hp extract than 
when used individually. 
An interesting constituent that is unique to certain species of the Hypericum genus is 
hypericin.  Hypericin can exert cellular effects due to its ability to bind to distinct cellular 
compartments (17).  Hypericin is lipophilic and is therefore insoluble in many solutions. 
However, hypericin can bind to serum albumin and this complex helps to overcome low 
insolubility issues in aqueous physiological solutions (17).  Hypericin localizes in 
membranes like the endoplasmic reticulum, Golgi apparatus, and even nuclear membranes 
(18).   
The mechanism of hypericin‟s anti-viral and cytotoxic activities has been well-
characterized.  Light-activated hypericin has been intensively studied due to its photo-
activation by a broad spectrum of visible light.  Hypericin has several fluorescence excitation 
peaks from 260-600 nm, with the most effective wavelengths between 590-610 nm (18).  
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When activated by light, hypericin produces singlet oxygen, superoxide radicals and 
semiquinones, all of which are important for its mechanism of cytotoxicity (17).  There have 
been two proposed mechanisms for photosensitization of hypericin that are currently 
accepted. In type I photosensitization, the triplet state hypericin is generated by photo-
excitation, and directly interacts with the substrate by electron and/or proton transfer to 
produce free radicals (17).  The free radicals may interact with oxygen to produce oxygen 
radicals such as hydroxyl or superoxide anion radicals and peroxides.  In type II 
photosensitization, photo-excited hypericin transfers its energy to the triplet ground state of 
oxygen to generate reactive singlet oxygen (17).  Reactive oxygen species that are generated 
in the photosensitization process may damage cell components to lead to cell death. It is 
generally accepted that the π electrons are responsible for the light-activated properties (19).  
These electrons absorb visible and ultraviolet light.  The 2 hydroxy and 3 methyl groups that 
flank each side of hypericin do not lay in the same plane, causing repulsion and placing a 
strain on the benzenoid structure (19).  The increased energy state of the π electrons may lead 
to formation of temporary bonds with singlet oxygen (19).  Despite structural similarity to 
hypericin, pseudohypericin has been characterized to a lesser extent, as most of the research 
focuses on the bioactivities of light-activated hypericin.   
Interactions of constituents 
Although individual constituents have diverse bioactivities alone, the interactions of 
constituents may be important for the biological activities of Hp extracts.  Flavonoids may 
increase the biological activity of other compounds either synergistically or by other 
mechanisms (20).  Schmitt et al. (2006) observed that Soxhlet ethanol Hp extracts were 
cytotoxic to cultured HaCaT keratinocyte cells, however, this cytotoxicity was not light-
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dependent, even though hypericin and pseudohypericin were both present in the extracts (21).  
The light independent toxicity of these extracts suggested that other constituents of Hp were 
able to reduce the hypericin-associated phototoxicity.  Furthermore, constituents were 
identified within these Hp extracts, namely porphyrins and chlorogenic acid that were able to 
attenuate hypericin‟s light-dependent toxicity (22).  Wilhelm et al. (2001) found that 
flavonoids, especially quercitrin (223 µM), were needed in an Hp fraction because they were 
important for decreasing the phototoxicity of Hp extracts in HaCaT skin cancer cells (23), 
but Schmitt et al. (2006) tested a flavonoid-rich fraction, which did not attenuate hypericin‟s 
phototoxicity in the same cell line (22).  Furthermore, Mirossay et al. found that 10 µM 
quercetin had a significant protective effect against cytotoxicity of 10 µM hypericin in HL-60 
promyelocytic cells (24).  In the forced swimming test model of anti-depressant activity, a 
fraction of procyanidins was not active alone, but was significantly active when 
pseudohypericin and hypericin were added (25).  Procyanidins and the flavonoid hyperoside 
increased the water solubility of pseudohypericin and hypericin up to 400 fold (26).   When 
the flavonoid rutin and Hp extracts, which were each inactive alone, were combined, there 
was a strong anti-depressant effect as characterized by the forced swimming test (27).  This 
could be due to the improved bioavailability of hypericin.  Therefore, interactions between 
chemicals are anticipated to be responsible for producing bioactivities in Hp preparations.   
Stability of constituents 
The stability of active constituents for extended periods of time in different 
preparations is essential for the bioactivity of Hp extracts.  Hyperforin and related 
phloroglucinols in a lipophilic extract were unstable when exposed to heat and light and 
degraded in as little as 14 days after preparation (15).  The oxidation of hyperforin present in 
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Hp mixtures was less in ethanolic extracts as compared to lipophilic solutions, and extracts 
prepared in ethanol and exposed to heat and light increased the stability of hyperforin to at 
least six months (28).  Wirz et al. (2001) found that pseudohypericin and hypericin were 
stable at -20º C and 4º C in light and dark conditions but degradation occurred at room 
temperature in both conditions (29).   
Bilia et al. (2001) tested a commercial sample of Hp dried extract and dried Hp 
extracts mixed with magnesium stearate, ascorbic and citric acids for photo-stability of 
constituents (rutin, hyperoside, isoquercitrin, quercitrin, hyperforin, hypericin, and 
pseudohypericin) using transparent gelatin capsules or 6 colored capsules and amber or 
transparent secondary containers (30).  Thermal stability testing was performed for 3 months 
either at 25° C or 40º C.  All constituents were photosensitive and the different capsules and 
pigments influenced the stability of different classes of constituents.  The addition of 
antioxidants in the dried Hp extract did not reduce degradation when compared to the dried 
Hp extract without antioxidants.  For secondary containers, degradation of constituents was 
found when using transparent secondary containers but the amber containers decreased the 
photosensitivity of all the constituents as compared to the transparent containers.   The long-
term stability of hyperforin and hypericin was less than 4 months.    Juergenliemk et al. 
(2003) studied the aqueous dissolution of phenolic compounds from Hp in a coated tablet 
preparation (26).  The flavonoid glycosides were well dissolved, followed by the flavonoid 
aglycones.  Hypericin and hyperforin were dissolved to a lesser extent.  A quercetin 
glycoside, hyperoside, was most effective at solubilizing hypericin.  The addition of 
hyperoside increased the concentration of hypericin in the water phase up to 400 fold (26). 
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In summary, degradation of compounds may occur if exposed to light and/or higher 
temperatures.  Clear vials exacerbated degradation of compounds and ethanol solutions may 
keep compounds in a more stable state than when in lipophilic solutions.  The addition of 
flavonoids to hypericin may help solubilize hypericin in aqueous solutions.  Hp extracts 
should be stored in the freezer, protected from light, and in solutions that limit degradation of 
the compounds. 
Constituents and Hp extracts were dissolved in dimethylsulfoxide (DMSO) and kept 
frozen at -30° C in the dark.  Light exposure was avoided to eliminate photoactivation.   All 
constituents, and specifically hypericin and hyperforin, were detected in the Hp extracts and 
fractions at similar concentrations when they were assessed analytically on two separate 
dates at least 4 months apart, suggesting that these compounds were stable in the laboratory 
conditions during the times that they were used for treatments. 
Bioavailability 
In addition to constituent stability, it is also important to understand the 
bioavailability of constituents present in Hp extracts.  Bioavailability is defined as the 
proportion of compound administered intravenously that appears in the plasma over time 
when the compound is administered orally (31).  This is measured as area under the curve 
and represents the proportion of the compound that is absorbed from the gastrointestinal tract 
(31).  Generally, bioavailability can be described by the following formula (32):  
  
Bioavailability= amount of drug absorbed from test formulation           x 100% 
                            amount of drug absorbed from reference formulation 
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Bioavailability can differ due to a number of factors such as chemical form, pH, solubility, 
and particle size of compounds, and age, sex, and physical state of the patient, as well as time 
of administration, intestinal conditions, other drugs, and disease conditions (32). 
Bioavailability of constituents present in Hp may also differ due to Hp plant or preparation, 
or dose and route of administration. Bioavailability of a single compound may not be the 
same as when it is present in a complex mixture like an Hp extract.   
Sattler et al. (1997) attempted to study a mechanism by which hypericin can 
overcome the epithelial barriers of the intestinal tract by using a Caco-2 human colon 
carcinoma cell model (33).  Cyclodextrin was used because it can increase the bioavailability 
of co-administered compounds that have low water solubility, like hypericin (Sattler).  
Hypericin in combination with cyclodextrin resulted in uptake of 3-5% after 5 hours at 37º C 
and 0.12% after 5 hours at 4º C.  Pre-incubation with hypericin for 1 hour increased the 
uptake to 13% at 37º and 7% at 4º C.  A liposomal formulation was also used in the study to 
mimic an oily formulation of Hp that may be used by consumers.  The liposomal formulation 
increased the solubility of hypericin in Krebs-Ringer buffer; however, no difference was 
detected in the binding and transport of hypericin.  A confocal laser scanning microscope 
was used to fluorescently visualize hypericin in the cells.  There was significant 
accumulation of hypericin in both the cell and nuclear membranes.  In a Caco-2 cell model, 
Kamuhabwa et al. (1999) determined the in vitro transport and uptake of hypericin (34).  
With 80-200 µM treatment to the apical side of the monolayer, the appearance of hypericin 
in the basolateral compartment was less than 0.5% in 5 hours.  There was a lag time of 2-3 
hours, suggesting that gradual saturation of membrane binding sites had occurred, with 4-8% 
cellular accumulation of hypericin with saturation after 3 hours.  
17 
 
A variety of flavonoids are present in Hp, including an aglycone, quercetin, and its 
glycosylated conjugates.  The chemical structure of flavonoids may determine how 
compounds are absorbed.  Most flavonoids are in the diet as glycosides and since the 
glycosides are hydrophilic, absorption in the small intestine is limited (35, 36).  Aglycones 
can be absorbed, undergo first pass hepatic metabolism, or excretion in urine or bile (37).  
Intestinal bacteria can further catabolize the aglycones into smaller phenolics that can be 
reabsorbed via the bile duct or catabolized for energy (37).   For glycosylated conjugates, gut 
microflora produce glycosidase enzymes that release the aglycone from its sugar (38). 
Extensive degradation of flavonoids by the gut microflora may result in decreased 
bioavailability as compared to those with slow degradation rates because the fast degrading 
flavonoids are less likely to be absorbed (37).  In a Caco-2 cell model, Murota et al. (2000) 
showed that quercetin glucosides were capable of passing through the epithelial cell 
monolayer but their efficiency was lower than the aglycone quercetin (39).  In human trials, 
orally administered rutin and quercetin (50-65 mg/kg body weight) were not found in urine 
or plasma in unaltered forms (40).  However, 53% of the orally administered dose was 
recovered as aglycone in the feces within 3 days and the authors assumed that the remaining 
quercetin was subject to microbial degradation in the lower bowl.  Several metabolites 
appeared but neither rutin nor quercetin was detected in the urine.  Ishii et al. (2001) found 
that after 500 mg oral dose of rutin in humans, rutin was detected and measured in plasma 
(41).  Further, a metabolite of orally ingested quercetin, miquelianin, was able to cross small 
intestine and central nervous system barriers in vitro suggesting that quercetin metabolites 
might not only enhance bioavailability of other compounds, but might have considerable 
bioactivity alone (42). 
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A number of studies have been performed on the bioavailability of caffeic acid and 
derivatives.  Azuma et al. (2000) orally administered rats 700 µmol/kg body weight of 
chlorogenic or caffeic acid and blood was collected from the tail up to 6 hours after 
administration (43).  Ingested caffeic acid was present in the rat blood circulation in 
metabolite forms.  In contrast, after chlorogenic acid administration, only traces of caffeic 
acid metabolites were detected in the plasma up to 6 hours after administration and 
chlorogenic and small amounts of caffeic acid were detected in the small intestine 6 hours 
after administration.  The results suggested that chlorogenic acid was not well-absorbed from 
the digestive tract, unlike caffeic acid.  Lafay et al. (2006) studied the absorption and 
metabolism of caffeic and chlorogenic acids in the small intestines of rats (44).  Chlorogenic 
or caffeic acids (50 µM) were perfused into the small intestine.  The net absorption (influent 
flux minus effluent flux of phenolic acids and metabolites) accounted for 8 and 20% of the 
perfused chlorogenic and caffeic acids, respectively.  Part of the chlorogenic acid was 
recovered in the gut effluent as caffeic acid.  No chlorogenic acid was detected in either 
plasma or bile, and less than 0.4% phenolic acids were secreted in bile.  In summary, it seems 
that chlorogenic acid may not be as bioavailable as caffeic acid. 
The bioavailability of individual constituents, like flavonoids, hypericin, and caffeic 
acid derivatives, have been studied numerous times in either cell or animal bioavailability 
models, but pseudohypericin and hyperforin have mainly been studied directly from Hp plant 
material, and not as pure compounds.  Staffeldt et al. (1991) administered a single oral dose 
of 300, 900, or 1800 mg dried Hp extract corresponding to 250, 750, or 1500 µg of hypericin 
and 526, 1578, and 3156 µg pseudohypericin, respectively (45).  The median maximal 
plasma levels (Cmax) were greater for pseudohypericin and the median lag-time of absorption 
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was prolonged for hypericin when compared to pseudohypericin, 0.3 versus 1.1 hours, 
respectively.  Similarly, Kerb et al. (1996) found that the maximum serum concentration was 
reached more quickly with pseudohypericin because the lag time was longer for hypericin 
(46).  Also, hypericin was better absorbed with a Cmax from 100 µg dose of 1-1.1 µg/L and 
0.7-0.9 µg/L for hypericin and pseudohypericin, respectively. Hypericin was not detected in 
urine.  Hypericin was presumed to be excreted in the bile since it was not detectable in the 
urine, even after glucuronidase and sulfatase treatment.  Increased lag time may be due to 
absorption of hypericin at distal enteral sites (47), which could lead to variation of absorption 
due to food interaction after oral intake.  Liebes et al. (1991) showed that the distribution half 
life and elimination half life (T1/2) for 350 µg injected hypericin in mice was 2.0 and 38.5 
hours, respectively (48).  This data was similar to data from human studies.  Biber et al. 
(1998) gave 300 mg tablets of Hp extract containing 14.8 mg hyperforin orally to rats.  
Plasma levels of hyperforin could be followed up to 24 hours after administration (49).  At 
3.5 hours after administration, maximal plasma levels were 280 nM.  Hyperforin kinetics 
were similar to pseudohypericin kinetics with T1/2 of 9 hours, Cmax at 3 hours, and a 1 hour 
retention time.  Hyperforin could be detected in the blood.   Biber et al. (1998) fed rats Hp 
WS 5572 extracts at 300 mg/kg (5% hyperforin) and quantified plasma levels of hyperforin 
(49).  The dose was well-tolerated and the Cmax of hyperforin was 3 hours with a peak of 370 
ng/ml.  Keller et al. (2003) administered 15 mg/kg hyperforin or equivalent dose of Hp 
extract orally to mice and found that hyperforin could be detected in the brain after an oral 
dose (50).  The maximum plasma concentration was 1.4 µmol/L with mean whole brain 
concentration of 32 ng/g. Cervo et al. (2002) administered Hp extracts containing either 4.5 
or 0.5% hyperforin intraperitoneally to rats (51).  The effective dose in the rat forced 
20 
 
swimming test as a measure of anti-depressant activity was 6.25 mg/kg of the 4.5% 
hyperforin extract given intraperitoneally, but the levels of hyperforin did not reach the lower 
limit of detection in brain tissue, but yielded plasma concentrations similar to the plasma 
Cmax found by Biber et al. (49).  A sufficient brain concentration of hyperforin was found 
after 3 intraperitoneal injections (within 24 hours) of hyperforin dicyclohexylammonium salt, 
a more stable form of hyperforin.  Butterweck et al. (2003) studied the oral bioavailability of 
hypericin alone or with procyanidin B2 or hyperoside in the plasma levels of rats (52).  
Hypericin was given at 0.2 mg/kg alone or with either 2.5 mg/kg procyanidin B2 or 2 mg/kg 
hyperoside in flavonoid free diets.  The oral bioavailability of hypericin was increased by 
58% in the presence of procyanidin B2 and 34% in the presence of hyperoside (52).   
In one of the most comprehensive bioavailability studies of Hp to date and the only 
study to address the pharmacokinetic profiles of Hp flavonoids in humans, Schulz et al. 
(2005) administered 612 mg dry Hp extract (STW-3, Laif 600) to 18 healthy male volunteers 
as a single oral dose once or for 14 days (53).  Hypericin, pseudohypericin, hyperforin, 
quercetin, and isorhamnetin (methylated quercetin) levels were determined for 48 hours after 
the single dose and for 24 hours at the end of 2 weeks of continuous dosing.  Similar results 
were obtained for multiple and single dosing.  The maximal plasma hypericin concentration 
was 3.14 ng/ml and Cmax was reached at 8.1 hours.  The T1/2 was 23.8 hours.  The maximal 
plasma pseudohypericin concentration was 8.5 ng/ml with  Cmax at 3 hours and T1/2 at 25.4 
hours.  Maximal plasma quercetin concentration was 47.7 ng/ml with a Cmax of 1.2 hours and 
T1/2 of 5.5 hours.  Methylated quercetin (isorhamnetin) maximal plasma concentration was 
7.6 ng/ml with Cmax of 1.5 hours and T1/2 of 4.5 hours. 
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Since hypericin and pseudohypericin are hydrophobic, they have access to the 
hydrophobic parts of the cell membranes and although they are similar in structure, 
pseudohypericin and hypericin differ in absorption rates.  Their poor bioavailability may be 
due, in part, to accumulation in the intestinal lining after oral administration.  The flavonoids 
seem to be bioavailable, depending upon which groups are attached to the aglycone.  
Chlorogenic acid also appears to be bioavailable, but to a lesser extent than the flavonoids 
and caffeic acid.  In general, the order of bioavailability of common Hp constituents seems to 
be: most bioavailable hyperforin, quercetin, quercetin glucosides, chlorogenic acid, and least 
bioavailable pseudohypericin and hypericin.  Again, interactions of compounds seem 
important for the bioavailability of key compounds, in particular the ability of flavonoids to 
influence the bioavailability of other compounds present in Hp. 
Since the Hp plant has a wide range of bioactivities, it is important to understand the 
bioavailability of individual constituents present in the plant to aid in determining which 
constituents are responsible for specific bioactivities. While hyperforin and the flavonoids 
seem to be most bioavailable based on these studies, the naphthodianthrones may not be as 
bioavailable.  However, more research needs to explore the bioavailability of individual 
constituents when given as a standardized Hp preparation.  Future work should also focus on 
interactions of constituents in complex mixtures and the impact of interactions on 
biovailability.  
Adverse effects 
Hp preparations are widely used as treatments, so it is also important to understand 
any adverse effects associated with taking these preparations (14).  Two main unwanted side 
effects have been reported: herb-drug interactions involving the hepatic cytochrome enzymes 
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and skin photosensitivity (14).   Adverse effects associated with the use of Hp are generally 
mild and those most frequently reported include: gastrointestinal symptoms, dizziness, 
confusion, and tiredness with similar effects to placebo (14). Hypericism, a condition 
referring to sensitivity to sunlight following ingestion of Hp, has been described in some 
animals like cattle that graze on Hp plants (14).  
More serious adverse effects have been reported in patients taking Hp supplements; 
however, the overall reporting of adverse effects appears to be minimal.  In placebo-
controlled trials, the frequency of adverse effects with Hp was similar to that of placebo (54).  
More than 10,000 patients taking an Hp supplement were monitored in surveillance studies.  
Studies using these patients confirmed the overall high tolerability of Hp supplements, 
especially compared to synthetic anti-depressants (55, 56).  A European study of 3,250 
patients taking Hp preparations showed an adverse drug reaction incidence of 2.4% for Hp 
supplements when used for the treatment of mild-to-moderate depression (57).  Side effects 
that were reported included: gastrointestinal irritations (0.6%), allergic reactions (0.5%), 
fatigue (0.4%), and restlessness (0.3%).  In addition to these symptoms, two potential cases 
of induced mania were reported in bipolar patients taking 900 mg Hp extract daily (58).  Due 
to the natural cycle of bipolar disorder, it was undeterminable whether treatment with Hp was 
the cause of the mania (58). 
Serious adverse effects may also come from the interactions of Hp with other drugs.  
Hp treatments often interact with prescription drugs such as human immunodeficiency virus 
(HIV) protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir), oral contraceptives, 
triptans that bind to serotonin receptors (sumatriptan, naratriptan, rizatriptan, zolmitriptan), 
and selective serotonin re-uptake inhibitors (citalopram, fluoxetine, fluvoxamine, paroxetine, 
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sertraline) (13).  Therefore, caution should be taken when using Hp supplements with other 
medications.  
Recent studies have shown that Hp extracts and isolated constituents may be 
responsible for drug interactions.  Cytochrome p450 (CYP) enzymes, especially CYP3A, are 
important mediators of drug metabolism (59).  CYP3A has been estimated to metabolize 
60% of all drugs (59).  It has been proposed that differences in the clearance of drugs can be 
explained by variation in hepatic CYP3A in humans (59).  P-glycoprotein- (P-gp)-mediated 
transport is important for influencing intracellular drug concentration.  P-gp, expressed in the 
liver and intestine, is a membrane-localized drug transport protein that can transport 
compounds that are foreign to the body from the cells, limiting bioavailability (59).  
Therefore, if compounds stimulate cytochrome p450, the effectiveness of the drug is reduced 
whereas if cytochrome p450 is inhibited, the drug‟s effect may be prolonged and/or 
strengthened, which could lead to an overdose effect.  P-gp and CYP3A are colocalized in 
the intestine and liver.  Schuetz et al. (1998) found that, under some circumstances, P-gp can 
influence the basal expression of CYP3A (60).  
Studies using in vitro models first showed the ability of Hp to affect enzymes 
important in drug metabolism and clearance.  Obach et al. (2000) studied the effect of 
amentoflavone, hyperforin, hypericin, and commercially available Hp extracts on the 
inhibition of CYP enzymes in vitro (61).  Amentoflavone competitively inhibited CYP3A4, 
CYP2C9, and CYP1A2 with Ki (dissociation constant of the inhibitor) values of 0.038, 0.32, 
and 0.95 µM, respectively.  Hyperforin non-competitively inhibited CYP2D6 with a Ki value 
of 1.5 µM and competitively inhibited CYP2C9 and CYP3A4 with Ki values of 1.8 and 0.48 
µM, respectively.  The commercially available Hp extracts inhibited all 5 enzymes.  Tian et 
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al. (2005) studied the effects of Hp extracts, hypericin, and hyperforin on P-gp activity in 
LS180 human colonic adenocarcinoma cells and LLC-GA5-CO150 (over-expressing P-gp) 
human colonic adenocarcinoma cells, respectively (62).  No acute effects were observed with 
Hp extract, hypericin, or hyperforin.  Both the Hp extract (containing not less than 0.3% 
hypericin) at 75 µg/ml and 1 µM hyperforin increased P-gp expression in the LLC-GA5-
CO150 cells, with removal of the compound restoring the level of P-gp back to baseline.  The 
level of hyperforin in the Hp extracts was sufficient to attribute the activity of the extract to 
hyperforin.  Hypericin (0.1 µM) had no effect in the P-gp overexpressing cells.  
Using cell culture models, Gutmann et al. (2006) studied the effect of hypericin, 
hyperforin, and extracts containing these constituents, as well as an „artificial‟ extract made 
up of constituents at concentrations present in the extract in LS 180 human colon cancer cells 
(63).  Hypericin and hyperforin at 10 µM increased multi-drug resistant transporter 1 and 
CYP3A4 gene expression and quercitrin increased CYP3A4 expression. Extracts containing 
hyperforin increased multi-drug resistant transporter 1 expression but none of the extracts 
increased CYP3A4 expression.  The effects of the Hp extracts were similar to the effects of 
the „artificial‟ extracts.  Komoroski et al. (2004) studied the effect of hypericin and 
hyperforin on mRNA and protein levels and activity of CYP enzymes in isolated human 
hepatocytes from nine donors (64).  In a 1 hour acute treatment, 5 µM and 10 µM hyperforin 
inhibited CYP3A4 activity, but hypericin had no effect on CYP3A4 activity.  Hypericin and 
hyperforin both increased the mRNA and protein levels and activity of CYP3A4 and 
CYP2C9, but had no effect on CYP1A2 and CYP2D6.    
In addition to affecting CYP enzymes, Hp extracts have also been shown to affect 
enzymes that regulate the expression of CYP enzymes.  Hp activated the nuclear receptor 
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pregnane X receptor (PXR).  In humans, PXR regulates CYP3A4 (65).  Moore et al. (2000) 
tested three Hp extracts (made from 3 commercially available Hp capsules and extracted in 
ethanol) and constituents (hyperforin, amentoflavone, isoquercitrin, quercetin, isoquercitrin, 
hyperoside, kaempferol, luteolin, myricetin, rutin, hypericin, pseudohypericin, β-sitosterol, 
umbelliferone, scopoletin) to identify which extracts or compounds activated PXR in primary 
human hepatocytes (66).  All three extracts activated PXR and hyperforin was the only 
constituent able to activate PXR (IC50 of 23 nM). To date, hyperforin appears to be the most 
potent PXR activator identified.  In addition, the three Hp extracts (7-75 µg/ml) and 
hyperforin (1 µM) induced CYP3A4 expression.   
One of the rare adverse effects reported in certain individuals using Hp supplements, 
especially those with fair skin, is photosensitivity.  Since Hp extracts contain constituents 
that require light-activation for bioactivities such as anti-viral and anti-proliferative activities, 
the phototoxicity of Hp extracts and constituents have been studied. In a single dose study, 
Schempp et al. (2000) administered 1800 mg Hp extract to 12 healthy volunteers (67).  The 
mean serum total hypericin concentration was 43 ng/ml and the mean skin blister fluid 
concentration was 5.3 ng/ml (67).  When the subjects were given 300 mg Hp extract three 
times daily for 7 days, the mean serum total hypericin concentration was 12.5 ng/ml and the 
mean skin blister fluid was 2.8 ng/ml.  These concentrations were too low to be phototoxic 
(<100 ng/ml).  Administration of Hp oil (110 µg/ml hypericin) or Hp ointment (30 µg/ml 
hypericin) to forearms of volunteers before exposure to solar-stimulated radiation was 
performed and visual assessment detected no change in erythema after application although 
photometric measurement revealed an increase in erythema index with oil.  This suggested 
that Hp preparations with higher concentrations of hypericin need to be evaluated for 
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phototoxicity (67).  Barnes et al. (2001) administered oral hypericin at 0.05 mg/kg for 28 
days to human immunodeficiency virus (HIV) positive patients.  Some patients developed 
mild symptoms of photosensitivity on exposure to sunlight and two patients developed 
intolerable symptoms when the dose was increased to 0.16 mg/kg daily (14).  Gulick et al. 
(1992) administered hypericin orally at 0.5 mg/kg daily or intravenously at 0.25 mg/kg two 
or 3 times weekly to 30 HIV-infected patients (68).  Sixteen patients discontinued the study 
before completion due to moderate or severe phototoxicity.   Severe phototoxicity was found 
in 11 patients.  Hp extracts administered in these studies appeared to be less phototoxic than 
pure hypericin.  Therefore, Hp extracts may be more beneficial therapeutically than hypericin 
due to the potential for interactions of compounds in Hp that may attenuate hypericin‟s 
detrimental toxicity. 
Data concerning single dose, reproductive toxicity, and long-term safety of Hp are 
limited.   Leuschner et al. (1996) found the no-effect single dose to be above 5000 mg/kg in 
mice and rats and chronic toxicity in both rats and dogs revealed only weight loss and minor 
pathological changes in the liver and kidney (69).  A study by Garrett et al. (1982) found no 
significant tissue lesions or adverse effects on the liver in rats fed Hp as 5% of the daily diet 
for 119 days (70).  This study reported that Hp induced hepatic enzyme activities.  Schwarz 
et al. (2003) studied the effect of Hp extracts and constituents on carcinogen formation.  Hp 
extracts (10-100 µg/ml) inhibited ultimate carcinogen formation from benzo[a]pyrene-7, 8-
dihydrodiol by human cytochrome p450 enzyme subtype 1A1 (CYP1A1) (71).  All 
constituents tested except rutin had strong inhibitory activity with an IC50 of 0.5 µM for 
hypericin, 1.2 µM for hyperforin, 1.5 µM quercetin, and 8 µM pseudohypericin (71). 
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In summary, it appears that the effect of flavonoids on the cytochrome enzyme 
system is minimal.  However, there are more significant effects seen with Hp extracts, 
hypericin, and hyperforin.  Hyperforin and Hp extracts, but not hypericin, affected PXR, 
which regulates CYP isozymes.   Many of these effects often depend on the model system 
and concentration of constituent or Hp extract used.  Data concerning the effect of Hp on 
these genes in macrophages is not currently available.  Additional data supports the use of Hp 
extracts rather than hypericin because constituents in Hp may attenuate hypericin‟s 
detrimental phototoxicity.  Although preliminary studies suggested that Hp extracts are 
generally safe, more research needs to define the role of interactions of constituents to 
support safety of Hp preparations. 
Photodynamic therapy with Hypericum perforatum extracts and constituents 
Photodynamic therapy (PDT) is defined as the systemic administration of a 
photosensitizer and targeted delivery of visible light to a specific site or lesion (72).  
Hypericin, due to its anti-proliferative activity upon light exposure, has been considered as a 
photosensitizer in PDT.  Hypericin produces reactive oxygen species (ROS) and kills tumor 
cells through photosensitization (72).  PDT also causes cytokine and inflammatory mediator 
release from cells, which produces an inflammatory response.   
There are many downsides of using hypericin for treatment including low solubility, 
high cost of production, and lack of stability in solution (73).  Furthermore, medical 
application has been severely restricted due to the lipophilic nature of the compound, making 
intravenous injections difficult.  Clinical trials with hypericin have confirmed the 
effectiveness of hypericin-PDT for the treatment of recurrent mesothelioma, basal and 
squamous cell carcinoma, and for the inhibition of malignant glioma, pituitary adenoma, and 
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cutaneous T cell lymphoma (72).  A topical preparation of hypericin is currently undergoing 
phase I clinical trials for the treatment of skin cancer, warts, and psoriasis (73).  Hypericin 
treatment may also be useful for fluorescence detection of neoplastic lesions in bladders, 
using a photodynamic method (73). 
The use of Hp extracts for PDT may offer greater benefits than using synthesized 
hypericin.  Benefits include: low cost and easy production, wide availability, decreased side 
effects and phototoxicity, and better water solubility.   However, it is a challenge to find a 
defined Hp extract that has been studied extensively in many different model systems. 
Anti-depressant properties of Hypericum perforatum extracts and constituents 
The anti-depressant properties of Hp are well-known and have been intensively 
studied in the last few decades.  Examination of the effects of Hp extracts on depression has 
been performed using both in vitro and in vivo methods, and more recently using clinical 
trials.  In vitro studies used mainly hydroethanolic (50-60%) or hydromethanolic (80%) 
crude or purified extracts (1).  Hydroethanolic extracts have been shown to inhibit type A 
monoamine oxidase (MAO-A), which is an enzyme whose substrates include hormones and 
neurotransmitters.  The inhibition of MAO-A is one of the key mechanisms used in 
conventional therapy for depression (74, 75), along with the inhibition of gamma 
aminobutyric acid (GABAA)/ benzodiazepine receptors (76), and dopamine-β-hydroxylase 
(77).  Hydromethanolic Hp extracts inhibited uptake of serotonin, noradrenaline, and 
dopamine in synaptosomal preparations (78).  One study compared an Hp extract devoid of 
naphthodianthrones and flavonoids and containing 40% hyperforin versus a hydromethanolic 
Hp extract (79).  They found that the Hp extract devoid of naphthodianthrones and 
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flavonoids and containing 40% hyperforin potently inhibited serotonin, dopamine, 
noradrenaline, GABA, and L-glutamate uptake. 
Constituents of Hp have also been studied in in vitro models.  Hyperforin inhibited 
uptake of serotonin, dopamine, noradrenaline, and GABA with IC50 values of 0.05- 0.1 
µg/ml and L-glutamate with an IC50 of 0.5 µg/ml (80).  Hypericin inhibited dopamine-β-
hydroxylase from 1-10 µM (81), and had low activity against MAO at 0.001 µM (82).   
Hypericin bound to GABAA receptors and at the serotonin receptor (76).  Pseudohypericin 
inhibited dopamine-β-hydroxylase with an IC50 of 3 µM (81).  In comparison, the IC50 values 
of dopamine-β-hydroxylase for the flavonoids were at least 50 µM, but the flavonoids 
strongly inhibited type A MAO (74, 75).   However, neurochemical activity associated with 
treatment of flavonoids constituents has been reported at concentrations far greater than 
could be achieved through a clinically relevant treatment using an Hp extract (83).    
In vivo models have been used to explore the anti-depressant effects of various Hp 
extracts.  Indications for anti-depressant efficacy were found in animal models based on 
stress-induced behavior tests like the forced swimming test, the mouse tail suspension test, or 
the rat learned helplessness test (1). It is difficult to compare across studies because no dose-
response data comparing different Hp extracts with each other and standard anti-depressants 
was performed.  One study that did address this issue lacked an appropriate control group and 
therefore conclusions cannot be made regarding this study (84).  De Vry et al. investigated 
two commercially available Hp extracts, 80% methanol (LI 160) and 50% ethanol (Ze 117), 
and imipramine and fluoxetine in depression and alcoholism models in rats (85).  The two 
extracts performed comparably in both models, with slightly less efficacy than imipramime 
and fluoxetine (85). The constituents that were present in each of the extracts were not 
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identified as part of this study; therefore it is difficult to identify the constituents responsible 
for the activities of the two different extracts.  The behavioral effects of a hydroethanolic 
crude Hp extract versus a CO2 fraction containing mainly hyperforin was studied (86). The 
crude Hp extract containing 4.5% hyperforin produced similar results to the CO2 fraction 
devoid of hypericin and containing 38.9% hyperforin after repeated doses, but the crude 
extract increased dopaminergic responses while the CO2 fraction increased serotonergic 
responses.  In another study, two different Hp extracts (ethanolic vs. CO2) were compared 
and the anti-depressant closely correlated with hyperforin level (74).  High doses of either 
extract did not reveal any anti-depressant like activity, however; the repeated oral 
administration of either for three days dose-dependently reduced the immobility time of rats 
and learned helplessness.  The Hp CO2 extract given at 30 mg/kg/day orally and the Hp 
ethanolic extract administered at 300 mg/kg/day orally to rats were almost as effective as 10 
mg/kg/day intraperitoneal injection of imipramine.   Butterweck et al. (1997) studied the 
effect of Hp fractions on the forced swim test and tail suspension test in mice (87).  Two 
fractions significantly reduced the immobility time in the forced swim test: fraction II which 
was rich in flavonoids, and fraction IIIc which was rich in naphthodianthrones.  A 
procyanidin fraction and pure procyanidin B2 and C1 increased the water solubility of both 
hypericin and pseudohypericin.  Therefore, they speculated that the bioavailability of 
hypericin and pseudohypericin would increase in the presence of these compounds.  
Butterweck et al. (2003) studied the effect of Hp extracts and hyperforin on the forced 
swimming test in mice (88).  Three Hp extracts were used: a CO2 extract at 500 mg/kg with 
no hyperforin and 0.14% hypericin and an extract with 12% flavonoids (25 mg/kg rutin, 25 
mg/kg hyperoside, 26.9 mg/kg isoquercitrin, 10 mg/kg quercitrin, 3.8 mg/kg quercetin, and 
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3.7 mg/kg amentoflavone) and no hypericin or hyperforin, or a 60% ethanolic extract 
containing 3.2% hyperforin and 0.15% hypericin.  Pure hyperforin was used at 8 mg/kg.  The 
only treatment that was inactive was the 60% ethanolic extract containing 3.2% hyperforin 
and 0.15% hypericin.  These results supported the role of flavonoids in the anti-depressant 
activity of Hp.  Thus, extracts devoid of hypericin and hyperforin still show anti-depressant 
activities and therefore these constituents were not solely responsible for the anti-depressant 
activities of Hp extracts (88). 
A meta-analysis of randomized controlled clinical trials of preparations of Hp was 
performed by Linde et al. (1996) which included 27 trials and 1757 patients classified as 
having a mild-to-moderate depressive disorder (89).  Seventeen of the trials compared Hp to 
placebo (1 using a combination of four other herbs and Hp), and ten of the trials compared 
Hp to a conventional anti-depressant including imipramine, amitryptyline, maprotiline, or 
desipramine.  Hp extracts were administered at doses from 350-1800 mg and the trials lasted 
from 4-6 weeks.  Results from the meta-analysis confirmed Hp preparations were 
significantly superior to placebo for the short-term treatment of mild-to-moderate and Hp 
preparations were as effective as conventional anti-depressants.  Patients reporting side 
effects from using either Hp preparation or conventional anti-depressant were 26.3% and 
44.7%, respectively.  However, this meta-analysis has been scrutinized due to one or more 
major methodological flaws like the use of sub-therapeutic doses of tricyclic anti-depressants 
(TCAs), high placebo responder rates indicating mild, transient depressive episodes, 
improper analysis of the side effects or adverse drug reactions associated with taking the Hp 
preparation, and lack of standardized diagnosis to accurately represent the patient population 
suffering only from mild-to-moderate depreesion.  A meta-analysis of six well-designed 
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clinical trials that included 651 patients with mild-to-moderate depressive disorders revealed 
Hp to be only 1.5 times more effective than placebo (56).  Surprisingly, Hp was equally 
efficacious to low doses of TCAs such as amitryptyline, imipramine, and maprotiline.  In this 
analysis, the incidence of side effects with Hp was 50% less than with TCAs.  The authors 
selected only those studies comparing Hp to placebo or standard anti-depressant treatment in 
patients classified according to the Diagnostic and Statistical Manual of Mental Disorders-IV 
or –III-R or International Statistical Classification of Diseases and Related Health Problems-
10.  All studies defined treatment effects using the Hamilton Depression Scale scores.  
Although previous methodological concerns were addressed, the authors acknowledged 
concerns with these studies including lack of objective standardized outcome measures, 
psychiatric evaluations conducted by primary care physicians, lack of follow up with 
patients, and inadequate study duration (13). 
Despite the attention given to hyperforin as an anti-depressant constituent, additional 
work has shown that the anti-depressant activity of Hp extracts may not be due to hyperforin 
alone.  There have been discrepancies between observed and theoretical IC50 values for 
hyperforin, indicating that hyperforin is not the sole constituent responsible for anti-
depressant activity (80).  In summary, in vitro and in vivo data supports that Hp has anti-
depressant activity.  Although some constituents have been implicated in the activity, future 
work will highlight the role of interactions of constituents in Hp extracts.  Finally, clinical 
trials found that patients using Hp as a treatment for mild-to-moderate depression 
experienced results better than placebo with at least similar efficacy to TCAs, and with 
perhaps fewer side effects than those patients taking TCAs to treat mild-to-moderate 
depression.   
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Anti-viral properties of Hypericum perforatum extracts and constituents 
Another bioactivity with extensive support in the literature is the anti-viral activity of 
Hp and constituents.  In 1988, Meruelo et al. (1988) showed that 50 µg light-activated 
hypericin and pseudohypericin dissolved in ethanol and diluted to 1% in phosphate buffered 
saline prevented viral infections (106 focus forming units) following administration of Friend 
leukemia virus, a retrovirus that induced rapid splenomegaly and acute erythroleukemia, both 
in cell culture and in vivo with low toxicity in cell culture at concentrations producing 
dramatic anti-viral effects (90).  No infectious virus particles were recovered from spleen 
cells.  Carpenter and Kraus (1991) reported that the photosensitization of hypericin must 
occur to produce inactivation of equine infectious anemia virus (91). One study by Fehr et al. 
(1995) showed that oxygen is not required for the virucidal activity of hypericin (92). 
However, in a later study by the same group, Park et al. (1998) showed that the virucidal 
activity was somewhat dependent on oxygen because the anti-viral activity of hypericin 
decreased 100 fold under hypoxic conditions (93).  To summarize, light increased the anti-
viral potency of hypericin by at least 100 fold (91, 92, 93).  Thus, many factors need to be 
controlled to obtain optimal hypericin activity. 
Since then, much work has focused on hypericin‟s ability to produce light-activated 
anti-viral effects, although recent work suggests that hypericin is able to produce anti-viral 
effects in the absence of light activation as well.  Hudson et al. (1993) reported that light was 
required to activate hypericin in conditions where hypericin inactivated HIV-1, but when the 
concentration of hypericin reached a cytotoxic level, there was a light-independent anti-viral 
effect (94).  Takahashi et al. (1989) found both hypericin and pseudohypericin inhibited 
protein kinase C (PKC) with an IC50 of 3.4 and 28.8 µM, respectively and suggested that the 
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anti-retroviral activity of hypericin could be due to inhibition of PKC; however, light 
conditions were not described in these studies (95).  Therefore, the relationship between 
hypericin and PKC inhibition in anti-viral activity remains unclear. 
The effectiveness of hypericin against hepatitis C was determined in vivo (96).  
Hypericin was administered to 12 patients chronically infected with hepatitis C for 8 weeks 
at 0.05 mg/kg body weight orally each day or 7 patients were administered hypericin for 8 
weeks at 0.1 mg/kg body weight orally each day.  No subject had significant changes in 
plasma hepatitis C RNA level, and 5 of 12 patients given 0.05 mg/kg hypericin and 7 of 8 
patients administered 0.1 mg/kg hypericin developed severe phototoxic reactions.  Lavie et 
al. (1995) described the potential of hypericin for inactivation of viruses in blood transfusions 
(97).  Illumination of hypericin for 1 hour with fluorescent light achieved complete 
inactivation of infective doses of HIV in whole blood or diluted packed red cells.  Steinbeck-
Klose et al. (1993) administered hypericin intravenously (2 mls) twice weekly plus 3 Hp 
tablets 2 times per day for 40 months in 18 HIV-infected people in 1993 (98).  Only 2 
patients encountered an opportunistic infection during the study period.  The other patients 
showed stable or increasing cluster of differentiation 4 (CD4) values for helper T cells with 
an improved CD4/cluster of differentiation 8 (CD8) ratio.  In addition, hemoglobin, 
leukocyte, and platelet levels were stable in these patients and no cytomegalovirus, Epstein-
Barr virus, or herpes complications were observed throughout the study.  The study reported 
no detectable HIV RNA after 40 months treatment in the 16 patients and surprisingly no 
significant side effects were associated with the hypericin treatment.  In contrast to this study, 
phase I studies with hypericin have generally observed multiple detrimental side effects and 
phototoxic reactions.  Thus the in vivo effectiveness of hypericin still needs to be explored. 
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Other constituents present in Hp extracts also have anti-viral activity.  Quercetin at 
100 µM had virucidal activity against herpes simplex I, respiratory synctial, and 
parainfluenza 3, which are all enveloped viruses (99,100). Ma et al. (2001) showed 
amentoflavone inhibited respiratory syncytial virus with an IC50 of 102 µM (101).  Lin et al. 
(1997) reported amentoflavone was moderately active against HIV-1 reverse transcriptase 
with an IC50 of 119 µM but was ineffective at inhibiting HIV-1 in phytohemagglutin-
stimulated peripheral blood mononuclear cells (102).  Robinson et al. (1996) reported that L-
chicoric acid, a caffeic acid derivative, inhibited HIV-1 at 421 µM independent of toxicity 
(103). 
In addition to the anti-viral activity of Hp constituents, Hp extracts also possess anti-
viral properties.  Taher et al. (2002) tested the effectiveness of Hp extracts on UV-induced 
activation of HIV gene expression in stably transfected HIVcat/HeLa cells (104).  Hp 
extracts inhibited the ultraviolet light (UV)-induced (30 J/m2 for 30 minutes) activation of 
HIV gene expression in a dose-dependent manner.  A 30 minute pre-incubation with Hp 
extracts before UV irradiation blocked nuclear factor-kappa B (NF-κB) activation, but p38 
MAPK was not inhibited.     
Most of the anti-viral work with constituents of Hp has been done with hypericin.  
Recently, Hp extracts have been tested and shown to have anti-viral activities and other 
constituents that exhibit anti-viral activity may be identified.  To date, hypericin, 
pseudohypericin, quercetin, amentoflavone, and chichoric acid have been shown to elicit 
anti-viral activities, with hypericin being the most potent anti-viral constituent of Hp, at least 
in light-activated conditions. 
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Anti-proliferative and cytotoxic properties of Hypericum perforatum extracts and 
constituents 
 
Most of the early work studying the cytotoxic properties of Hp used either methanolic 
or ethanolic Hp preparations.  Martarelli et al. (2004) used an Hp methanolic extract as a 
treatment on PC-3 human prostate adenocarcinoma cells and found that the Hp extract at 
1.41 mg/ml, corresponding to 100 µM hyperforin and 8.4 µM hypericin, significantly (p-
value < 0.05) reduced the cell number by 80% (105).  The PC-3 cells were injected into the 
prostate of athymic nude mice and ten days after injection, Hp extract was administered at 15 
mg/kg daily for 25 days.  Treatment with Hp resulted in tumors that were 70% smaller than 
controls.  Unfortunately, light conditions were not described in these experiments.  Roscetti 
et al. (2004) used a methanolic Hp extract on K562 human erythroleukemic cells pretreated 
with Hp extracts for 1 hour in the dark and put back in the incubator for 24 and 48 hours 
(106).  Treatment with Hp flower (0.5, 1.0, 2.5, 5 µg/ml) significantly (p <0.05) and dose-
dependently inhibited cell growth as assessed by cell counts and apoptosis as assessed 
byflow cytometryand fluorescence microscopy.  However, the lack of light-activation data 
does not allow for comparisons between light and dark activities of the Hp extracts.  
Hostanska et al. (2002) used aqueous ethanolic Hp extracts either from fresh or dried Hp 
plant on K562 human erythroleukemic cells, U937 human leukemic monocytic cells, LN229 
human brain tumor cells, and normal human astrocytes in the dark, followed by exposure to 
7.5 J/cm2 white light for 10 minutes (107).  The Hp extracts made from fresh material 
displayed more pronounced activity than the Hp extract made from dried plant material.  The 
growth inhibitory activity of the extracts was more pronounced against K562 and U937 cells 
than for the LN229 and normal human astrocyte cells.   A lipophilic Hp extract was 
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examined for cytotoxicity of T24 human bladder cancer cells (108).  The IC50 for the total 
extract was 4-5 µg/ml and a lipophilic methanolic fraction of this extract inhibited cell 
growth by 60% at 0.95 µg/ml.  Hypericin and pseudohypericin were not present in the 
fraction.  The hyperforin concentration in the total extract was 1.75 µM and 0.3 µM in the 
fraction.  However, the amount of pure hyperforin needed to achieve similar inhibition on 
cell growth was 3.4-9.3 µM.  These results suggested that there were cytotoxic constituents 
present in the fraction other than hypericin, pseudohypericin, and hyperforin.  Kapsokalyvas 
et al. (2005) reported the photodynamic action of a polar methanolic fraction of Hp against 
HL-60 leukemia cells (109).  Cell death was induced from treatment with a 50 µg/ml fraction 
and 75 J/cm2 laser irradiation (523 nm) corresponding to 174.7 J/cm2 for 7 minutes.  Schmitt 
et al. (2006) performed a comprehensive assessment of light-activated and dark cytotoxicity 
of Hp extracts ranging in polarity in NIH 3T3 mouse fibroblasts, SW480 human colon cancer 
cells, and HaCaT human skin keratinocytes (22).  All extracts exhibited significant 
cytotoxicity; the ethanol extracts showed the least cytotoxicity (55-93%) whereas the hexane 
extracts had the most cytotoxicity (96-99%).  The overall absence of light-sensitive toxicity 
of the Hp extracts suggested that hypericin and pseudohypericin were not the only 
constituents playing a role in the toxicity of the extract, in agreement with previous studies.   
The ability of individual constituents to affect cell proliferation has also been 
determined in certain cell lines.  Hostanska et al. (2003) reported hyperforin inhibited the 
growth of K562, U937, and LN229 cells with IC50 values between 14.9 and 19.9 µM (110).  
The inhibitory effect was greater in the K562 (22% cell growth inhibition at 10 µM) and 
U937 (31% cell growth inhibition at 10 µM) cells.  A dose-dependent (10-80 µM) loss of 
membrane asymmetry associated with apoptosis was seen in all cell lines along with 
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externalization of phosphatidylserine on the cell membrane, another marker of apoptosis.  In 
U937 cells, hyperforin at 1-5 µM increased the activity of caspases-3 and -9 and in K562 
cells increased the activity of caspases-8 and -3.  Schempp et al. (2002) studied the cytotoxic 
effects of hypericin and pseudohypericin on Jurkat human leukemia cells (111).  Treatments 
were performed in dark or under light-activated (5 J/cm2) conditions.  The IC50 for hypericin 
and pseudohypericin was 1.98 and 3.84 µM, respectively (111). There was no cytotoxicity 
associated with dark treatment conditions.  There was a dose-dependent increase in DNA 
fragmentation after treatment with photo-activated hypericin and pseudohypericin.  Blank et 
al. (2001) studied the effect of up to 10 µM hypericin on the growth of highly metastatic 
murine breast adenocarcinoma (DA3HI) and squamous cell carcinoma (SQ2) tumors in 
culture (112).  Light-activated hypericin (7.2 J/cm2 for 30 minutes) inhibited the growth of 
both the cell lines, whereas; a dose-dependent decline was observed in the dark treatments 
that was less than the effect in light-activated conditions, especially in the SQ2 cells.  Next, 
they administered 5 mg/kg hypericin intraperitoneally to mice bearing the same tumors.  
Hypericin treatment slowed tumor growth and prolonged animal survival in the absence of 
light.  Blank et al. administered 10 mg/kg hypericin by injection in a single dose 50 days 
after inoculation with murine breast adenocarcinoma and squamous cell carcinoma cells 
(113).  Long term animal survival (50 days) in the murine breast adenocarcinoma-inoculated 
mice increased from 15.6% in controls to 34.5% for hypericin treatment.  In the squamous 
cell carcinoma-inoculated mice, survival increased from 17.7% in control animals to 46.1% 
in hypericin treatment animals.  Utsumi et al. (1995) found that light-activated hypericin 
(0.3-12.5 µg) inhibited Friend leukemia virus-induced splenomegaly in mice (114).  They 
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also found that hypericin inhibited PKC by 50% at 0.1 µM under constant light for 3 
minutes.   
Hypericin, pseudohypericin, and hyperforin all have cytotoxic properties but also 
other constituents may contribute to the cytotoxicity of the Hp extracts. The effectiveness of 
the individual constituent or the unfractionated Hp extract depended on cell type and time or 
intensity of light activation.  In general, pseudohypericin and hypericin were less toxic in the 
dark treatments than in the light-activated treatments.  The ability of cell lines to 
differentially respond to treatment with Hp may be due to differences in the expression of 
genes important for regulating the metabolism of drug compounds, among other differences.   
Anti-oxidant properties of Hypericum perforatum extracts and constituents 
Activated phagocytic cells, such as macrophages, produce reactive oxygen species 
(ROS).  ROS, commonly called free radicals, include hydrogen peroxide, superoxide radical 
anion, hydroxyl radical, alkylperoxyl radical, nitric oxide, singlet oxygen, and hypochlorous 
acid.  ROS have very short half lives (nanoseconds to milliseconds) and can react with 
biological molecules to injure cells and tissues (115).  ROS released from macrophages can 
cause considerable damage by indirectly interacting with DNA of the neighboring cells 
through signaling mechanisms (116). 
Recently, more emphasis has been placed on the anti-oxidant capabilities of Hp 
extracts.  Constituents of Hp, especially flavonoids, are of particular interest in anti-oxidant 
activity.  Wang et al. (2006) studied the effect of quercetin on 1,1-diphenyl-2-pictylhydrazyl-
induced radical scavenging in cultures of RAW 264.7 macrophage cells stimulated with 1 
µg/ml LPS for 15 hours (117).  Quercetin significantly inhibited radicals induced by 1,1-
diphenyl-2-pictylhydrazyl with an IC50 of 8 µM.  Kanupriya et al. (2006) studied the effect of 
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flavonoids on tert-butylhydroperoxide-induced free radical formation and cytotoxicity in U-
937 human macrophage cells (118).  The cells were incubated with flavonoid and 200 µM 
tert-butylhydroperoxide for 24 hours.  The most effective free radical scavenging dose of 
quercetin was 147 µM with approximately equal free radical scavenging at 296 µM.  Cell 
viability was reduced approximately 20% with 147 µM quercetin treatment.    Kono et al. 
(1998) studied the free radical scavenging activity of chlorogenic acid (119).  Chlorogenic 
acid was an active scavenger and was twice as active as caffeic acid at 150 µM.    In contrast 
to the anti-oxidant constituents found in Hp, hypericin has been shown to have increase free 
radical formation when light-activated (122, 123).  Therefore, the balance between pro- and 
anti-oxidant compounds in the extracts may affect the activity of the whole extract.  Couladis 
et al. (2002) tested an Hypericum triquetrifolium Turra extract for anti-oxidant activity.  They 
identified four constituents present within the extract, quercetin, rutin, chlorogenic acid, and 
amentoflavone that possessed anti-oxidant activity (120).  The anti-oxidant activity of 
amentoflavone was similar to the α-tocopherol positive control, whereas the other 
constituents possessed less anti-oxidant activity.  Zou et al. (2004) tested the anti-oxidant 
activity of a flavonoid rich Hp extract containing rutin, hyperoside, quercitrin, isoquercitrin, 
and quercetin (121).  The Hp extract was effective at quenching 1,1-diphenyl-2-
pictylhydrazyl and scavenging superoxide radicals with an IC50 of 11 µg/ml for quenching 
and 54 µg/ml for scavenging, respectively.   
In summary, many constituents present in Hp extracts have anti-oxidant properties 
such as flavonoids, but hypericin was pro-oxidant.  Special attention had been given to the 
flavonoids that are present in Hp as anti-oxidants, but recently, Hp extracts as complex 
mixtures have received more consideration.  Future work may explore the interactions of 
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constituents in complex Hp preparations.  Since the production of ROS in macrophages is a 
response to phagocytosis or stimulation with various agents, the ability of constituents 
present in Hp to reduce ROS formation may be critical for helping the macrophage regulate 
an immune response.  However, the intricate balance between pro- and anti-oxidant 
constituents needs to be explored further to draw conclusions about the anti-oxidant activities 
of Hp extracts. 
Anti-inflammatory properties of Hypericum perforatum extracts and constituents 
Inflammation is a complex host response to stimuli and involves the production of a 
variety of cytokines, lipid mediators, and signaling cascades.  Despite intensive efforts to 
study other bioactivities of Hp preparations, few comprehensive research studies have been 
performed to define the mechanisms of anti-inflammatory activity of Hp and identify 
constituents present in Hp that are responsible for the activity.  Most studies used a single Hp 
extract and measured one inflammatory outcome.  However, more recent evidence for the 
anti-inflammatory activity of Hp has been provided by human clinical trials using Hp as a 
treatment of atopic dermatitis, an inflammatory skin disease which is associated with high 
levels of eosinophils and immunoglobulin E.   
Using cell culture models, Herold et al. (2003) demonstrated that a hydroalcoholic 
freeze-dried Hp extract containing hypericin, saponins, flavonoids, carotenoids, alcaloids, 
vitamins, and minerals inhibited 5- lipoxygenase (L0) by 4% at 200 µg and by 12% at 600 µg 
but not COX-2 in cell free systems (124).  Using alveolar A549/8 and colon DLD-1 cells, 10-
100 µg/ml Hp extract inhibited human inducible nitric oxide synthase (iNOS) mRNA, 
protein, and nitric oxide (NO) production in both cell lines in a dose dependent manner 
42 
 
(125).  In the A549/8 cells, treatment with Hp extract down-regulated the activation of 
STAT-1, due to inhibition of JAK2 activity, but did not affect the activation of NF-κB (125).   
Using in vivo inflammation models, Raso et al. (2002) orally administered 30 or 100 
mg/kg Hp dried extracts prepared from flowering tops containing 0.27% hypericin and 2.5% 
hyperforin twice daily to mice three days prior to and up to 3 days after carrageenan-induced 
paw edema (126).  Only the 100 mg/kg dose of Hp extract significantly decreased the 
carrageenan-induced paw edema.  Oral treatment with the Hp extract for 14 days decreased 
LPS- and interferon γ-induced COX-2 and iNOS protein expression in peritoneal 
macrophages.  Kumar et al. (2001) administered 100 or 200 mg/kg of 50% aqueous ethanolic 
extract of Indian Hp prepared from leaves, stems, and flowers orally to mice and measured 
carrageenan-induced paw edema and cotton pellet-induced granuloma before and 1, 2, 3, 4, 
and 6 hours post injections (127).  Hp administered at both doses showed significant 
reduction in both inflammatory endpoints.  A freeze-dried Hp extract suppressed the 
carrageenan- and prostaglandin E1- induced inflammation and leukocyte infiltration in Wistar 
albino rats (128).  An Hp extract administered at 50 and 300 mg/kg significantly reduced 
carrageenan-induced paw edema by 53.7 and 75.3%, respectively compared to 90% 
inhibition for 50 mg/kg fluoxetine and 60.7% inhibition mediated by administration of 72 
mg/kg etodolac (129).  Sosa et al. (2007) compared three Hp extracts or fractions 
(hydroalcoholic extract, ethylacetic acid fraction, lipophilic extract) and 5 pure compounds 
(hypericin, amentoflavone, hyperoside, isoquercitrin, hyperforin) administered topically on 
croton-oil induced ear edema in mice (130).  The lipophilic extract significantly decreased 
inflammation to the greatest extent, followed by the ethylacetic acid fraction and the 
hydroalcholic extract with an IC50 of 220, 267, and >1000 µg/cm
2, respectively.  Three 
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constituents were more potent than the indomethacin positive control (IC50 of 0.26 µg/cm
2).  
These were amentoflavone, hypericin, and hyperoside with IC50 values of 0.16, 0.25, and 
0.25 µg/cm2, respectively.  The IC50 values for isoquercitrin and hyperforin were 1 µg/cm
2.  
An Hp methanolic extract given at 30 mg/kg orally in a bolus prior to carrageenan induction 
decreased tumor necrosis factor-α (TNF-α) and interleukin-1β (131). In lung tissue samples, 
intracellular adhesion molecule-1, nitrotyrosine, and poly (ADP-ribose) polymerase as 
assessed by immunohistochemistry and NF-κB and STAT-3 as assessed by electrophoretic 
mobility shift assay were also significantly reduced by the Hp extract.   
In a randomized, placebo-controlled, double blind clinical trial, Schempp et al. (2003) 
assessed the effectiveness of an Hp cream standardized to 1.5% hyperforin for the treatment 
of subacute atopic dermatitis (132).  Twenty one patients suffering from mild-to-moderate 
atopic dermatitis were treated twice daily for four weeks and treatment to the left or right 
sides of the body were randomly assigned.  Eighteen patients completed the study and the 
severity of skin lesions was determined by the modified scoring index SCORing Atopic 
Dermatitis.  The severity of the lesions lessened with both the placebo and Hp extract; 
however, the Hp cream was significantly superior to vehicle (p<0.05) on all visits (days 7, 
14, and 28 of the treatment regimen).   
Some of the constituents of Hp (hypericin, pseudohypericin, hyperforin, flavonoids, 
biflavonoids, chlorogenic acid) have been tested for anti-inflammatory activity in cell culture 
systems as seen in Table 1.  Treatment conditions for hypericin included 16 hour incubation 
with hypericin before irradiation with 4 J/cm2 ambient light for 15 minutes.  Pseudohypericin 
was not studied in similar systems.  Inconsistencies among concentrations of effective 
treatments may be due to dose of LPS, treatment time, or concentration used. 
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Table 1.  Anti-inflammatory activity of select constituents identified in Hypericum 
perforatum extracts 
 
Constituent Cell Type Result  
Ref- 
erence 
quercetin guinea pig epidermis Inhibition of PLA2
a; 0.1-100 µM 133 
 
rabbit peritoneal neutrophils Inhibition of PLA2; IC50
b=57 µM 134 
 
PBMCsh Inhibition of COX-2c activity; IC50=76 µM 135 
 
PBMCs Inhibition of 5-LOd; IC50=0.8 µM 135 
 
PBMCs Inhibition of 12-LO; IC50=12 µM 135 
 
RAW 264.7 macrophages Decreased LPSe-induced PGE2
f
; 40 µM 136 
 
RAW 264.7  macrophages Decreased COX-2 protein; 80 µM 136 
 
RAW 264.7 macrophages Decreased LPS-induced NOg; 20 µM 137 
 
RAW 264.7 macrophages Decreased LPS-induced NO; 16-500 µM 138 
 
sheep seminal vesicles Increased COX-2 activity; 5-5000 µM 139 
rutin RAW 264.7 macrophages No inhibition of PGE2; 40-80 µM 136 
 
guinea pig epidermis Inhibition of PLA2; 10 and 100 µM 133 
 
RAW 264.7 macrophages Decreased LPS-induced NO 30-60 µM 140 
amento-
flavone J774 macrophages No inhibition of PGE2; 100 µM 141 
 
MM6 cells No inhibition of COX-2 protein, 3-30 µM 142 
chlorogenic 
acid human PMBCs Decreased 5-LO; IC50=1-2 µM 142 
hyperforin human PMBCs No inhibition of 12-LO; 0.3-10 µM 142 
 
human platelets No inhibition of 15-LO; 0.3-10 µM 142 
 
T24 cells Increased PGE2 levels; 150 nM 143 
hypericin HeLa cells Increased PGE2 levels; 125nM 143 
 
T24 cells Increased COX-2 protein, 150 nM 143 
 
HeLa cells Increased COX-2 protein, 125 nM 143 
aPLA2=phospholipase A2,
bIC50=dose for 50% inhibition, 
cCOX-2=cyclooxygenase-2, dLO=lipoxygenase, 
eLPS=lipopolysaccharide, fPGE2= prostaglandin E2, 
gNO=nitric oxide,hPBMCs=peripheral  
blood mononuclear cells 
 
Quercetin has firm support in the literature for its‟ anti-inflammatory activity whereas rutin 
does not, at least in these model systems.  Hyperforin may be pro- or anti-inflammatory 
based on the model system used.   
 Some of the constituents of Hp have been also been tested for anti-inflammatory 
activity in vivo.  Rotelli et al. injected mice with carrageenan and rutin at 150 mg/kg or 
quercetin at 75 mg/kg.  Paw volume was measured by volume displacement and the percent 
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inhibition of carrageenan-induced inflammation was calculated, but no histopathological 
evaluation was described (144).  Quercetin inhibited edema by 66% but rutin did not inhibit 
edema in this model.  Experimental arthritis was induced using an adjuvant in combination 
with carrageenan in rats and rutin at 150 mg/kg or quercetin at 75 mg/kg was administered 
intraperitoneally.  Measurements were made on day 0 (day of injection) and days 6, 7, and 21 
after injection.  In the chronic phase (7-21 days after injection), only rutin was able to 
decrease tissue damage on all days.  Quercetin had no significant action on days 7, 12, and 
21.  Oral administration of 160 mg/kg quercetin daily for 5 days to rats in an intradermal 
experimental adjuvant-induced arthritis model resulted in a decrease of clinical signs as 
compared to control (146).  Intracutaneous injections of 60 mg/kg daily for 5 days also 
decreased clinical signs of arthritis; however, injection of 30 mg/kg daily for 5 days did not 
decrease arthritic signs.  The anti-inflammatory activity of rutin and quercetin was studied in 
an adjuvant arthritis model in rats. Rutin and quercetin were administered intraperitoneally at 
80 mg/kg one hour before carrageenan injection and once every day up to 30 days after 
carrageenan injection (147).  Both rutin and quercetin decreased edema in the acute phase of 
inflammation (days 1-6 after carrageenan injection), but only rutin decreased edema in the 
chronic phase (days 7-30 after carrageenan injection).  Quercetin had no significant anti-
inflammatory activity on days 7, 12, 21, and 28 (145).   The anti-inflammatory activity of 
quercitrin was studied using paw edema induced by a number of sources including 
carrageenan, scald edema, cotton pellet-induced granuloma, and adjuvant arthritis in mice, 
rats, or guinea pigs (148).  Quercitrin was administered at 50, 100, or 200 mg/kg 
intraperitoneally.  All three doses inhibited paw edema induced by carrageenan.  Quercitrin 
administered at 200 mg/kg inhibited scald edema induced by 54° C water.  However, 
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quercitrin did not inhibit cotton pellet-induced granuloma or adjuvant arthritis induction in 
rats.  Chlorogenic acid was administered to rats orally at 50 and 100 mg/kg 60 minutes prior 
to carrageenan injection (149).  Both doses significantly inhibited carrageenan-induced paw 
edema as early as two hours after injection.  These results suggested that quercitrin may 
possess inhibitory potential against acute inflammation but not chronic inflammation.   
Since there are approximately 360 species in the Hypericum genus, species other than 
Hp, but containing some of the same constituents, have been tested for anti-inflammatory 
activity.  Savikin et al. (2006) tested ethanol extracts of aerial parts from 5 different species 
of Hypericum grown in Serbia and Montenegro: H. barbatum Jacq., H. hirsutum, H. richeri 
Vill., H. androsaemum L., and Hp.  In the carrageenan-induced rat paw edema test, dose-
dependent anti-inflammatory activity was seen for all extracts when administered orally 
(150).  H. hirsutum and both wild and cultivated H. perforatum produced the greatest 
decrease in edema.  Ozturk et al. (2002) injected male Wistar rats intraperitoneally with 25-
60 mg/kg H. triquetrifolium Turra. extract 30 minutes before carrageenan injection (151).  
Paw volume was measured before and 1-6 hours after injection.  Intraperitoneal 
administration of the extracts inhibited paw swelling dose-dependently at 2, 3, 4, 5, and 6 
hours after carrageenan injection. Sanchez-Mateo et al. (2006) topically administered aerial 
H.  reflexum L. Fil infusion, methanol extract, and fractions to 12-O-tetradecanoylphorbol-
13-acetate-induced ear inflammation in mice (152).  The methanol extract, butanol fractions, 
and chloroform fractions of H. reflexum L. Fil administered topically at 0.25-1.0 mg/ear all 
significantly reduced the 12-O-tetradecanoylphorbol-13-acetate -induced ear edema in mice.   
All of the H. glandulosum Ait. infusions, extracts, and fractions (0.25-1.0 mg/ear) tested 
significantly reduced edema (p<0.05) whereas only the methanol extract and butanol and 
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chloroform fractions of H. canariense L. reduced edema.  Light conditions were not 
described in this study.  Finally, Hillwig et al. (2008) described the anti-inflammatory 
activity, as characterized by a reduction of LPS-induced PGE2 level in RAW 264.7 mouse 
macrophages, of Hypericum gentianoides methanol extracts and fractions containing 
acylphlorglucinols (153).  Clearly, the anti-inflammatory activity of the Hypericum genus is 
not limited to Hypericum perforatum; however, comparison between Hp and other species 
suggest that Hp is as effective as other species.   
Many of the constituents found in Hp extracts possess anti-inflammatory activity 
including flavonoids and hyperforin.  However, pro-inflammatory compounds, like light-
activated hypericin, are also present in the Hp extracts.  Hp extracts and extracts made from 
different species of Hypericum possess anti-inflammatory activity that may vary depending 
on dose and type of preparation.  One of the main limitations with screening only for 
reductions in LPS-induced PGE2 is that there are many other mediators, like cytokines or 
other inflammatory proteins, that may be affected in different ways by Hp extracts or 
constituents.  Thus, screening of this type may indicate the effect of the Hp extract on a 
limited set of targets important in the inflammatory response, such as COX-2 and cPLA2, but 
not other signaling pathways that may be just as important for the anti-inflammatory activity. 
Additional testing in other cell models may provide a better understanding of the role of Hp 
as anti-inflammatory botanical.   
Signaling properties of Hypericum perforatum extracts and constituents 
Signaling pathways activated in RAW 264.7 macrophage cells in response to stimuli 
are complex.  In the activation of macrophages,  Toll-like receptor (TLR) 4 is one of the 
primary components needed for the induction of LPS-induced signaling (154).  In addition to 
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close physical proximity of LPS and TLR4, proteins that may also complex with TLR4 to 
transduce intracellular signals include heat shock proteins, chemokine receptors, caspase 
activators, adaptor proteins, and possibly other TLRs (154).  Activation of MAPK pathways 
via TLR4 result in cPLA2 activation and the production of pro-inflammatory lipid mediators 
as shown in Figure 1 below.   
Prostaglandin H2
Arachidonic Acid
Prostaglandin G2
Specific isomerases
TXA2 PGE2 PGD2 PGI2 PGF2
5-HPETE
LTA4
8-HPETE
12-HPETE
15-HPETE
Phospholipids
5-Lipoxygenase
5-Lipoxygenase
Phospholipase A2
8, 12, 15-Lipoxygenase
COX-1
COX-2
Phospholipase C
Abbreviations:
HPETE=hydroxypentaeicosanoic acid
COX=cyclooxygenase
TXA2=thromboxaneA2
PG=prostaglandin
LTA4=leukotriene A4
  
Figure 1.  Prostaglandin biosynthesis pathway 
 
PGE2 is the one of the products of arachidonic acid metabolism by COX-2.  PGE2 can 
promote cell growth and survival, and enhance cell migration, adhesion, and motility (155).   
PGE2 production in endotoxin-stimulated macrophages is dependent on PLC and cPLA2 
(156).  Qi and Selhammer found that TLR4 was necessary for LPS-induced cPLA2 activation 
and lipid release, including prostaglandins, in RAW 264.7 macrophage cells (157).  In 
addition to TLR4, TLR3 appears to be important in eicosanoid production.  Knockdown of 
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TLR3 by small interfering RNA prevented PGE2 secretion and COX-2 expression in 
response to ligand; furthermore, TLR3 signaling involved cPLA2 activation (158).  The role 
of MyD88 was not explored in this study.  Therefore, TLR3 and TLR4 may act together to 
elicit an inflammatory response.   
COX-2 expression in LPS-stimulated macrophages is dependent on NF-κB (159). 
NF-κB is one of the transcription factors activated by LPS (154).  Nuclear factor-κB inhibitor 
α (IκBα) binds to NF-κB dimers and blocks nuclear localization signals and when IκBα is 
phosphorylated and subsequently degraded, NF-κB can translocate to the nucleus and 
activate the transcription of genes important for inflammation, including cytokines and COX-
2 (154).  A reduction in IκBα levels was observed when LPS was co-administered with a 
MEK kinase inhibitor, suggesting that components of the extracellular signal-related kinase 
(ERK) pathway are involved in regulating IκBα protein expression and turnover (160).  
Furthermore, LPS has been shown to stimulate degradation of IκBα (161).  In macrophages, 
the IκKα subunit plays a negative regulatory role by phosphorylating NF-κB subunits Rel-A 
and Rel on sites that accelerate their nuclear turnover, thereby contributing to the termination 
of NF-κB-mediated gene induction (161).   
The JAK-STAT pathway incorporates an important signaling mechanism for 
cytokines and growth factors in inflammation (162).  The intricate balance between STAT 
proteins, namely STAT1 and STAT3, may determine the balance of pro- and anti-
inflammatory functions (161).  STAT1 genes may promote inflammation and antagonize 
proliferation whereas STAT3 target genes may promote proliferation and antagonize 
inflammation, although STAT3 knockout mice experience more inflammation than wild-type 
mice (164).  STAT1 was necessary for the macrophage response to LPS (165) and STAT1 
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may play a critical role in the activation of innate immune mechanisms following LPS 
challenge (166). JAKs are kinases that regulate the JAK-STAT pathway and suppressor of 
cytokine signaling proteins (SOCS) antagonize STAT activation by feedback inhibition.  
JAK2 was phosphorylated immediately after LPS stimulation in RAW 264.7 macrophages 
via TLR4 (167) and SOCS3 attenuated LPS-induced STAT activation (168).   
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Figure 2.  Potential interactions between JAK-STAT and MAPK pathways 
 
Signaling pathways implicated in anti-inflammatory activity do not act independently 
from one another as seen in Figure 2 above.  NF-κB may also be a convergence point for 
some of the activation pathways.  There is considerable cross-talk between the JAK-STAT 
and eicosanoid biosynthesis pathways at multiple levels, most likely mediated by MAPK-
regulated pathways (162).  Kovarik et al. (1998) showed that LPS caused phosphorylation of 
STAT1 on serine 727 through a pathway requiring p38 MAPK, but not MAPKAP-2(169).  
JAK2 was not necessary for the phosphorylation of STAT1 and activated JAK2 alone was 
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not sufficient for phosphorylation.  It is likely that JAK kinases regulate the phosphorylation 
of Rac1, an upstream activator of the p38 pathway, by phosphorylating and activating a 
substrate protein that functions as a guanine nucleotide exchange factor for Rac1 (170).  
SOCS3 can bind to RasGAP, negative regulator of Ras, and reduce its activity, which would 
reduce the activity of the MAPK pathways (170).  ERK, c-Jun-N-terminal kinase (JNK), and 
p38 pathways, in addition to STAT3, were involved in SOCS3 gene expression (168), but 
stable transfection of mouse macrophages with constitutively active SOCS3 DNA did not 
inhibit LPS-induced NF-κB activation (171).   Additionally, PLCβ1 is the only PLCβ isoform 
that possesses a MAPK phosphorylation site in its C-terminal tail, suggesting that it can be 
regulated by MAPKs (172). 
Literature on the effect of Hp extracts on signaling is limited, however; more is 
known about the signaling properties of constituents present within Hp.   Bork et al. (1999) 
studied the effect of hypericin on the transcription factor NF-κB (173).  Hypericin at 2 µM 
inhibited phorbol 12-myristate 13-acetate and TNF-α-induced activation of NF- κB, but not 
hydrogen peroxide-induced activation of NF-κB in HeLa cervical cancer cells or in murine 
TC10 endothelial cardiac cells.  Unfortunately, no information on light status during these 
treatments was provided.  These results suggested that hypericin was not acting as an anti-
oxidant and that hypericin may be acting upstream of NF- κB, however; it is difficult to 
assess the impact of light activation from this study since light conditions were not described.  
Assefa et al. (2002) studied the effect of hypericin-photodynamic therapy (PDT) on MAPKs, 
which are upstream activators of the transcription factor NF- κB (174).  PDT with 66-81 nM 
hypericin, which was pre-incubated for 16 hours on the cells and then treatments were 
irradiated for 15 minutes at 4 J/cm2, increased the phosphorylation of JNK and p38 MAPK, 
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but irreversibly inhibited phosphorylation of ERK2 in HeLa cells.  JNK1 and p38 protected 
the HeLa cells from apoptosis as inhibiting these two MAPKs exacerbated apoptosis markers 
in the cells. 
Hendrickx et al. found that PDT in conjunction with 125 nM hypericin led to the up-
regulation of COX-2 and release of PGE2 in HeLa cells (143).  The selective activation of 
p38 MAPKα and β mediated the COX-2 up-regulation at both protein and messenger levels.  
A p38 inhibitor, PD169316, abrogated COX-2 expression and transcriptional regulation by 
NF-κB was not involved.  Furthermore, the half life of the COX-2 mRNA was shortened 
with inhibition of p38 MAPK, suggesting that p38 MAPK is important for stabilizing the 
COX-2 transcript.  Over-expressing p38 MAPK increased the cells‟ ability to resist apoptosis 
and inhibiting p38 MAPK exacerbated cell death and prevented PGE2 secretion.  Hendrickx 
et al. (2003) found that cPLA2 was an upstream mediator of the p38-COX-2 signaling 
cascade (143).  PDT with 500 nM hypericin inhibited cPLA2 in HeLa cells and protected the 
cells from apoptosis.  Inhibition of p38 MAPK suppressed the hypericin-PDT-induced COX-
2 expression, PGE2 and vascular endothelial growth factor release, and tumor-induced 
endothelial cell migration, suggesting that inhibiting p38 MAPK may decrease the 
inflammatory response induced by treatment with light-activated hypericin.   
In addition to hypericin, the effect of quercetin, amentoflavone, and hyperforin on 
MAPK signaling has been studied in various cell types.  Using RAW 264.7 macrophage 
cells, Cho et al. (2003) found that 10-200 µM quercetin treatment significantly reduced the 
phosphorylation of ERK and p38 MAPK but not JNK MAPK by LPS treatment (175).  
Furthermore, quercetin treatment inhibited NF- κB activation.  200 µM quercetin inhibited 
iNOS expression by inhibiting p38 MAPK and inhibited TNF-α induction by LPS-induced 
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RAW 264.7 cells by inhibiting JNK leading to the inhibition of activator protein 1 (AP-1)-
DNA binding (176).  Quercetin doses from 5-50 µM also decreased TNF-α gene expression 
and protein levels as well as NF-κB1 gene expression in human peripheral blood 
mononuclear cells (177).  Morikawa et al. (2003) found that local injection of 10 mg/kg 
quercetin 1 hour before carrageenan challenge decreased the release of TNF-α and 
macrophage inflammatory protein 2 from carrageenan-induced air-pouch exudates 
(containing less than 60% neutrophils in the quercetin-treated animals) and also inhibited 
COX-2 expression from exudates in rats (145).  In RAW 264.7 macrophage cells, treatment 
with 60 µM amentoflavone blocked  LPS-induced activation of NF- κB, but AP-1 was 
unaffected (140).  Zhou et al. (2004) showed that hyperforin may possess pro-inflammatory 
properties by inducing interleukin-8 gene expression in human intestinal epithelial cells 
through activation of AP-1 but not NF-κB (178).    
Little has been done to explore the effect of Hp extracts on signaling pathways 
involved in the inflammatory response.  The main focus of studies of this nature has been 
hypericin and flavonoids, which appear to decrease signaling pathways important for 
inflammation.  Additionally, the effect of Hp extracts on these pathways needs to be 
explored.  Since interactions of compounds are important, individual constituents and the 
interactions of constituents needs to be related back to the complex mixtures that they 
originated in.   
Gene expression studies using Hypericum perforatum extracts and constituents 
Gene expression in macrophages is greatly affected by the addition of LPS, and in 
particular, genes involved in inflammation can be up- or down-regulated depending on time 
of LPS stimulation.  A study by Wells et al. (2003) identified LPS-inducible genes in primary 
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bone marrow-derived macrophages treated with LPS for 0-21 hours.  LPS-inducible genes 
had obvious functions such as endocytosis and phagocytosis, along with 18% of the 
differentially expressed genes involved in cell signaling, 10% involved in antigen 
presentation, and 4% in cytokine or chemokine functions (179).  Ravasi et al. (2002) 
examined LPS-inducible subclones of RAW 264.7 mouse macrophages cells treated with 
LPS using cDNA microarrays (180).  They found that not all genes that were putative LPS-
inducible genes, like TNF, were induced by LPS in all subclones.  Clustering revealed groups 
of genes that were likely to be co-expressed in subclones and ontology analysis showed that 
these genes were generally regulatory genes like JunD, cyclins, MAPKS, and p53 or genes 
involved in immune function, like interferon inducible genes, iNOS, and chemokines.  LPS 
treatment of murine peritoneal macrophages for 3 hours up-regulated COX-2, SOCS3, 
interleukin- 6 and -1B, IκBα, JAK2, STAT1, and PLC (181).  LPS treatment for 1 or 4 hours 
of THP-1 macrophages significantly affected 72 out of 465 genes (15.4%) studied including 
COX-2, IκBα, and TNF-α (182).  In mouse macrophages treated for 2 hours with LPS, 1,055 
of 13,000 probe-sets (8.1%) were LPS responsive (183).  In mouse macrophages treated for 6 
hours with LPS, there were 1,270 LPS responsive genes (3.9 %) with at least a 2 fold 
increase or decrease in RAW 264.7 mouse macrophages treated with LPS for 6 hours (184).   
Schreiber et al. (2006) profiled DNA binding in U937 cells before and 1 hour after LPS 
stimulation and found that NF-κB bound 157 genes in unstimulated and 326 genes in LPS-
stimulated conditions (185).  NF-κB target genes were enriched in immune response and 
transcriptional regulation ontologies and up-regulated genes included COX-2 and TNF. 
Large scale studies examining the effect of Hp extracts or fractions on gene expression are 
lacking.  Perhaps this is due to the recent emphasis on identifying active constituents.  
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However, it is important to analyze the effects of Hp extracts and fractions and active 
constituents at concentrations present in the extracts or fractions at a large scale level.  In 
addition, analyses of this magnitude may allow for additional information concerning 
signaling pathways affected by the treatment.  The effect of 1 µM hyperforin and an Hp 
extract containing 0.05 µM hypericin was studied using microarray analysis in HepG2 
human hepatocellular liver carcinoma cells (186).  Both the Hp extract and hyperforin 
increased expression of CYP3A4, CYP1A1, CYP1A2, flavin containing monoxygenase 
(FMO5), and multi drug resistance protein MRP2 and decreased expression of CYP4F2 and 
NAD dehydrogenase NQG1.  Treatment with Hp extract or hyperforin decreased the 
expression of genes important for cholesterol biosynthesis and increased the expression of 
genes important for glycolysis and facilitated transport, suggesting that increased glucose 
transport was occurring (186).  Both treatments also increased the expression of genes 
important for intracellular calcium binding proteins and decreased the expression of 
endoplasmic reticulum stress-regulated genes important for the unfolded protein response 
and protection from apoptosis suggesting that Hp extracts and hyperforin also affect energy 
metabolism, calcium regulation, and cell survival/death.  This data confirmed that putative 
bioactive constituents should be compared against a fraction or extract to determine the role 
in the activity of the complex Hp mixture.  Currently, no data is available concerning the 
effect of Hp preparations on macrophages using microarray technologies. 
Hypothesis and objective 
The long term goal of this research is to identify the mechanisms by which Hp 
extracts and constituents exert anti-inflammatory properties.  The original hypothesis driving 
this research was that Hp extracts exert anti-inflammatory activity through p38-dependent 
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inhibition of inflammation in RAW 264.7 macrophages.  Although the original hypothesis 
was not proven by the data presented in this dissertation, inflammatory pathways were 
identified that may have a significant role in the anti-inflammatory activity of Hp.  In 
particular, interactions of these inflammatory pathways with the p38 pathway may play an 
important role in the anti-inflammatory activity of Hp.  By exploring the role of individual 
constituents and interactions of constituents in  macrophages, we can begin to model the role 
of these active constituents in the activity of the Hp extracts.  Future work may use genetic 
approaches to knock-down genes or pathways of importance in inflammation to further 
define the role of individual or interacting constituents in the anti-inflammatory activity of 
Hp extracts. 
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Abstract 
Hypericum perforatum (Hp) is commonly known for its anti-viral, anti-depressant, 
and cytotoxic properties, but traditionally Hp was also used to treat inflammation.  In this 
study, the anti-inflammatory activity and cytotoxicity of different Hp extractions and 
accessions and constituents present within Hp extracts were characterized.  In contrast to the 
anti-viral activity of Hp, the anti-inflammatory activity observed with all Hp extracts was 
light-independent.  When pure constituents were tested, the flavonoids, amentoflavone, 
hyperforin, and light-activated pseudohypericin displayed anti-inflammatory activity, albeit 
at concentrations generally higher than the amount present in the Hp extracts. Constituents 
that were present in the Hp extracts at concentrations that inhibited the production of 
prostaglandin E2 (PGE2) were pseudohypericin and hyperforin, suggesting that they are the 
primary anti-inflammatory constituents along with the flavonoids, and perhaps the 
interactions of these constituents and other unidentified compounds are important for the 
anti-inflammatory activity of the Hp extracts. 
Introduction 
Hypericum perforatum (Hp) is an herbaceous perennial plant native to Europe and 
Asia (1).  Traditionally, Hp extracts were used both externally, for treatment of 
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inflammation, wounds, and skin diseases, or internally, for treatment of anxiety, headache, 
bedwetting, neuralgia, inflammation, and mild-to-moderate depression (2).  The use of Hp 
supplements has been prevalent for many years, but increased use of these supplements and 
the identification of bioactive constituents present within Hp have intensified interest in the 
mechanisms by which Hp extracts exert specific bioactivities, such as inhibiting 
inflammation (1).   
Hp extracts possess anti-inflammatory properties in a wide variety of in vivo systems.  
The cyclooxygenase (COX) enzymes metabolize arachidonic acid to eicosanoids.  The 
products of COX-2 metabolism of arachidonic acid are the 2-series prostanoids, of which 
prostaglandin E2 (PGE2) is important in mediating pain, inflammation, and swelling (3). Raso 
et al. found that 100 mg/kg by gavage of Hp root dry powder extract twice daily significantly 
inhibited COX-2 protein levels and significantly reduced carrageenan-induced paw edema in 
mice (4).  Herold et al. reported that a hydroalcoholic Hp extract significantly inhibited 5-
lipoxygenase but did not affect COX-2 protein in cell free systems (5).    Mice fed 50-300 
mg/kg Hp extract by gavage showed a dose-related and significant inhibition of carrageenan-
induced paw edema (6).  A 50% ethanol Hp extract administered at both 100 and 200 mg/kg 
reduced inflammation and analgesia in carrageenan-induced paw edema and cotton pellet-
induced granuloma (7), and an Hp extract suppressed inflammatory and leukocyte infiltration 
in carrageenan- and prostaglandin E1-induced Wistar rats (8).    
The minimal dose of Hp to provide a therapeutic effect is unknown; however, Hp 
treatments generally range from 500-650 mg/day and vary depending upon study design (9).  
Others report that the dosage for a fluid or powder extract would be the amount of extract 
equivalent to 0.5-3.0 mg hypericin and pseudohypericin daily (2).  Relatively few studies 
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have determined the levels of many constituents present in plasma after administration of Hp 
extracts. Schulz et al. (2005) administered 612 mg of dry Hp extract to 18 healthy male 
volunteers as a single oral dose for 14 days.  The maximal plasma concentrations for 
hypericin, pseudohypericin, and quercetin were 3.14, 8.5, and 47.7 ng/mL, respectively (10). 
The bioactive constituents of Hp extracts are complex and include many different 
classes of chemicals (11).  Two of these classes of constituents are present in only select 
plant species: naphthodianthrones such as hypericin and pseudohypericin and 
phloroglucinols like hyperforin (11).  Other classes of constituents present within Hp are also 
present in many plant species; these include the flavonoids and biflavonoids, tannins, 
procyanidins, and caffeic acid derivatives, among others.  The flavonoids present in Hp are 
quercetin, the aglycone form, and its‟ glycosylated derivatives, quercitrin, isoquercitrin, 
hyperoside, and rutin, while a biflavonoid present in Hp is I3‟, II8-biapigenin, also known as 
amentoflavone.   
Although individual constituents have been shown to provide bioactivity alone, the 
interaction among constituents may account for diverse bioactivities of the supplements.  
Work by Schmitt et al. (2006) supports the role of unknown compounds in the bioactivity of 
Hp extracts in which chlorogenic acid and porphyrin, which were present in Hp extracts,  
attenuated hypericin‟s light-dependent toxicity in HaCaT keratinocytes (12, 13). 
 Because comprehensive research on the anti-inflammatory constituents of Hp is 
lacking, to begin to identify the anti-inflammatory constituents we hypothesized that Hp 
extracts made using several extraction procedures and accessions would yield distinct 
chemical profiles which could be related to the anti-inflammatory activity of the Hp extracts.  
The goal of this study was to identify Hp extracts from different extraction procedures and 
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Hp accessions that maximize anti-inflammatory activity in RAW 264.7 macrophage cells.  
To assess which constituents may be responsible for the anti-inflammatory activity seen in 
the extracts, constituents known to be present within Hp were also tested for anti-
inflammatory activity in the same model system. Because Hp extracts are known to possess 
cytotoxic properties, the cytotoxicity of these Hp extracts and constituents was also assessed.  
The dependence of the anti-inflammatory activity on light activation of Hp extracts, a 
treatment condition important for several Hp bioactivities, was also evaluated.  
Materials and Methods 
Plant material and extractions 
All plant material was obtained from either Frontier Natural Products Co-op (FNPC) 
(Norway, IA) or the North Central Regional Plant Introduction Station (NCRPIS) (Ames, IA) 
of the U.S. Department of Agriculture and processed as described in Schmitt et al. (12).  Six 
accessions of Hp were provided by the NCRPIS: Plant Introductions (PI) 325351 and 371528 
and the commercial varieties, Common, „Medizinal‟ (Elixir™) (Ames 27452), „Helos‟ 
(Ames 27453), and „Topas‟ (Ames 27455).  Accessions PI 325351 and 371528 were 
collected in the former Soviet Union; Common was grown from seeds supplied by Johnny‟s 
Selected Seeds (Winslow, ME) and the other varieties were grown from seeds supplied by 
Richter‟s Herb Specialists (Goodwood, Ontario, Canada).  „Topas‟, bred to increase overall 
commercial production, was developed in Germany and Elixir™, bred to contain a higher 
amount of napthodianthrones, and „Helos‟, bred for tolerance to anthracnose disease, were 
developed in Denmark (14, 15).   
Six grams of dried plant material were extracted by either Soxhlet extraction for 6 h 
or room temperature shaking for 24 h, evaporated to dryness, and dissolved in 15 mL of 
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dimethyl sulfoxide (DMSO) (Sigma, St Louis, MO) as previously described (12) .  Extracts 
were stored at -30º C in the dark and used as stock solutions for treatments.  Because 
preliminary testing determined that the highest amount of DMSO that could be added onto 
the cells was 0.1% of the media and because the Hp extracts were dissolved in DMSO, each 
stock extract was added at a final DMSO concentration of 0.1% of the media that was added 
onto the RAW 264.7 cells for an initial test of anti-inflammatory activity.  Thus, the extracts 
were initially compared at different µg/ml concentrations based on adding 0.1% DMSO 
allowing comparison of the relative anti-inflammatory activity of the constituents extracted 
from 6g of dried plant material.   Hp extracts screened in this way will be referred to as 
“highest concentration tested” in this manuscript.  The stock extract was further diluted in 
DMSO to allow for comparisons of the extracts at the same (µg/mL) concentration.    
Endotoxin levels of the plant extracts were assayed using the Limulus Amebocyte 
Lysate Test (BioWhittaker, Inc.; Walkersville, MD) because the presence of high levels of 
endotoxin in the extracts would stimulate the macrophages to release inflammatory mediators 
including PGE2.   Endotoxin levels ranged from 0.001 to 0.2 endotoxin units per milliliter 
(EU/mL).  Because the extracts were further diluted in media, the range of endotoxin levels 
present in the RAW 264.7 macrophage cell media was 0.000001-0.0002 EU/mL.  Pure 
endotoxin up to 5 EU/mL did not significantly increase the RAW 264.7 cells‟ production of 
PGE2 in the assay (data not shown). 
Chemicals 
Hypericin was purchased from Molecular Probes (Eugene, OR) and pseudohypericin 
from Calbiochem-Novabiochem (La Jolla, CA).  Chlorogenic acid, quercetin, hyperoside, 
hyperforin, and rutin were purchased from Fisher Scientific (Hanover Park, IL) and 
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quercitrin, isoquercitrin, and amentoflavone were purchased from ChromaDex (Santa Ana, 
CA).   
Cell culture 
RAW 264.7 macrophages were purchased from the American Type Culture 
Collection (ATCC; Manassas, VA) and cultured in high glucose Dulbecco‟s Modified 
Eagle‟s medium (4500 mg/L D-glucose) (Invitrogen; Carlsbad, CA) and supplemented with 
100 UI/ml penicillin/streptomycin (Invitrogen) and 10% Fetal Bovine Serum (FBS) 
(Invitrogen).  Cells were maintained in a 5% CO2 incubator with 70% humidity at  37° C 
until 70% confluent in 75 cm2 flasks.   
Cell treatments 
Cells were plated at a density of 1.0 x 105 cells/ well in 24-well cell culture plates and 
allowed to attach overnight.  Cells were incubated with or without 1 µg/mL 
lipopolysaccharide (LPS) (Escherichia coli 02B:B6) (Sigma) and solvent alone, DMSO, or 
plant extract or constituent simultaneously for 8 h.  DMSO concentration did not exceed 
0.1% of the media, an amount determined by preliminary testing.  Four controls were 
included in each treatment: media alone, media and DMSO, media and LPS, and media and 
LPS and DMSO.  In addition, 10 µM quercetin and 6 µM baicalien were used as positive 
controls to ensure the assay was working properly. 
After initial testing of FNPC plant material in ambient light, the anti-inflammatory 
and cytotoxicity screening was always performed in both light-activated and dark conditions, 
due to the well-known light-activated properties of the naphthodianthrone compounds 
hypericin and pseudohypericin present within the Hp extracts.  Experimental conditions for 
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light activation were as previously described (12).  Cell supernatants were collected on ice, 
and stored in a -70° C freezer for use in the PGE2 assay as described below.   
PGE2 assay 
The supernatant samples were assayed with a Prostaglandin E2 EIA kit (GE 
Biosciences; Piscataway, NJ) according to manufacturer‟s instructions.  Supernatants were 
diluted 1:15 in water to ensure the concentration of PGE2 present within the samples were 
within the linear range of the standard curve for the assay.   
Cytotoxicity assay 
CellTiter96® Aqueous One Solution cell proliferation assay (Promega Corporation; 
Madison, WI) was used as previously described in Schmitt et al. (2006) with an 8-hour 
treatment incubation instead of 24-hour treatment incubation to parallel the anti-
inflammatory studies (12).  Following the 8 hour incubation, treatment solutions were 
removed and fresh media and CellTiter96® dye were added for 3 hours and 15 minutes (12).  
The metabolized dye solutions were transferred to 96-well plates for absorbance 
measurement at 490 nm.  The number of viable cells for each treatment was compared to the 
media + DMSO solvent control.  Light-activated and dark treatments of 20 µM hypericin 
were used as positive controls to ensure the assay was working properly. 
LC-MS Analysis  
Samples in DMSO were diluted 1:2 with methanol prior to injection into an Agilent 
Technologies 100 ion trap liquid chromatography- electron spray ionization- mass 
spectrometer, with a coupled UV absorption detector (LC-MS-UV).  Standards were injected 
in triplicate for each concentration, and extracts were injected in duplicate.  A Synergi Max-
RP 150 x 4.6 mm column (Phenomenex, Torrance, CA 90501) was used for analytical 
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separation.  For the mobile phase an acetonitrile/methanol (ACN/MeOH) 9:1 v/v (A) and 10 
mM ammonium acetate (B) gradient was used.  The gradient consisted of 85A/15B in 10 min 
to 80A/20B, then to 100% B in 25 min and held for 5 min at 40° C.  The flow rate was 0.75 
mL/min (16).  External calibration curves for standards were constructed from coupled UV 
absorption data at 254 nm. 
Concentrated stock Hp extracts were analyzed by LC-MS-UV, and calculations were 
made to estimate the concentration of constituents present in the amount of Hp extract used 
as a treatment at the highest concentration tested.  The data are presented in this way for 
comparison between the amount of constituents needed to observe an effect and amount of 
constituent that would be present in the Hp extracts when tested at the highest concentration.  
Statistical Analysis 
The anti-inflammatory data was logarithmically transformed to eliminate unequal 
variances and skewed distribution.  An F-protected two-way ANOVA was used followed by 
a Tukey-Kramer test for multiple comparisons for all PGE2 samples (17).  For the anti-
inflammatory data in tables, the data are shown as mean percent reduction in LPS-induced 
PGE2 levels ± the 95% confidence interval as compared to media + LPS + DMSO control.  
For the anti-inflammatory data presented in graphs, original PGE2 levels ± standard error are 
shown and statistical significance was determined by an F-protected two-way ANOVA 
followed by a Tukey-Kramer test for multiple comparisons as compared to the media + LPS 
+ DMSO control.  For cytotoxicity, data were presented as mean percent reduction in cell 
viability ± standard error and the p-value was adjusted using the Dunnett-Hsu method for 
multiple comparisons against the media + DMSO control (20).  To determine light versus 
dark differences, the data was compared using the Tukey-Kramer test for multiple 
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comparisons.  For LC-MS-UV detection of compounds in NCRPIS Hp extracts, data was 
presented as mean ± standard error and differences in concentrations of constituents for each 
extract was determined using a one-way ANOVA for each constituent followed by a Tukey-
Kramer test.  p values less of < 0.05 were considered to be statistically significant. 
Results 
Anti-inflammatory Activity of Extracts of FNPC Hp Plant Material Prepared by Different 
Extraction Procedures 
 To determine the relative bioactivity of material within the Hp extracts made by 
different extraction procedures, an initial screen was conducted using the FNPC Hp extracts.  
None of the extracts made from FNPC plant material significantly reduced PGE2 levels when 
added to the media without LPS (data not shown).  Soxhlet extracts generally reduced LPS-
induced PGE2 levels greater than room temperature extracts (room temperature extracts not 
shown) and all of the Soxhlet extracts significantly reduced PGE2 levels at the highest 
concentration tested (Table 1).  Although the HPLC analysis suggested that the Soxhlet and 
room temperature extracts had similar chemical profiles, the Soxhlet method extracted more 
plant material than the room temperature shaking method (12).    Only the room temperature 
70% ethanol (-chloroform) extract tested at 65 µg/mL significantly reduced LPS-induced 
PGE2 levels by 66%.  The other room temperature extracts tested [70% ethanol, chloroform, 
hexane, and 70% ethanol (-hexane)] reduced LPS-induced PGE2 levels from 0-46% at 
concentrations ranging from 6-74 µg/mL.  Although the Soxhlet hexane extract caused the 
greatest reduction in LPS-induced PGE2 levels (81%) at the lowest concentration (17 µg/mL) 
tested in the screening among the Soxhlet FNPC extracts, Soxhlet chloroform and Soxhlet 
ethanol extracts were used for the remaining studies for two reasons.  First, ethanol extracts 
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are used primarily in the supplement industry, and second, chloroform extracts do not contain 
the light-activated hypericin and pseudohypericin compounds, which allows for 
determination of the anti-inflammatory nature of other compounds in the extract under light-
activated and dark treatment conditions.  
 The cytotoxicity of the FNPC Hp extracts was reported in Schmitt et al. (12).  All of 
the ethanol and chloroform extracts and the Soxhlet hexane extract possessed significant 
cytotoxicity against NIH3T3 mouse fibroblasts, SW480 human colon cancer cells, and 
HaCaT human keratinocytes.  The concentrations of the extracts tested in Schmitt et al. (12) 
were higher than those used in the initial anti-inflammatory screen due to the greater 
sensitivity of RAW 264.7 macrophage cells to DMSO.   
Quantification of Constituents Present within NCRPIS Hp Plant Material Extracts 
 The NCRPIS Soxhlet ethanol and chloroform extracts were characterized by LC-MS-
UV for detection of constituents present within the extracts.  Chlorogenic acid was one of the 
most abundant constituents detected in the accessions (Table 2).  Higher levels of 
chlorogenic acid were observed for Soxhlet ethanol Common, „Helos‟, and Elixir™ than PI 
325351, PI 371528, and „Topas‟.  Rutin was the most abundant flavonoid detected in all 
accessions, whereas the levels of other flavonoids detected differed among accessions.  
Higher levels of rutin were observed for Soxhlet ethanol Common, PI 325351, „Helos‟ and PI 
371528, „Topas‟ and Elixir™ than „Topas‟ and PI 371528.  Levels of hyperforin, 
isoquercitrin, hyperoside, quercitrin, amentoflavone, hypericin, and pseudohypericin in the 
Soxhlet ethanol extracts differed among the accessions. Very few constituents were detected 
in the Soxhlet chloroform extracts, but hyperforin was the most abundant and quercitrin and 
amentoflavone were detected in selected soxhlet chloroform extracts.  Quercitrin was 
83 
 
 
 
detected in the Soxhlet chloroform Common and „Helos‟ extracts, amentoflavone was 
detected in the Soxhlet chloroform Common, „Helos‟, and „Topas‟ extracts, and hypericin 
was detected in the Soxhlet chloroform Elixir™ extract. 
Anti-inflammatory Activity and Cytotoxicity of NCRPIS Hp Accession Extracts 
 An initial screen was conducted using the NCRPIS Soxhlet ethanol and chloroform 
Hp accession extracts at the concentration extracted from 6 g of dried plant material.    None 
of the extracts significantly reduced the level of PGE2 produced without LPS (data not 
shown).  No differences between light-activated and dark treatments were observed, and data 
were pooled across this variable for presentation.  The accession Elixir™ (8 µg/mL) Soxhlet 
chloroform extract reduced LPS-induced PGE2 levels (43% reduction) at the lowest 
concentration observed in this screening (Table 3).  All Soxhlet ethanol extracts of Hp 
accessions were able to significantly reduce LPS-induced PGE2 levels, albeit at higher 
concentrations than in the Soxhlet chloroform extracts.  Next, we tested both the Soxhlet 
chloroform and Soxhlet ethanol extracts of four Hp accessions at 8 µg/mL (Figure 1). 
Accession Elixir™ reduced LPS-induced PGE2 levels in both the Soxhlet chloroform and 
Soxhlet ethanol extracts.  The other accessions exhibited little anti-inflammatory activity at 
this dose.   
 The cytotoxicity of the NCRPIS Hp extracts was also assessed.  There was no 
significant difference between light-activated and dark treatments for any of the Hp extracts 
and data were pooled across this variable.  All Hp extracts tested at their highest 
concentration produced significant cytotoxicity as compared to the solvent control except for 
the Soxhlet chloroform Elixir™ extract at 8 µg/mL (Table 3).  Reductions in PGE2 levels 
ranged from 89-93% and 43- 85% for Soxhlet ethanol and chloroform extracts, respectively, 
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whereas the percent reductions in cell viability were 35-41% and 23-49%, respectively.  
Therefore, some of the reduction in PGE2 may have been due to cytotoxicity in the RAW 
264.7 macrophage cells.   However, none of the Hp extracts assayed at 8 µg/mL produced 
statistically significant cytotoxicity (4-23% reductions in cell viability in chloroform extracts, 
23-28% reductions in cell viability in ethanol extracts) suggesting that the anti-inflammatory 
activity of accession Elixir™ at 8 µg/mL (43 and 47% reductions for chloroform and ethanol, 
respectively) was not simply due to cytotoxicity of the cells (Table 4).  To further support 
this, no reductions in LPS-induced PGE2 levels were observed with „Helos‟, PI 371528, and 
„Topas‟ at 8 µg/mL, despite 17-22% reductions in cell viability, suggesting that this range of 
cytotoxicity was not directly reflected in PGE2 levels in this assay (Table 4).     
To further evaluate the activities of these Hp extracts, dose-response studies were 
conducted for Soxhlet ethanol extracts of accessions Common, PI 371528, and Elixir™.  
Soxhlet ethanol extracts of accessions PI 371528 and Elixir™ showed a dose-dependent 
inhibition of PGE2 at higher concentrations (Figure 2).  At lower concentrations, only 
accession Elixir™ was able to significantly reduce PGE2.  Significant cytotoxicity was 
observed for PI 371528 at 11.5, 15, and 30 µg/mL and for Elixir™ at 30 µg/mL (Table 4).  
Thus, some of the reductions in PGE2 levels in these Soxhlet ethanol Hp accession extracts 
could be due to cytotoxicity.  
Anti-inflammatory Activity and Cytotoxicity of Constituents Identified within Hp Extracts 
The anti-inflammatory activity of constituents identified within Hp extracts 
(hyperforin, quercetin, quercitrin, isoquercitrin, rutin, hyperoside, amentoflavone, 
chlorogenic acid, pseudohypericin, and hypericin) was studied.  Because there was no 
significant difference between dark and light-activated treatments for most constituents, data 
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were pooled across this variable in Table 5.  Pseudohypericin and hypericin were the only 
constituents that displayed differences between dark and light-activated treatments and are 
displayed in Figure 3.  Hyperforin significantly decreased PGE2 levels at 40 and 80 µM. 
Quercetin significantly reduced PGE2 at 5-40 µM (Table 5).  Quercitrin and isoquercitrin 
reduced PGE2 levels at 5-20 µM.  Rutin was the only flavonoid that did not significantly 
reduce LPS-induced PGE2 levels at the doses tested.  Amentoflavone significantly reduced 
PGE2 levels at 10 µM.   Chlorogenic acid did not reduce PGE2 levels at concentrations up to 
40 µM.  The range of concentrations of the individual constituents tested for bioactivity 
spanned the amounts detected in the extracts as tested at the highest concentration for each 
extract (Table 2).   Constituents that were not detected within the extracts or detected at 
levels too low to quantify were not included in this concentration range.  Although 
amentoflavone concentrations in the Hp extracts at their highest concentration ranged from 
0.2 to 2 µM, since 10 µM amentoflavone was needed to significantly reduce PGE2 levels, 
amentoflavone was not tested at concentrations below 1 µM. 
The cytotoxicity of the constituents identified within Hp extracts was also assessed. 
No significant differences between light-activated and dark treatments were observed for 
constituents except for pseudohypericin and hypericin (Table 6 and Figure 3A).  Significant 
cytotoxicity was observed with 20 µM isoquercitrin and hyperoside (40% and 35% 
reductions in cell viability, respectively) (Table 5).  However, 20 µM isoquercitrin and 
hyperoside also significantly reduced PGE2 levels to a greater extent (66% and 56% 
reductions, respectively) (Table 6), suggesting that although there was cytotoxicity present at 
this dose, it probably did not account for all the reduction in PGE2. 
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Hypericin at 2 µM produced significantly greater cytotoxicity in light-activated 
treatments than in the dark, with no reductions in PGE2 (Table 6).  Hypericin at 20 µM 
increased PGE2 levels both with and without LPS in the light-activated condition (Figure 
3A).  Hypericin at 20 µM produced significant cytotoxicity in light-activated conditions but 
not in the dark, and a significant difference between light-activated and dark treatments was 
observed (Table 6).  Hypericin at 20 µM exhibited 86% reduction in cell viability while 
significantly increasing PGE2 levels, thus, the increase in PGE2 by 20 µM hypericin may 
have been attenuated by this cytotoxicity. 
Pseudohypericin exhibited light-activated effects on both PGE2 levels and 
cytotoxicity.  When light-activated at 2 µM, pseudohypericin slightly but significantly 
increased PGE2 levels as compared to control when LPS was not added (Figure 3B).  
Pseudohypericin at 1 and 2 µM significantly reduced LPS-induced PGE2 levels in light-
activated but not dark treatments (Figure 3B).  Pseudohypericin at 0.02, 0.2, and 0.5 µM did 
not alter PGE2 production without or with LPS. Pseudohypericin at 1 and 2 µM produced 
significant cytotoxicity in light-activated conditions and there were significant differences 
between light-activated and dark treatments for 1 and 2 µM pseudohypericin (Table 6).   The 
cytotoxicity of light-activated pseudohypericin may have contributed to the reduction in 
PGE2 production in the light. 
Discussion 
Many studies have assessed the anti-inflammatory activity of Hp extracts both in cell 
culture and in vivo (4-8).  These previous studies usually examined one Hp extract made 
from one extraction procedure and from a single accession of Hp.  The present paper expands 
upon the earlier studies; however, since our work involved assessing anti-inflammatory 
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activity by only one assay, LPS-induced PGE2 production, other anti-inflammatory endpoints 
must be studied to further extend these observations.  The identification of accessions and 
extraction procedures that exhibit greater anti-inflammatory activity with less cytotoxicity 
may lead to improved Hp botanical supplements. Furthermore, although cytotoxicity and 
anti-viral studies are often performed in light-activated and dark treatment conditions, the 
light-dependence of the anti-inflammatory activity of Hp extracts had not been studied. To 
our knowledge, this is the first report demonstrating that the anti-inflammatory activity of Hp 
extracts is light-independent. The Hp accessions tested displayed different anti-inflammatory 
activities at the highest concentrations tested with the greatest inhibition of PGE2 production 
(93% reduction) with Soxhlet ethanol accessions of PI 325351, PI 371528, and „Helos‟, 
which may reflect the genetic background or developmental differences among accessions.   
Accession Elixir™ clearly exhibited the greatest anti-inflammatory activity at lower 
concentrations in both Soxhlet chloroform and Soxhlet ethanol extractions. It is interesting 
that no differences were observed between light-activated and dark treatments for anti-
inflammatory activity contrary to previously reported results for anti-viral and other 
bioactivities (1, 12, 13, 19), suggesting that the constituents present within Hp extracts that 
exerted anti-inflammatory activity were not dependent on light-activation. Furthermore, both 
Soxhlet ethanol and Soxhlet chloroform Elixir™ extracts exhibited similar anti-inflammatory 
activity at 8 µg/mL suggesting that the compounds responsible for anti-inflammatory activity 
may be extracted in both ethanol and chloroform.    However, the only common constituent 
that was detected by LC-MS-UV analysis in both of the Elixir™ extracts was hypericin.  
Hypericin tested as a pure constituent did not reduce PGE2 levels, suggesting that unknown 
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compounds within these two extracts may explain the greater anti-inflammatory activity of 
Elixir™.    
Because hypericin has been shown to inhibit 12-lipoxygenase (20) and inhibit the 
release of arachidonic acid in human granulocytes (21), treatments with hypericin were 
performed to determine the effect of light-activation on anti-inflammatory activity.  
Hypericin showed no reduction in LPS-induced PGE2 levels as compared to controls in light-
activated or dark treatments up to concentrations of 20 μM.  Because hypericin 
concentrations between 0.05 and 0.2 µM would be present in the highest concentration of 
extract tested, it is unlikely that hypericin present within the Hp extract was reducing PGE2 
levels.  The concentration of pure hypericin needed to observe an effect was 20 µM both with 
and without LPS, but this was a pro-inflammatory effect.  Furthermore, 20 µM hypericin was 
significantly cytotoxic to the RAW 264.7 macrophage cells.  This is the first report of 
hypericin‟s effect on PGE2 levels in LPS-induced RAW 264.7 macrophages.   
Pseudohypericin displayed light-activated properties.  Pseudohypericin reduced PGE2 
with LPS and increased PGE2 without LPS.    In a lipoxygenase activity assay, 
pseudohypericin inhibited 12-lipoxygenase, although light conditions were not described 
(20).  These results support the role of pseudohypericin as an anti-inflammatory compound in 
stimulated cells, although data from Hp extracts presented here suggest that compounds 
responsible for the anti-inflammatory activity of extracts were not light-activated. The 
concentration of pseudohypericin needed to observe an anti-inflammatory effect was 1 µM, 
while the concentration of pseudohypericin present in the highest concentration of extract 
tested was 0.3-1 µM; thus, it is possible that pseudohypericin contributed at least to some 
extent to the anti-inflammatory activity of Hp extracts.  
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Hyperforin inhibited LPS-induced PGE2 levels at 40 and 80 μM.  The hyperforin 
concentration in Hp extracts at the highest concentration tested was 1-70 μM.  Therefore, 
higher concentrations of hyperforin may be contributing to the anti-inflammatory activity of 
Hp extracts. Albert et al. (2002) showed that hyperforin suppressed COX-1 product 
formation with an IC50 of 0.3 μM for thrombin-stimulated or 3 μM for ionophore-stimulated 
human monocytic MM6 (Mono Mac 6) cells, but hyperforin had no effect on COX-2 protein 
levels in LPS-stimulated MM6 cells (22).  This is the first report of hyperforin‟s effects in 
RAW 264.7 macrophage cells. 
Similar to our results with flavonoids, 40 and 80 μM quercetin significantly decreased 
LPS-induced PGE2 levels in RAW 264.7 macrophage cells at 40 and 80 μM while decreasing 
COX-2 protein at 80 μM (23).  Furthermore, rutin had no effect on LPS-induced PGE2 levels 
or COX-2 protein levels in RAW 264.7 macrophages at 40 and 80 µM (23).  Chlorogenic 
acid at 1-40 µM had no significant effect on LPS-induced PGE2 levels in RAW 264.7 
macrophages and 10 µM chlorogenic acid would be present in the Hp extracts at the highest 
concentration tested. Chlorogenic acid had no effect on LPS-induced PGE2 levels in J774 
macrophages up to 100 µM (24).   
Although cytotoxicity was observed at the highest concentration tested for all the Hp 
extracts except for the Soxhlet chloroform Elixir™, no significant cytotoxicity was observed 
at 8 µg/mL for the Hp accession extracts. However, the extracts did possess some moderate 
cytotoxicity that was not statistically significant.  The reduction in PGE2 for both the Hp 
extracts and constituents cannot be explained by cytotoxicity alone as evidenced by the Hp 
extracts at lower doses and the constituents and in agreement with Schmitt et al. (2006), the 
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Hp extracts exhibited light-independent cytotoxicity while the naphthodianthrones had light-
dependent cytotoxicity (12).   
In conclusion, Hp extracts possessed anti-inflammatory activity that varied with 
extraction solvent and accession. The profiles of known chemical constituents, flavonoids, 
biflavonoids, phloroglucinols and naphthodianthrones, varied among the different accessions 
tested.  Accession Elixir™ displayed the most anti-inflammatory activity at lower 
concentrations; both Soxhlet ethanol and Soxhlet chloroform extracts were active at a 
concentration of 8 µg/mL.  The cytotoxicity of Elixir™ at 8 µg/ml was not statistically 
significant and cannot solely account for the reductions in PGE2.    Finally, flavonoids, 
biflavonoids, phloroglucinols, and pseudohypericin were present within the extracts and 
possessed significant anti-inflammatory activity; however, the concentrations of these 
constituents in the Hp extracts at the highest concentration tested was far less than the 
concentration of pure constituent needed to observe a significant anti-inflammatory effect, 
with the exception of light-activated pseudohypericin at 1 µM in two of the Hp extracts and 
hyperforin at 70 μM in one of the Hp extracts.  Thus, the anti-inflammatory activity of Hp 
extracts cannot be explained by the presence of these constituents alone. Because Hp extracts 
showed light-independent anti-inflammatory activity, it is likely that interactions among 
identified and unidentified compounds account for the diverse activities seen in different 
accessions of Hp.   
Abbreviations Used 
Hp, Hypericum perforatum; PI, Plant Introduction; FNPC, Frontier Natural Products Co-op; 
NCRPIS, North Central Regional Plant Introduction Station; PGE2, Prostaglandin E2; LPS, 
Lipopolysaccharide. 
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Safety 
Organic solvents, such as hexane and chloroform, are toxic chemicals and should be properly 
handled in a fume hood. 
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Table 1.  Anti-inflammatory activity of extracts of FNPC Hp plant material prepared by 
different Soxhlet extraction procedures of dried Hp and tested at concentrations that represent 
the relative amount extracted from 6 g of plant material 
 
 
 
Soxhlet extraction 
[µg/mL] 
testeda 
% reduction in LPS-
induced PGE2
 b 
(95% CI) 
70% ethanol 116 78 (64-87)** 
chloroform 43 79 (64-87)** 
hexane 17 81 (61-91)** 
70% ethanol (-hexane) 65 73 (55-84)** 
70% ethanol(-chloroform) 69 82 (62-91)** 
 
a Concentration tested in µg/mL represents the final concentration of the extract in the media. 
Anti-inflammatory activity [b mean percent reduction in LPS-induced PGE2 levels as 
compared to media + LPS + DMSO control (95% confidence intervals)] was screened using 
the PGE2 assay (n=4 for each) in ambient light.  Addition of LPS to the culture media + 
DMSO control increased the level of PGE2 24-fold over media + DMSO control alone (0.08 
± 0.03 ng/mL for media + DMSO, 1.9 ± 0.3 ng/mL for media + DMSO + LPS).  Extracts in 
the culture media without LPS did not affect the concentration of PGE2 as compared to the 
media + DMSO control. **, p value < 0.0001 as compared to control. 
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Table 2.  Constituents identified and quantified within NCRPIS Hp extracts
Hp extracts were analyzed in the concentrated stock extract.  The data are represented as mean concentration ± standard error.  
“Detected” indicates detection by the MS; however, the amount was too low for quantification with the UV absorption data. “–” 
represents compounds not detected by the MS.  Mean values within each column with different letters were significantly different 
( a<b<c<d<e ) (p<0.05), and values with more than one letter were not significantly different from means sharing either of the 
letters. 
  
  compound concn ( µM ) 
accession extract 
chloro- 
genic acid rutin hyperoside 
iso- 
quercitrin quercitrin quercetin 
amento- 
flavone 
pseudo- 
hypericin 
hyper- 
icin 
hyper- 
forin 
Common EtOH 
25                       
± 0.1 b 
15            
± 0.02 b 
5                 
± 0.02 b 
1 
± 0.01 b 
0.2 
± 0.02 b 
1                 
± 0.02 c 
0.5 
± 0.006 a 
1                        
± 0.05 c 
0.2              
± 0.05 a 
22                 
±  0.05 
 CF - - - - 
0.08                
±  0.02 a 
- detected - - 
8                  
±  0.05 c 
PI 325351 EtOH 13                     
± 0.5 a 
13
± 0.1 b 
3                 
± 0.03 a 
0.5 
± 0.006 a 
0.2 
± 0.02 b 
0.5              
± 0.02 b 
0.2 
± 0.06 a 
0.5                     
±  0.003 b 
0.1             
± 2.5 a 
11                
± 0.02 c 
 CF - - - - - - - - - 
5                  
± 0.04 b 
PI 371528 EtOH 
11                     
± 0.4 a 
8             
± 0.06 a 
4          
±0.02 a, b 
0.9 
±  0.01 b 
0.1 
±  0.02 a, b 
0.2               
± 0.02 a 
0.2 
± 0.06 a 
0.3                     
±  0.006 a 
0.06                
±  3.9 a 
17                
±  0.03 d 
 CF - - - - - - - - - 
7                  
±  0.01 b, c 
'Helos' EtOH 
28                      
±  0.2 b 
13             
± 0.5 b 
7                 
± 0.03 c 
2 
±  0.0006 c 
0.3              
±  0.02 c 
0.8             
± 0.02 c 
2                        
± 0.06 b 
1                      
±  0.01 c 
0.4              
± 0.001 b 
70                
±  0.02 e 
 CF - - - - 
0.07                
± 0.02 a 
- detected - - 
6                  
±  0.04 b 
Elixir™ EtOH 
25                     
± 0.2 b 
11             
± 0.03 b 
7 
± 0.05 c 
0.8 
± 0.01 b 
0.2 
±  0.02 b 
0.5                
± 0.02 b 
0.7                       
± 0.06 a 
0.7                    
±  0.04 b, c 
0.6              
±  0.0004 
c 
11                
± 0.05 c 
 CF - - - - - - - - detected - 
'Topas' EtOH 
10                     
±  0.1 a 
9              
±  0.02 a 
3 
±  0.06 a 
0.4 
± 0.02 a 
0.1 
±  0.02 a, b 
0.2                
± 0.02 a 
detected 
0.2                     
±  0.05 a 
0.04                
±  0.005 a 
8                  
±  0.02 b, c 
 CF - - - - - - - - - 
1                  
±  0.04 a 
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Table 3.  Anti-inflammatory activity and cytotoxicity of NCRPIS accessions of dried Hp 
plant material tested to represent the relative amount extracted from 6 g of plant material 
 
 chloroform ethanol 
Accession 
[µg/mL] 
testeda 
% reduction in 
LPS-induced 
 PGE2
 b  
(95% CI) 
% 
reduction 
in cell 
viabilityc 
(±SE) 
[µg/mL] 
testeda 
% reduction in 
LPS-induced  
PGE2
 b  
(95% CI) 
% reduction  
in cell 
viabilityc 
(±SE) 
Common 14 50 (7-74)* 35 ± 4* 73 91 (87-94)** 38± 5*  
PI 325351 15 66 (36-82)* 41 ± 7** 147 93 (83-93)**  40 ± 6* 
PI 371528 12 80 (62-89)** 49 ± 3** 65 93 (84-93)** 41 ± 7** 
„Helos‟ 16 73 (49-85)* 49 ± 3 ** 181 93 (85-93)** 35 ± 2* 
Elixir™ 8 43 (35-51)* 23 ± 11  122 89 (75-89)** 36 ± 4*  
„Topas‟ 29 85 (73-92)** 32 ± 3* 110 92 (83-93)** 41 ± 4*  
 
a The concentration tested in µg/mL represents the final concentration of the extract in the 
media. Anti-inflammatory activity [b mean % reduction in LPS-induced PGE2 levels as 
compared to media + LPS + DMSO control (95% confidence intervals)] and cytotoxicity (c 
mean % reduction in cell viability as compared to media + DMSO control-treated cells ± 
standard error) of Hp extracts (n=8 for each).  Data represent light-activated and dark 
treatments combined as there were no significant differences between the light-activated and 
dark treatments for any of the extracts.  Addition of LPS to the culture media + DMSO 
control increased the level of PGE2 36-fold over media + DMSO control alone (0.16 ± 0.03 
ng/mL for media + DMSO, 2.9 ± 0.22 ng/mL for media + DMSO + LPS).  Extracts in the 
culture media without LPS did not affect the concentration of PGE2 as compared to the 
media + DMSO control. *, p value < 0.05 as compared to control.  **, p value < 0.0001 as 
compared to control.
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Table 4. Cytotoxicitya of NCRPIS Soxhlet ethanol extracts of accessions Common, PI 
371528, Elixir™, „Helos‟ and „Topas‟ 
 
accession extraction 
[ µg/mL] 
testedc 
% reduction in 
cell viability  
(±SE)  
Common ethanol 30 30 ± 6 
  15 20 ± 9 
  11.5 16 ± 13 
  8 17 ± 10 
PI 371528 ethanol 30 44 ± 8* 
  15 42 ± 6* 
  11.5 34 ± 13* 
  8 22 ± 3 
PI 371528 chloroform 8 22 ± 10 
Elixir™ ethanol 30 37 ± 3* 
  15 24 ± 8 
  11.5 25 ± 9 
  8 23 ± 10 
  5 18 ± 6 
  1 15 ± 11 
Elixir™ chloroform 8 23 ± 11 
„Helos‟ ethanol 8 23 ±10 
„Helos‟ chloroform 8 4 ± 8 
„Topas‟ ethanol 8 27 ± 11 
„Topas‟  chloroform 8 22 ± 10 
 
aCytotoxicity (b mean percent reduction in cell viability as compared to media + DMSO 
control-treated cells ± standard error) of Hp extracts (n=8 for each). c The concentration 
tested in µg/mL represents the final concentration of the extract in the media. Data represents 
light-activated and dark treatments combined as there were no significant differences 
between the light-activated and dark treatments for any of the extracts.  *, p value <0.05 as 
compared to control.
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Table 5.  Anti-inflammatory activitya and cytotoxicity of constituents identified within Hp 
extracts 
class constituent concn (µM) 
% reduction in LPS-
induced PGE2
 b
             
(95% CI) 
% reduction 
in cell 
viabilityc 
(±SE) 
phloroglucinol hyperforin 0.02, 2, 5, 10 0 (0-36) 3 ± 8 
   20 14 (0-43) 22 ± 6 
   40 48 (22-66)* 28 ± 4 
   80 62 (43-75)* 34 ± 11 
flavonoid quercetin 0.2, 2 0 (0-52) 0 ± 4 
   5 66 (21-85)* 1 ± 13 
   10 87 (78-92)** 14 ± 15 
   20 93 (84-97)** 29 ± 12 
   40 96 (90-98)** 33 ± 11 
  quercitrin 0.02, 0.2 0 (0-60) 0 ± 4 
   2 36 (0-72) 3 ± 8 
   5 54 (11-77)* 9 ± 9 
   10 67 (35-83)* 18 ± 20 
   20 71 (22-87)* 33 ± 15 
  isoquercitrin 0.02 0 (0-47) 0 ± 5 
   0.2 9 (0-53) 0 ± 12 
   2 31 (0-64) 13 ± 7 
   5 60 (8-83)* 22 ± 12 
   10 62 (23-85)* 23 ± 13 
   20 66 (43-94)* 40 ± 8* 
  rutin 0.2, 2, 5 0 (0-41) 0 ± 12 
   10 7 (0-57) 17 ± 8 
   20 17 (0-59) 18 ± 7 
   40 24 (10-60) 19 ± 16 
  hyperoside 0.2 8 (0-33) 22 ± 20 
   2 27 (0-63) 29 ± 10 
   5 42 (0-70) 33 ± 17 
   10 51 (5-75)* 37 ± 13 
   20 56 (15-78)* 35 ± 6* 
biflavonoid amentoflavone 1 38 (0-73) 8 ± 4 
   5 53 (0-79) 13 ± 5 
   10 77 (46-90)* 15 ± 14 
other 
chlorogenic 
acid 1, 5, 10, 20, 40 0 (0-54) 0 ± 6 
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Table 5. (continued) 
aAnti-inflammatory activity [b mean percent reduction in LPS-induced PGE2 level as 
compared to media + LPS + DMSO control (95% confidence intervals)] and cytotoxicity 
(cmean percent reduction in cell viability as compared to media + DMSO control-treated cells 
± standard error) (n=8 for anti-inflammatory treatments; n=8 for cytotoxicity treatments) of 
pure compounds identified within Hp extracts on RAW 264.7 macrophage cells.  Data 
represents light-activated and dark treatments combined as there was no difference between 
light versus dark treatments.  Pure compounds in the culture media without LPS did not 
affect the concentration of PGE2 as compared to the media + DMSO control. Addition of 
LPS to the culture media + DMSO control increased the level of PGE2 15 to 35-fold over 
media + DMSO control alone.  *, p value < 0.05 as compared to control.  **, p value <0.0001 
as compared to control.
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Table 6.  Cytotoxicitya of hypericin and pseudohypericin 
 
 % reduction in cell viability
b (±SE)  
treatment 
concn 
(µM) 
dark 
(± SE) 
light-activated 
(± SE) 
light v. dark 
statistical 
significance 
hypericin 0.02 0 ± 6 4 ± 8 - 
  0.5 0 ± 12 8 ± 3 - 
  2 8 ± 13 15 ± 4 # 
  20 23 ± 5 86 ± 3** ## 
pseudohypericin 0.02 0 ± 13 7 ± 9 - 
  0.2 10 ± 8 12 ± 8 - 
  0.5 22 ± 4 17 ± 11 - 
  1 20 ± 5 30  ± 4* # 
  2 26 ± 10 43  ± 7* # 
 
aThe cytotoxicity (bmean percent reduction in cell viability as compared to media + DMSO 
control-treated cells ± standard error) of pseudohypericin and hypericin was tested in RAW 
264.7 macrophage cells in both light-activated and dark treatments (n=4 for each).  *,  p 
value < 0.05 as compared to control.  **,  p value  < 0.0001 as compared to control. #, p 
value < 0.05 when light and dark treatments were compared.  ##,  p value < 0.0001 when 
light and dark treatments were compared. 
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Figure Legends 
Figure 1.  Anti-inflammatory activity of accessions of Soxhlet ethanol and chloroform 
NCRPIS Hp extracts at 8 µg/mL.  Anti-inflammatory activity was screened using the PGE2 
assay (n=8 for each).  Data are presented as mean LPS-induced PGE2 level ± standard error.  
Data represents light-activated and dark treatments combined as there were no significant 
differences between light-activated and dark treatments for each extract.  Addition of LPS to 
the culture media + DMSO control increased the level of PGE2 20 fold over media + DMSO 
control alone (0.1± 0.05 ng/mL for media + DMSO, 2.4 ± 0.3 ng/mL for media + LPS + 
DMSO).  Extracts in the culture media without LPS did not affect the concentration of PGE2 
as compared to the media + DMSO control.  *,  p value <0.05 as compared to media + 
DMSO control.   
 
Figure 2.  Anti-inflammatory dose-response of Soxhlet ethanol extracts of accessions 
Common, PI 371528, and Elixir™.  Anti-inflammatory activity was screened using the PGE2 
assay (n=8 for each).  Data presented as mean LPS-induced PGE2 level ± standard error.  
Controls were the same for each accession tested and are represented as a single bar.  
Elixir™ at 5 and 1 µg/mL did not significantly reduce PGE2 levels as compared to control 
with values of 1.7 ± 0.3 and 2.1 ± 0.5, respectively (data not shown).  Data represents light-
activated and dark treatments combined as there were no significant differences between 
light-activated and dark treatments for each extract.  Addition of LPS to the culture media + 
DMSO control increased the level of PGE2 13 fold over media + DMSO control alone (0.1± 
0.02 ng/mL for media + DMSO, 1.7 ± 0.2 ng/mL for media + LPS + DMSO).  Extracts in the 
culture media without LPS did not affect the concentration of PGE2 as compared to the 
media + DMSO control.    *,  p value <0.05 as compared to media + DMSO control.   
 
Figure 3.  Anti-inflammatory activity of hypericin (A) and pseudohypericin (B).  Anti-
inflammatory activity (mean PGE2 level ± standard error) of hypericin and pseudohypericin 
was screened using the PGE2 assay (n=4). Addition of LPS to the culture media + DMSO 
control increased the level of PGE2 12-fold over media + DMSO control alone (0.18± 0.09 
ng/mL for media + DMSO, 2.1 ± 0.3 ng/mL for media + LPS + DMSO) for pseudohypericin 
and 18 fold (0.17 ± 0.02 ng/mL for media + DMSO, 3.0 ± 0.6 ng/mL for media + DMSO + 
LPS) for hypericin.  *,  p value <0.05 as compared to media + DMSO or media + LPS + 
DMSO control.  #,  p value <0.05 for significant difference between light-activated and dark 
treatments for corresponding dose.   
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Figure 1. 
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CHAPTER 4.  PSEUDOHYPERICIN IS NECESSARY FOR THE LIGHT-
ACTIVATED INHIBITION OF PROSTAGLANDIN E2 PATHWAYS BY A 4 
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FRACTION 
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Abstract 
Hypericum perforatum (Hp) has been used medicinally to treat a variety of conditions 
including mild-to-moderate depression. Recently, several anti-inflammatory activities of Hp 
have been reported.  An ethanol extract of Hp was fractionated with the guidance of an anti-
inflammatory bioassay (lipopolysaccharide (LPS)-induced prostaglandin E2 production 
(PGE2)), and four constituents were identified.  When combined together at concentrations 
detected in the Hp fraction to make a 4 component system, these constituents (0.2 µM 
chlorogenic acid, 0.08 µM amentoflavone, 0.07 µM quercetin, and 0.03 µM 
pseudohypericin) explained the majority of the activity of the fraction when activated by 
light, but only partially explained the activity of this Hp fraction in dark conditions.  One of 
the constituents, light-activated pseudohypericin, was necessary, but not sufficient to explain 
the reduction in LPS-induced PGE2 of the 4 component system.  The Hp fraction and the 4 
component system inhibited lipoxygenase and cytosolic phospholipase A2, two enzymes in 
the PGE2-mediated inflammatory response.   The 4 component system inhibited the 
production of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), and the Hp 
fraction inhibited the anti-inflammatory cytokine interleukin-10 (IL-10).  Thus, the Hp 
106 
 
fraction and selected constituents from this fraction showed evidence of blocking pro-
inflammatory mediators, but not enhancing inflammation-suppressing mediators.   
Keyword Index 
Hypericum perforatum, anti-inflammatory, prostaglandin E2, RAW 264.7, pseudohypericin, 
flavonoids  
Introduction 
The synthesis of prostaglandins plays a critical role in normal physiological processes 
as well as acute and chronic inflammatory states (Dubois et al., 1998; Portanova et al., 1996) 
and the key enzymes involved in prostaglandin biosynthesis are prostaglandin endoperoxide 
synthases, also known as cyclooxygenases.  Cyclooxygenase-1 (COX-1) is responsible for 
housekeeping functions such as maintenance of gastric mucosa (Smith et al., 1996).  
Cyclooxygenase-2 (COX-2) is induced by lipopolysaccharide (LPS) to produce 
prostaglandins, of which prostaglandin E2 (PGE2) is one of the main mediators of 
inflammation (Minghetti et al., 1999; O‟Sullivan et al., 1992).  Cytosolic phospholipase A2 
(cPLA2) releases arachidonic acid, the substrate for COX and lipoxygenase (LOX) enzymes, 
from membrane phospholipids.   
Cytokines mediate the inflammatory response in a complex manner, during its early, 
middle, and late stages.  Tumor necrosis factor-α (TNF-α), an early pro-inflammatory 
cytokine, is involved in the pathogenesis of many inflammatory diseases and can regulate the 
growth, proliferation, and viability of leukocytes (Aggarwal, 2000; Calamia, 2003).  
Interleukin-10 (IL-10), an anti-inflammatory cytokine predominant in the later phases of 
inflammation, is a potent inhibitor of macrophage function, and IL-10 can block the synthesis 
of TNF-α and can inhibit COX-2 induction (Niiro et al., 1995; de Waal-Malefyt et al., 1991).  
107 
 
Preparations that can modulate one or many of the mediators of inflammation may be useful 
for the treatment of inflammatory diseases.   
Hypericum perforatum (Hp) contains unusual compounds such as hypericin, 
pseudohypericin, and hyperforin, as well as compounds present throughout the plant 
kingdom (Bilia et al., 2002).  Raso et al. (2002) found that giving 100 mg/kg of Hp extract by 
gavage to mice two times daily significantly reduced COX-2 protein levels in peritoneal 
macrophages.  Hp extracts and many of the constituents in these extracts (light-activated 
pseudohypericin, flavonoid compounds, hyperforin) reduced LPS-induced PGE2 production 
in RAW 264.7 macrophages (Hammer et al., 2007).    Furthermore, Hp extracts exhibited 
light-independent reductions in LPS-induced PGE2, but pseudohypericin significantly 
decreased LPS-induced PGE2 at 1 and 2 µM only in light-activated conditions and 20 µM 
hypericin increased PGE2 with and without LPS only in light-activated conditions.   This data 
established that although individual constituents like pseudohypericin and hypericin needed 
activation by light to produce an effect on PGE2, confirming previously reported light-
activated bioactivities of hypericin (Bilia et al., 2002; Carpenter et al., 1991), Hp extracts did 
not differ in light-activated and dark conditions, contrary to previously reported bioactivities 
(Bilia et al., 2002; Schmitt et al., 2006a; Schmitt et al., 2006b). Other compounds like the 
flavonoids and caffeic acid derivatives did not differ in light-activated and dark treatments 
(Hammer et al., 2007).  It is vital to understand the effects of isolated active constituents as 
well as combinations of active constituents to relate the bioactivity of the constituents to the 
bioactivity of extracts (Spinella, 2002).   Of 10 potentially bioactive constituents tested, only 
the concentration of pseudohypericin detected in the Hp extracts (0.2 to 1 µM) was above the 
level of pure constituent (1 µM) needed to observe a significant reduction in PGE2 production 
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in RAW 264.7 mouse macrophages (Hammer et al., 2007).  However, pseudohypericin‟s 
presence in the extracts did not appear to account for the activity of the extracts, suggesting 
that the interactions of the constituents may be important (Hammer et al., 2007).  
Bioactivity-guided fractionation was used to identify constituents present in an Hp 
ethanol extract that may be responsible for the anti-inflammatory activity of the extract.  Our 
hypothesis was that flavonoid compounds were contributing to the anti-inflammatory activity 
of the Hp extracts, along with other constituents that may interact with the flavonoids.  To 
test this hypothesis, we used a strategy intended to enrich the fractions in flavonoids, and 
evaluated the fractions for a reduction in LPS-induced PGE2 production.  To compare our 
anti-inflammatory results to a known compound, we used concentrations of quercetin 
exceeding the levels found in Hp extracts and that have previously been shown to inhibit 
inflammatory endpoints of interest as a positive control.   
Results/ Discussion 
The bioactivities of Hp fractions from four rounds of iterative fractionations are 
presented in Table 1.  The original Hp ethanolic extract significantly inhibited LPS-induced 
PGE2 production in RAW 264.7 mouse macrophages at both 10 and 20 µg/ml.  There was a 
significant reduction in cell viability associated with the 20 µg/ml dose of the Hp extract, 
although the reduction in PGE2 (46% of PGE2 control) could not be fully explained by this 
decreased cell viability data (58% of cell viability control).  This original Hp extract was 
fractionated using ethanol, chloroform, or hexane into three fractions (1A: ethanol, 1B: 
hexane, and 1C: chloroform).  The most active fraction from the first round of fractionation 
at 10 µg/ml was fraction 1C when compared with other fractions; 36% of the PGE2 
production compared to control and 74% of cell viability compared to control.  
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Subfractionation of fraction 1C by column chromatography with a solvent series of 
chloroform (CHCl3), acetonitrile (CH3CN), and methanol (MeOH) led to 4 fractions (2A, 2B, 
2C, 2D), of which, 10 µg/ml of fraction 2C most significantly decreased PGE2 as compared 
to control (44% of PGE2 control, 96% of cell viability control) and was the most active of the 
second round fractions at 10 µg/ml.  Fraction 2C was further sub-fractionated using column 
chromatography with 1:1 CH3CN:CHCl3 to 1:1 MeOH: CH3CN (3A, 3B, 3C, 3D, 3E, 3F).  
Of the third round fractions, fraction 3A significantly decreased PGE2 (22% of PGE2 control, 
85% of cell viability control) at a concentration as low as 10 µg/ml.  Fraction 3A was further 
sub-fractionated using column chromatography with a step gradient from 10% 
CH3CN:CHCl3 to 100% MeOH into 7 fractions (4A, 4B, 4C, 4D, 4E, 4F, 4G).  The most 
active fraction from the last round of fractionation was fraction 4F (58% of PGE2 control, 
101% of cell viability control) at 2 µg/ml; however, the reduction in PGE2 was not 
statistically significant.     
The concentrations of 10 constituents were quantified in the original Hp extract and 
the four most active fractions (1C, 2C, 3A, 4F) are shown in Table 2.  The most abundant 
constituents in the original Hp extract were hyperforin (12.5 µM), chlorogenic acid (6.1 µM), 
rutin (2.7 µM), and hyperoside (1.6 µM) (Table 2).  After the first round of fractionation, the 
concentrations of all the constituents in fraction 1C were at or below 1 µM.  It is possible that 
agents that suppressed the inhibition of PGE2 production were removed in the earlier stages 
of fractionation since the concentration of putative active constituents decreased successively 
from the extract to fraction 1C and then to fraction 2C.  In addition, unknowns comprised a 
larger portion of the later subfractions because the concentration of constituents decreased as 
the fractionation progressed, although activity remained about the same and was even greater 
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from fraction 2C to 3A. The ratios of the 4 putative bioactive constituents in the fraction 
seemed to follow the pattern: greatest amount of chlorogenic acid, followed by roughly equal 
amounts of quercetin and amentoflavone, and the least amount of pseudohypericin (Table 2 
figure legend).  Ratio analysis of the levels of the four constituents in the extract and active 
fractions suggested that the greatest activity was obtained when the levels of chlorogenic 
acid, quercetin, and amentoflavone were approximately the same and that these 
concentrations were two to three times higher than pseudohypericin, as seen with fraction 
3A.  Additionally, the lowest activity was seen when only chlorogenic acid and 
pseudohypericin were detected, as seen with fraction 4F.   Although compounds such as 
hypericin may have non-reversibly adsorbed to the silica gel column, results from the PGE2 
assay confirmed that at least one fraction was active from each round as the fractionation 
progressed.  Additionally, flavonoids were compounds of particular interest in this 
fractionation and in previous studies, hypericin was shown to increase PGE2 production in 
LPS-induced RAW 264.7 mouse macrophages (Hammer et al., 2007). 
Since fraction 3A was significantly active in the PGE2 assay and from the later rounds 
of fractionation, experiments were conducted to determine if combining its putative bioactive 
constituents (chlorogenic acid, amentoflavone, quercetin, and pseudohypericin) into a 4 
component system at the amount detected in fraction 3A could explain the reduction in PGE2 
by fraction 3A.  These constituents were also studied together as a 4 component system at ten 
times and one hundred times the amount detected in fraction 3A.  None of the four 
constituents alone reduced PGE2 in light-activated or dark conditions (Table 3).  
Combinations of the four constituents revealed that combinations without pseudohypericin 
were not effective at reducing PGE2.  Two-way and three-way combinations with 
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pseudohypericin seemed to explain some of the light-activated activity of the Hp fraction, 
however; not to as great of an extent as the 4 component system. The combination of all four 
constituents (34% of PGE2 control, 101% of cell viability control) was sufficient to explain 
the anti-inflammatory activity of fraction 3A (12% of PGE2 control, 85% of cell viability 
control) in light-activated conditions. Furthermore, this combination of constituents was even 
more effective at reducing PGE2 in light-activated than dark conditions.  Hyperforin and 
hypericin were not added to the 4 component system because they were only detected in the 
fraction and were not able to be quantified using standard curves of the pure compound.  
However, later experiments determined that adding 0.01 µM or 0.001 µM hyperforin to the 4 
component system did not change the reduction in PGE2 associated with the system (data not 
shown) and hypericin increased the production of PGE2 and had significant cytotoxicity 
associated with low doses in the RAW 264.7 macrophage cells (Hammer et al., 2007).  Thus, 
the 4 component system explained the light-activated activity of the Hp fraction but not the 
dark activity and pseudohypericin was necessary for the light-activated activity. 
Since the four constituents together seemed to best account for the reductions in PGE2 
of the fraction, further explorations compared only the 4 component system with the Hp 
fraction to determine if comparable synergy existed in other endpoints.  To assess the 
reduction in PGE2 associated with fraction 3A and the 4 component system, COX-1 and 
COX-2 protein levels (Figure 1) and enzyme activities (Figure 2) were examined.  LPS-
treated groups are shown in Figure 1 and treatments without LPS are described in the legend 
for COX-1 and COX-2 protein levels.  No change in COX-1 protein level was detected 
among treatments without the addition of LPS and COX-1 protein levels were 
indistinguishable in the LPS and non-LPS treated controls.   No change in COX-1 protein 
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level was detected with the fractions or 4 component system when LPS was added (Figures 
1a and 1b).   COX-2 protein level was increased with the addition of LPS to the culture 
media and there was no change in COX-2 protein level when the treatments were added 
without LPS (Figure 1).  The positive control, 100 µM quercetin, significantly decreased the 
LPS-induced COX-2 protein level, as described in the Figure 1 legend.  COX-2 protein was 
reduced when fraction 3A and 100x the 4 component system were included in light-activated 
conditions (Figured 1a and 1c), but not in dark treatment conditions (Figure 1 legend).  
Fractions 1C and 2C did not reduce LPS-induced COX-2 protein levels in light-activated 
conditions (Figures 1a and 1c), further confirming the PGE2 data showing that fraction 3A 
was the most anti-inflammatory among the active fractions. 
Consistent with the lack of induction of COX-1 protein, no change in COX-1 activity 
was detected with fraction 3A or the 4 component system (Figure 2a).  In contrast, fraction 
3A significantly decreased COX-2 activity as compared to media + LPS + DMSO control in 
both light-activated and dark conditions, whereas the 4 component system significantly 
decreased COX-2 activity only in light-activated conditions (Figure 2b).  The positive 
control, 25 µM quercetin, significantly reduced COX-2 activity (Figure 2b).  COX-2 activity 
was similar among treatments without LPS (Figure 2b).    
To further assess the breadth of anti-inflammatory capabilities of fraction 3A and to 
compare the activity of the Hp fraction with the activity of the 4 component system, we 
examined cPLA2 activity and lipoxygenase inhibition, as well as TNF-α and IL-10 
production in the RAW 264.7 macrophage cells.  The positive control, 25 µM quercetin, 
significantly reduced LPS-induced cPLA2 and lipoxygenase activity (Figures 3a and 3b). 
Fraction 3A decreased LPS-induced cPLA2 activity as compared to the control in both light-
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activated and dark conditions, but the 4 component system significantly decreased LPS-
induced cPLA2 activity only in light-activated conditions (Figure 3a).  The light-activated 4 
component system displayed similar lipoxygenase inhibitory activity as fraction 3A, and 
there was no significant difference between light-activated and dark conditions for either 
treatment (Figure 3b).  Fraction 3A did not reduce the pro-inflammatory cytokine TNF-α at 
either 8 or 24 hours, nor did the 4 component system at 8 hours (Figures 4a and 4b).  The 4 
component system significantly reduced TNF-α at 24 hours in the light (Figure 4b).  The 
levels of the anti-inflammatory cytokine IL-10 were reduced by fraction 3A at both 8 and 24 
hours in light-activated and dark conditions (Figure 5a and 5b).  Only the light-activated 4 
component system did not significantly inhibit the anti-inflammatory cytokine IL-10 at 8 and 
24 hours, although the level of IL-10 was not sustained at the level of the media + LPS + 
DMSO control.  The complexity of this data suggests that perhaps the 4 component system 
and fraction 3A affect prostaglandin biosynthesis pathways in similar ways, but not the 
production of IL-10 and TNF-α, two cytokines important in inflammation. 
 The most intriguing observations from these experiments are that the combination of 
chlorogenic acid, amentoflavone, quercetin, and pseudohypericin, at their respective 
concentrations in fraction 3A, explained the light-activated inhibition of LPS-induced PGE2 
production by fraction 3A and that pseudohypericin was necessary for the activity of 4 
component system.  However, 1 µM light-activated pure pseudohypericin was required to 
significantly reduce PGE2 (Hammer et al., 2007) and pure pseudohypericin at 0.03 µM did 
not reduce PGE2. In previous studies, greater than 5 µM quercetin and 10 µM amentoflavone 
were required to significantly reduce PGE2, and chlorogenic acid up to 40 µM did not reduce 
PGE2 by itself (Hammer et al., 2007).    Since one or more of these constituents were needed 
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in addition to pseudohypericin in combination experiments to effectively reduce PGE2, we 
postulated that the synergistic interactions among these constituents were important in the 
RAW 264.7 macrophages and that pseudohypericin was necessary, but not sufficient for the 
light-activated anti-inflammatory activity.  Notably, the 4 component system did not explain 
the activity of fraction 3A in the dark. 
Synergistic interactions have previously been described for the anti-depressant 
activities of constituents present in Hp extracts, although light conditions were not controlled.  
In the forced swimming test model of anti-depressant activity, a fraction of procyanidins was 
not active alone, but was significantly active when pseudohypericin and hypericin were 
added (Butterweck et al., 1998).  Interestingly, procyanidins increased the water solubility of 
hypericin up to 400 fold (Juergenliemk, 2003a).  When the flavonoid rutin, which was 
inactive in the forced swimming test alone, was combined with inactive Hp extracts, there 
was a strong anti-depressant effect (Noeldner and Schotz, 2002).  The present report is 
perhaps the first identification of interactions of constituents in Hp necessary for an anti-
inflammatory activity of an Hp extract.   
The reduction by Hp of PGE2 and COX-2 protein levels confirms that the eicosanoid 
pathway may be an important pathway for the anti-inflammatory activity of Hp. The Hp 
fraction 3A and the 4 component system inhibited cPLA2 activity, which could limit the 
amount of arachidonic acid available to the COX-2 enzyme.  Both the Hp fraction and 4 
component system also inhibited lipoxygenase activity.  Limiting arachidonic acid would 
also limit the availability of the substrate to the lipoxygenase enzymes.  Future studies could 
explore if products of lipoxygenases such as lipoxins or leukotrienes are also affected by 
these treatments.   
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The light-activated 4 component system reduced the pro-inflammatory cytokine TNF-
α at 24 hours and the 4 component system in the dark treatment condition inhibited the anti-
inflammatory cytokine IL-10 at both 8 and 24 hours.  The Hp fraction inhibited IL-10 
production at both time points examined, but not TNF-α production.    Since TNF-α would be 
produced early in the inflammatory process and perhaps at the same time as PGE2, select 
bioactive constituents may act in the early phases of inflammation.  Therefore, Hp or select 
constituents may decrease pro-inflammatory mediators, but not increase mediators involved 
in suppressing inflammation at later stages.  Also, the light-activated 4 component system did 
not significantly inhibit IL-10, but the IL-10 level was not sustained at the level of the 
control, suggesting that the bioactive constituents may impact pro-inflammatory mediators 
more than anti-inflammatory mediators.  However, the modulation of cytokines and other 
mediators in inflammation is complex.   
Data on the bioavailability of constituents shown to be responsible for a given 
bioactivity is also critical for predicting in vivo effects and the synergistic interactions of the 
constituents might be important for bioavailability.  Murota et al. (2000) showed that 
quercetin glucosides were capable of passing through the Caco-2 epithelial cell monolayer, 
but their efficiency was lower than the aglycone quercetin.  The bioavailability of 
pseudohypericin might be increased by the presence of the flavonoid quercetin and/or 
biflavonoid amentoflavone, since the oral bioavailability of hypericin, which has a structure 
very similar to pseudohypericin, was increased by 34% with the addition of the flavonoid 
hyperoside in rats (Butterweck et al., 2003).  Hyperoside increased the water solubility of 
hypericin by 58% in vitro using the octanol/water partition coefficient (Juergenliemk et al., 
2003).  Further, a metabolite of orally ingested quercetin, miquelianin, was able to cross 
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small intestine and central nervous system barriers in vitro (Juergenliemk et al., 2003b), 
suggesting that quercetin metabolites might not only enhance bioavailability of other 
compounds, but might have considerable bioactivity alone. 
Besides increased bioavailability, other plausible explanations to consider are that 
compounds from the 4 component system may alter the production of reactive oxygen 
species (ROS), reduce the light-activation of pseudohypericin, or affect electron transport, all 
processes which may affect the light-activated cytotoxicity of hypericin or pseudohypericin.  
Data concerning these processes are very limited for pseudohypericin, however, the light-
activation and subsequent effects of hypericin have been well documented.  There is also 
data available concerning other compounds found in Hp. Quercetin has been shown to be a 
strong singlet oxygen quencher and have anti-oxidant properties (Tournaire et al., 1993; 
Korkina and Afanasev, 1997). Quercetin (10 µM) had a significant protective effect against 
cytotoxicity of 10 µM hypericin in HL-60 promyelocytic cells, most likely by reducing ROS 
(Mirossay et al., 2001).  Chlorogenic acid (10 µM) attenuated the cytotoxicity of 20 µM 
hypericin in HaCat human keratinocytes (Schmitt et al., 2007b).  Couladis et al. (2002) tested 
an Hypericum triquetrifolium Turra extract for anti-oxidant activity.  Interestingly, four 
constituents were identified that were present within the extract; quercetin, rutin, chlorogenic 
acid, and amentoflavone, and each constituent possessed anti-oxidant activity.  The 
antioxidant activity of amentoflavone was similar to the α-tocopherol positive control, 
whereas the other constituents possessed less anti-oxidant activity.  It is plausible that 
quercetin, chlorogenic acid, and amentoflavone may play a role in lessening ROS damage 
from pseudohypericin.  Perhaps a combination of enhanced bioavailability and other 
mechanisms like decreased ROS production or reduced light-activation or electron transfer 
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may aid the synergistic interactions of constituents to produce a 4 component system with 
comparable light-activated anti-inflammatory activity to the Hp fraction. 
Conclusions and Concluding Remarks 
An anti-inflammatory bioactivity-guided fractionation of an Hp extract led to the 
identification of four constituents (chlorogenic acid, amentoflavone, quercetin, and 
pseudohypericin) that in concert explained the reduction in LPS-induced PGE2 of an Hp 
subfraction in light-activated conditions.  Pseudohypericin was necessary but not sufficient 
for the reduction in LPS-induced PGE2.  The data presented here and current literature 
supports that the Hp fraction exerts effects on COX-2 and upstream mediators.  These data 
highlight the possibility that unknown and/or unidentified compounds contribute 
significantly to the activity of fraction 3A in the dark.  These experiments verify the need for 
more data on the synergistic interactions of constituents present in botanical extracts and 
their interactive roles in bioactivity. 
Experimental 
General Experimental procedures 
Cell culture 
 RAW 264.7 mouse macrophages were purchased from the American Type Culture 
Collections (ATCC; Manassas, VA) and cultured as previously described (Hammer et al., 
2007).  Treatments for the PGE2 and cell viability assays were performed as previously 
described (Hammer et al., 2007).   The assays were always performed in both light-activated 
and dark conditions, because the naphthodianthrones present within Hp extracts display well-
described light-activated properties.  Details on the light-activation and dark treatments were 
previously published in Schmitt et al. (2006a).  
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PGE2 and Cytotoxicity Assays 
Samples were assayed with a Prostaglandin E2 EIA kit (GE Biosciences, Piscataway, 
NJ) or CellTiter96® Aqueous One Solution cell proliferation assay (Promega Corporation, 
Madison, WI) as previously described (Hammer et al., 2007). 
COX activity assay 
The COX activity assay was used according to manufacturer‟s instructions (Cayman 
Chemicals; Ann Arbor, MI).  The kit measures the peroxidase activity of cyclooxygenase 
colorimetrically by addition of arachidonic acid and monitoring the appearance of oxidized 
N‟, N‟, N‟, N‟-tetramethyl-p-phenylenediamine (TMPD) at 590 nm. Quercetin (25 µM) was 
used as a positive control to demonstrate inhibition of COX-2 activity because Al-Fayez 
showed the 50% inhibitory dose of quercetin was 5 µM (Al-Fayez et al., 2006). 
cPLA2 and Lipoxygenase Inhibitory Assays  
Cells were plated in petri dishes and allowed to attach for 24 hours.  Cells were 
treated with or without fraction or constituent and with or without LPS for 8 hours and 
further processed as described by the manufacturer.  Activity was measured using the cPLA2 
assay kit or the lipoxygenase inhibitor screening assay kit (both Cayman Chemical Company; 
Ann Arbor, MI).  Quercetin (25 µM) was used as a positive control to demonstrate inhibition 
of cPLA2 and lipoxygenase because Lindahl and Tagesson (1993) showed quercetin less than 
100 µM inhibited cPLA2 activity and Deng et al. (2007) showed that quercetin inhibited 50% 
of 5-LO and 15-LO at 5.9 and 0.52 µM, respectively. 
TNF-α and IL-10 Assays 
Cells were treated as previously described (Hammer et al., 2007) and supernatants 
were collected on ice and frozen at -70° C until assayed using a TNF-α and IL-10 mouse 
119 
 
ELISA plate (BD Biosciences Pharmingen, San Diego, CA) with methods described by the 
manufacturer and similar to Senchina et al. (2007).  Quercetin (25 µM) was used as a 
positive control to demonstrate inhibition of TNF-α and increase in IL-10 because Comalada 
et al. (2006) showed that quercetin decreased TNF-α production (50% inhibitory dose was 20 
µM) and 25 quercetin increased IL-10 production in bone marrow-derived macrophages. 
Western Blotting 
After an 8 hour treatment, cells were rinsed twice with cold 1X phosphate buffered 
saline (PBS).  Lysis buffer (50 mM Tris-hydrochloride, 2 mM ethylenediamine tetraacetic 
acid, 2 mM ethylene glycol tetraacetic acid, 150 mM sodium chloride, 2 mM 
phenylmethanesulphonylfluoride, 25 mM leupeptin, 10 mM aprotinin, 10 mM sodium 
fluoride, 10 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 0.5% Triton X-100) 
was added to the dishes on ice and the cells were dissociated from the plate by scraping.  The 
lysate was centrifuged at 4° C, and the supernatant was removed.  The protein concentration 
in each lysate was determined using the bicinchonic acid and copper sulfate protein assay 
(Sigma; St. Louis, MO).  Western blot separation and detection was used as previously 
described (Przybyszewski et al., 2001).  COX-1 and COX-2 rabbit polyclonal antibodies 
(Santa Cruz Biotechnology; Santa Cruz, CA) were diluted 1:1000 in 5% milk Tris buffered 
saline with 0.5% Tween-20.  Semi-quantitative representation was achieved by using the 
ImageQuaNT program.  Three replicates of each treatment were analyzed on separate blots.  
Blots were normalized for consistency by using a repeat control present on each blot.  
Quercetin (100 µM) was used as a positive control to demonstrate reduction in COX-2 
protein level because Raso et al. (2002) showed 50 µM quercetin decreased COX-2 protein 
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in J774A.1 macrophages.  Quercetin was not shown on the blots to facilitate comparisons 
among the graphs, however; the values for quercetin are given in the figure legend. 
Compound Identification and Quantification using LC-MS-UV Analysis 
An Agilent Technologies 100 Ion Trap Liquid Chromatography- Electron Spray 
Ionization-Mass Spectrometer, with a coupled UV absorption detector (LC-MS-UV) was 
used for quantification of compounds, as previously described (Hammer et al., 2007).  
Specifically, ten compounds were identified based on the availability of standards and 
identification in a previous publication (Hammer et al., 2007).  Compounds identified were: 
chlorogenic acid, rutin, hyperoside, isoquercitrin, quercitrin, quercetin, amentoflavone, 
pseudohypericin, hypericin, and hyperforin (Juergenliemk and Nahrstedt, 2001; Williams et 
al., 2006).   Each standard was run on the LC-MS. The peaks from the Hp fractions were 
confirmed by evaluating the retention time and mass spectra of each peak with the retention 
time and mass spectra for the standard of interest.  Stock solutions of each extract or 
subfraction were: 20 mg/ml for extract, 10 mg/ml for fraction 1C, 40 mg/ml for fraction 2C, 
10 mg/ml for fraction 3A, and 0.7 mg/ml for fraction 4F.    
Statistical Analysis 
The COX activity, cPLA2, lipoxygenase, TNF-α, IL-10, and protein data were 
logarithmically transformed to eliminate unequal variances and skewed distribution and an F-
protected two-way ANOVA was used followed by a Tukey-Kramer test for multiple 
comparisons for all samples (Snedecor and Cochran, 1989).  The PGE2, cytotoxicity, light 
versus dark treatments, and LC-MS-UV data were analyzed as previously described 
(Hammer et al., 2007).   P-values ˂ 0.05 were considered statistically significant.   
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Documentation of plants   
One accession of Hp, the commercial variety Common, was provided by the North 
Central Regional Plant Introduction Station (NCRPIS; Ames, IA).  Plant material was 
harvested in July 2004 from plants cultivated on site and processed as previously described 
(Schmitt et al., 2006).  Dried Hp plant material (108 grams; aerial parts) was extracted by 
Soxhlet extraction for 6 hours with 95% ethanol and yielded 38 grams of dry residue. Two 
grams of dry residue was dissolved in 10 mls dimethylsulfoxide (DMSO) (Sigma; St. Louis, 
MO) for the PGE2 screening of the original extract.   
For fractionation, the residue from an ethanol extract of Hp (36 g) was dissolved in 
10% aqueous ethanol (1100 mL) and extracted with hexanes (300 mL).    After the ethanol 
solution was extracted with CHCl3 (500 mL), all three fractions (1A, 1B, 1C) were 
concentrated in vacuo.  Samples of the resulting residues were tested for activity, and only 
the CHCl3 fraction (1C) displayed significant reduction in PGE2. 
The residue from fraction 1C (3.1 g) was dissolved in a minimum volume of CHCl3 
and further purified by normal phase column chromatography on silica gel.  Silica gel was 
chosen as a support for column chromatography to maximize the separation efficiency, even 
though the potential for non-reversible adsorption was recognized.  Elution with a solvent 
series consisting of CHCl3 (375 mL), a 1:1 mixture of CHCl3:CH3CN (475 mL), CH3CN 
(450 mL), and finally a 1:1 mixture of CH3CN:MeOH (500 mL) afforded four fractions  (2A, 
132 mg; 2B, 1.01 mg; 2C, 158 mg; and 2D,  951 mg; respectively) for a total recovery of 
73%.  After concentration in vacuo, bioassays of the four fractions identified fraction 2C as 
the most active and 2C was further purified by column chromatography on silica gel.  A 
solvent step gradient from 1:1 CH3CN:CHCl3 to 1:1 MeOH:CH3CN  afforded 6 fractions, 
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(3A, 1:1 CH3CN:CHCl3, 70 mL, 35.4 mg;  3B,  1:1 CH3CN:CHCl3, 70 mL, 61.5 mg; 3C, 
1.5:1 CH3CN:CHCl3, 135 mL, 16.1 mg; 3D, 3:1 CH3CN:CHCl3, 100 mL, then 100% 
CH3CN, 100 mL, 5.2 mg; 3E, 1:9 MeOH:CH3CN, 100 mL, then 1:5 MeOH:CH3CN, 100 
mL, 21.6 mg;  and finally 3F, 1:1 MeOH:CH3CN, 100 mL, 7.7 mg, respectively, representing 
99% recovery).    The fraction that displayed the most significant activity, fraction 3A, was 
finally purified by column chromatography on silica gel.  This fraction (34 mg) was placed 
on a column of silica gel (0.5 by 14 cm) and eluted with a step gradient from 10% 
CH3CN:CHCl3 to 100% MeOH to give the final 7 fractions 4A-G (4A, 1:9 CH3CN:CHCl3, 
100 mL, 6.2 mg; 4B, 1:9 CH3CN:CHCl3, 75 mL, 8.7 mg; 4C, 1:3 CH3CN:CHCl3, 75 mL, 
12.6 mg; 4D, 1:1 CH3CN:CHCl3, 75 mL, then 3:1 CH3CN:CHCl3, 75 mL, 4.9 mg; 4E, 1:5 
CH3CN:CHCl3, 20 mL, 3.8 mg; 4F, 1:5 MeOH:CH3CN, 50 mL, 1.4 mg; and 4G, 100% 
MeOH, 100 mL, 3.4 mg).   
Endotoxin levels of the extracts were assayed as previously described (Hammer et al., 
2007) to confirm that endotoxin present in the extracts did not affect PGE2 levels.   The range 
of endotoxin levels present was 0.000003 to 0.0001 endotoxin units/milliliter (EU/ml).  
Endotoxin up to 5 EU/ml did not significantly increase the RAW 264.7 cells‟ production of 
PGE2 in the assay (Hammer et al., 2007). 
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Table 1. Reduction in LPS-induced PGE2 and cell viability of Hp fractions and subfractions 
in RAW 264.7 mouse macrophages 
 
Fractionation Treatment [µg/ml] 
PGE2    
Percent of 
Control  
Cell Viability 
Percent of 
Control  
Original Ethanol Extract Extract 20 43 (28-67)* 58 ± 14* 
                     10 46 (21-98)* 97 ± 16 
Fractionation Round 1 Fraction 1A 24 25 (25-53)* 55 ± 18* 
Extract into 1A-1C 
 
10 63 (63-100) 80 ± 17 
 
Fraction 1B 22 16 (7-93)* 74 ± 13 
  
10 76 (21-97) 108 ± 28 
  Fraction 1C 10 36 (23-27)* 74 ± 17 
Fractionation Round 2 Fraction 2A 40 40 (37-100) 46 ± 20* 
Fraction 1C into subfractions 2A-2D 
 
10 59 (80-100) 96 ± 12 
 
Fraction 2B 76 14 (6-29)* 46 ± 20* 
  
40 42 (40-100)* 67 ± 15 
  
10 100 (87-108) 113 ± 21 
 
Fraction 2C 40 8 (4-18)** 40 ± 11* 
  
10 44 (27-71)* 96 ± 2 
 
Fraction 2D 40 17 (7-40)* 36 ± 3* 
    10 49 (20-100) 71 ± 6 
Fractionation Round 3 Fraction 3A 10 22 (10-51)** 85 ± 1 
Subfraction 2C into subfractions 3A-3F Fraction 3B 13 82 (34-100) 99 ± 3 
 
Fraction 3C 5 89 (40-100) 93 ± 5 
 
Fraction 3D 4 80 (33-100) 101± 5 
 
Fraction 3E 4 97 (90-115) 88 ± 2 
  Fraction 3F 4 36 (24-100) 99 ± 6 
Fractionation Round 4 Fraction 4A 2 100 (74-100) 109 ± 8 
Subfraction 3A into subfractions 4A-4F Fraction 4B 4 100 (51-100) 104 ± 11 
 
Fraction 4C 3 100 (64-100) 115 ± 21 
 
Fraction 4D 1 100 (45-100) 93 ± 23 
 
Fraction 4E 0.8 100 (50-100) 107 ± 15 
 
Fraction 4F 0.7 58 (20-100) 101 ± 7 
  Fraction 4G 0.8 63 (43-100) 98 ± 5 
Mean percent of LPS-induced PGE2 level as compared to media + LPS + DMSO control 
(95% confidence intervals) and mean percent of cell viability as compared to media + DMSO 
control-treated cells ± standard error of Hp fractions   n=8 for treatments.  PGE2 and cell 
viability data represents light-activated and dark treatments combined as there was no 
significant difference between the treatments.  The concentration of 10 µg/ml was chosen to 
compare fractions from each round of fractionation; fractions from rounds 3 and 4 were 
assayed at the highest concentration possible based on the amount of DMSO that can be 
added onto the cells.  Fractions in the culture media without LPS did not significantly affect 
the concentration of PGE2 as compared to the media + DMSO control. Addition of LPS to 
the culture media + DMSO control increased the level of PGE2 20-38 fold over media +  
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Table 1. (continued) 
DMSO control alone (0.1 ±0.05 ng/ml for media + DMSO, 2.7 ± 0.5 ng/ml for media + 
DMSO + LPS).  Quercetin (10 µM) positive control significantly inhibited PGE2 production 
(11(8-16) % of PGE2 control)  * p-value ˂  0.05 as compared to control.  ** p-value ˂  0.001 
as compared to control.   
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Table 2.  Constituents identified and quantified (µM) in 10 µg/ml of Hp extracts, fractions 
and subfractions 
 
Constituent  Extract Fraction 1C Fraction 2C Fraction 3Aa Fraction 4F 
Chlorogenic Acid 6.1 ± 0.34d 1.0 ± 0.1c  0.3 ± 0.01c 0.2 ± 0.11b 1.4 ± 0.003b 
Rutin 2.7 ± 1.7c Detected Detected - - 
Hyperoside 1.6 ± 1.5c 0.2 ± 0.002b 0.03 ± 0.01b - - 
Isoquercitrin 0.3 ± 0.1b Detected Detected - - 
Quercitrin 0.03 ± 0.01a 0.1 ± 0.01b 0.02 ± 0.04b - - 
Quercetin 0.2 ± 0.009b 0.1 ± 0.009b 0.02 ± 0.3b 0.07 ± 0.2a - 
Amentoflavone 0.2 ± 0.05b 0.09 ± 0.2ab 0.02 ± 0.4ab 0.08 ± 0.2ab - 
Pseudohypericin 0.2 ± 0.28b 0.04 ± 0.008a 0.001 ± 0.06a 0.03 ± 0.04a 0.01 ± 0.01a 
Hypericin 0.1 ± 0.03a Detected Detected Detected - 
Hyperforin 12.5 ± 0.5e 0.02 ± 0.003a Detected Detected - 
 
Constituents identified and quantified by LC-MS-UV analysis.  Identified compounds from 
fraction 3A provided the basis for the 4 component system. Ten metabolites were quantified 
for the original extract and each of the active fractions and subfractions.  n=3 for each.  The 
data is represented as mean concentration of constituents detected in 10 µg/ml extract or 
fraction ± standard error.  This concentration was chosen to facilitate comparison of levels of 
constituents between extracts and fractions.  “Detected” indicates detection by the MS; 
however the amount was too low for quantification with standard curves generated by the 
UV absorption.  “-“ represents constituents not detected by the MS.  Mean values within each 
column with different superscript letters were significantly different a<b<c<d<e (p<0.05) and 
values with more than one letter were not significantly different than means sharing either of 
the letters.  Ratios of chlorogenic acid: quercetin: amentoflavone: pseudohypericin in the 
extract and fractions are: extract, 30.5:1:1:1; fraction 1C, 25:2.5:2.3:1; fraction 2C, 
300:20:20:1, fraction 3A, 3.3:2.3:2.7:1; fraction 4F, 140:0:0:1.
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Table 3.  Reduction in PGE2 and cell viability by combinations of the putative bioactive 
constituents identified in Fraction 3A 
 
Treatment 
PGE2  
Percent of light-
activated 
control  
PGE2  
Percent of dark 
control     
Cell 
Viability 
Percent of  
Control      
Fraction 3A 12 (7-18)* 32 (3-48)* 85 ± 4 
Q 100 (98-100) 99 (96-105) 86 ± 16 
A 103 (96-106) 104 (99-110) 92 ± 8 
CA 115 (100-127) 122 (104-128) 103 ± 18 
PH 103 (98-109) 100 (98-114) 76 ± 11 
Q + A 90 (78-100) 92 (86-98) 116 ± 22 
CA + Q 100 (71-100) 100 (91-104) 112 ± 16 
CA + A 88 (80-99) 100 (76-108) 99 ± 7 
PH + Q 61 (39-85)* 98 (79-104)$ 87 ± 5 
PH + A 51 (16-84)* 83 (84-100)$ 96 ± 13 
PH + CA 93 (71-100) 102 (96-108) 104 ± 15 
CA + Q + A 95 (86-100) 99 (79-114) 80 ± 24 
Q + A + PH 50 (17-80)* 78 (85-99)$ 113 ± 17 
CA + Q + PH 69 (35-89)* 78 (50-98) 94 ± 13 
CA + A + PH 65 (36-96)* 74 (69-197) 101 ± 8 
CA, A, Q, PH 34 (29-36)* 78 (49-86)$ 101 ± 10 
10x CA, A, Q, PH 31 (24-35)* 68 (38-79)$ 102 ± 7 
100x CA, A, Q, PH 11 (5-17)* 53(31-59)*$ 95 ± 12 
 
Mean percent of LPS-induced PGE2 level as compared to media + LPS + DMSO control 
(95% confidence intervals) and mean percent of cell viability as compared to media + DMSO 
control-treated cells ± standard error of constituents identified in fraction 3A.  n=8 for anti-
inflammatory treatments; n=8 for cytotoxicity treatments. Q=0.07 µM quercetin, A= 0.08 
µM amentoflavone, CA= 0.2 µM chlorogenic acid, PH= 0.03 µM pseudohypericin.  
Cytotoxicity data represents light-activated and dark treatments combined as there was no 
difference between light-activated versus dark treatments.  Constituents in the culture media 
without LPS did not affect the concentration of PGE2 as compared to the media + DMSO 
control. Addition of LPS to the culture media + DMSO control increased the level of PGE2 
10-34 fold over the media + DMSO control alone (0.07 ±0.03 ng/ml for media + DMSO, 1.6 
± 0.4 ng/ml for media + DMSO + LPS).  Quercetin (10 µM) positive control significantly 
inhibited PGE2 production (11 (8-16) % of control).  * p-value ˂ 0.05 as compared to control.  
$ significant difference between light-activated and dark treatments. 
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Figure Legends 
Figure 1.  Representative western blots (Figure 1a) and semi-quantitative representation 
(Figure 1b) of the effect of light-activated Hp fractions (10 µg/ml) and 4 component systems 
on LPS-induced COX-1 and COX-2 protein levels in RAW 264.7 mouse macrophages.  The 
4 component system is composed of: 0.07 µM quercetin, 0.08 µM amentoflavone, 0.2 µM 
chlorogenic acid, 0.03 µM pseudohypericin.  Data is represented as mean percent of media + 
DMSO + LPS control ± standard error.  n=4 for each.  Treatments without LPS did not 
significantly affect either COX-1 or COX-2 protein as compared to media + DMSO control 
(average 98 ± 12% of control).  LPS increased the expression of COX-2 protein (29 ± 16 % 
of control for media + DMSO, 100 ± 17 for media + LPS + DMSO) but not COX-1 protein 
(100 ± 15 % of control for media + DMSO).  Dark treatments did not significantly affect 
LPS-induced COX-1 or COX-2 protein levels (average 99 ±15% of control).  Quercetin (100 
µM) used as a positive control for reduction in LPS-induced COX-2 protein (27 ± 22 % of 
control).  Quercetin did not affect LPS-induced COX-1 protein (103 ± 18% of control).  * p-
value ˂ 0.05 as compared to media + LPS + DMSO control.   
 
Figure 2.  The effect of fraction 3A and 4 component system on enzyme activity of COX-1 
(Figure 2a) and COX-2 (Figure 2b) in RAW 264.7 mouse macrophages.  Q=0.07 µM 
quercetin, A= 0.08 µM amentoflavone, CA= 0.2 µM chlorogenic acid, PH= 0.03 µM 
pseudohypericin.    Data is presented as mean COX-1 or COX-2 activity ± standard error 
(nmol/min/ml).  n=4 for each.  Quercetin (25 µM) was used as positive control.  * p-value ˂ 
0.05 as compared to media + LPS + DMSO control.  $ significant difference between light-
activated and dark treatments. 
 
Figure 3.  Inhibition of LPS-induced cPLA2 (Figure 3a) and lipoxygenase (Figure 3b) 
enzyme activity by fraction 3A and 4 component system in RAW 264.7 mouse macrophages 
(mean cPLA2 activity in µmol/min/ml ± standard error, and mean lipoxygenase activity ± 
standard error as percent of media + LPS + DMSO control).  n=4-6 for each.    Q=0.07 µM 
quercetin, A= 0.08 µM amentoflavone, CA= 0.2 µM chlorogenic acid, PH= 0.03 µM 
pseudohypericin.  Quercetin (25 µM) was used as positive control for cPLA2 and 
lipoxygenase. * p-value ˂ 0.05 as compared to media + LPS + DMSO control.  ** p-value ˂  
0.001 as compared to media + LPS + DMSO control.  $ significant difference between light-
activated and dark treatments.   
 
Figure 4.  The effect of fraction 3A and 4 component system on TNF-α production at 8 hours 
(Figure 4a) and 24 hours (Figure 4b) of treatment in RAW 264.7 mouse macrophages (mean 
level in pg/ml ± standard error).  n=3 for each.  Q=0.07 µM quercetin, A= 0.08 µM 
amentoflavone, CA= 0.2 µM chlorogenic acid, PH= 0.03 µM pseudohypericin.  Quercetin 
(25 µM) used as positive control.   * p-value ˂ 0.05 as compared to media + LPS + DMSO 
control.   
 
Figure 5.  The effect of fraction 3A and 4 component system on IL-10 levels (mean level in 
pg/ml ± standard error) of RAW 264.7 mouse macrophages treated for 8 hours (Figure 5a) 
and 24 (Figure 5b) hours.  n=3 for each.  Q=0.07 µM quercetin, A= 0.08 µM amentoflavone, 
CA= 0.2 µM chlorogenic acid, PH= 0.03 µM pseudohypericin.  Quercetin (25 µM) used as 
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positive control.  * p-value ˂ 0.05 as compared to media + LPS + DMSO control.  ** p-value 
˂  0.001 as compared to media + LPS + DMSO control.  $ significant difference between 
light-activated and dark treatments.  
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CHAPTER 5.  IDENTIFICATION OF PATHWAYS IMPORTANT FOR THE ANTI-
INFLAMMATORY ACTIVITY OF AN HYPERICUM PERFORATUM FRACTION 
AND FOUR PUTATIVE BIOACTIVE CONSTITUENTS IN RAW 264.7 MOUSE 
MACROPHAGES USING MICROARRAY ANALYSIS 
 
Modified from a paper to be submitted to Life Sciences pending cluster analysis addition to 
the manuscript 
 
Kimberly D.P. Hammer, Man-Yu Yum, Dan Nettleton, Philip M. Dixon, Diane F. Birt 
 
Abstract 
Hypericum perforatum extracts have been used to treat diseases including mild-to-
moderate depression and inflammatory conditions. It is particularly important to identify 
which constituents present in the Hp extracts are responsible for its‟ anti-inflammatory 
activity since consumers are taking Hp preparations to treat inflammation.  We used a 
combination of four putative bioactive constituents (amentoflavone, quercetin, chlorogenic 
acid, and pseudohypericin) that interacted synergistically to explain the light-activated anti-
inflammatory activity, as defined by a reduction in LPS-induced PGE2 production, of an Hp 
fraction in RAW 264.7 mouse macrophages and combined the constituents at concentrations 
detected in the fraction.  We used microarray gene expression analysis to identify key gene 
targets of both the combination of constituents, called the 4 component system, and fraction 
3A from an Hp ethanol extract. The Hp 3A fraction with or without LPS stimulation affected 
far more genes than the 4 component system with and without LPS.  Microarray analysis of 
differentially expressed genes identified signaling pathways, namely Janus kinase and signal 
transducer and activator of transcription (JAK-STAT) and eicosanoid pathways that could 
explain the reduction in PGE2 seen with both treatments in the LPS-stimulated macrophages 
and further analysis implicated 12 genes that may be particularly important targets for the 
activity of the 4 component system and the fraction with LPS stimulation. 
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Keywords 
gene expression, Hypericum perforatum, interactions, RAW 264.7 mouse macrophages, 
pseudohypericin, amentoflavone, quercetin, chlorogenic acid 
Introduction 
Inflammation is a complex process that occurs in response to a variety of stimuli.  
Macrophages can release inflammatory mediators such as prostaglandins and cytokines in 
response to signals from stimuli like lipopolysaccharide (LPS).  Genes with prominent roles 
in LPS-induced inflammation include cyclooxygenase-2 (COX-2), nuclear factor-kappa B 
(NF-κB), and tumor necrosis factor-alpha (TNF-α), among others (Bjorkbacka et al., 2004).  
It is well-established that chronic inflammatory states are associated with the pathogenesis of 
diseases including cancer, cardiovascular disease, rheumatoid arthritis, and Alzheimer‟s 
disease (Coussens and Werb, 2002).  Therefore, botanicals that can modulate key gene 
targets may be important for treating inflammatory-associated diseases. 
Hypericum perforatum (Hp) extracts contain a vast array of constituents including 
constituents unique to certain species of the Hypericum genus such as pseudohypericin, 
hypericin, and hyperforin (Bilia et al., 2002).  Hp extracts are complex mixtures and may 
exert a variety of bioactivities including anti-proliferative, anti-inflammatory, anti-
depressant, and anti-viral activities (St. John‟s wort: Hypericum perforatum, 1997).  
Mechanistic studies involving the anti-inflammatory activity of Hp have been limited to date. 
Previous research in our laboratory found that the concentrations of individual 
constituents in Hp extracts could not account for the anti-inflammatory activity of Hp 
extracts, as characterized by a reduction in LPS-induced prostaglandin E2 (PGE2) production 
in RAW 264.7 mouse macrophages (Hammer et al., 2007).  Furthermore, four compounds 
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present in Hp added together as a 4 component system replicated the light-dependent 
reduction of LPS-induced PGE2 production by an Hp sub-fraction when combined at 
concentrations that were detected in the fraction (0.07 µM amentoflavone, 0.08 µM 
quercetin, 0.2 µM chlorogenic acid, and 0.03 µM pseudohypericin) (Hammer et al., 2008).  
Pseudohypericin was necessary but not sufficient for the light-activated reduction in LPS-
induced PGE2 of the 4 component system.  This combination of constituents also exhibited 
similar inhibition of COX-2, lipoxygenase (LO), and phospholipase A2 (cPLA2) enzyme 
activity as the Hp fraction, but displayed different effects on the production of the pro-
inflammatory cytokine TNF-α and the anti-inflammatory cytokine interleukin-10 (IL-10) 
(Hammer et al., 2008).  This suggested that the Hp fraction and 4 component system might 
similarly affect the eicosanoid pathway, but have dissimilar impacts on other mediators such 
as pro- and anti-inflammatory cytokines.   
Few studies have utilized Hp extracts or fractions as treatments in large scale gene 
expression studies.  Krusekopf and Roots (2005) studied the impact of an ethanol Hp extract 
and one selected constituent at the concentration present in the extract, 1 µM hyperforin, on 
gene expression in HepG2 human hepatocellular carcinoma cells after 24 hours of treatment. 
Treatment with the Hp extract or hyperforin led to differential expression of 182 genes and 
201 genes, respectively. Treatment with the Hp extract led to increased expression of drug 
metabolizing enzymes like cytochrome p450 subtypes and decreased expression of genes 
involved in cholesterol biosynthesis, but increased expression of genes involved in 
glycolysis. 
The goal of these experiments was to relate the gene expression profiles of the four 
constituents combined into a 4 component system at concentrations present in the fraction to 
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the gene expression profiles of the Hp fraction to identify key genes that may be important 
for the activity of both treatments and to identify signaling pathways that may be important 
for the reduction in PGE2 production seen with Hp extracts, fractions, and constituents in 
RAW 264.7 macrophage cells.    We postulated that the eicosanoid pathway would be 
inhibited by both the fraction and 4 component system when LPS was added and that 
upstream signaling pathways, like the mitogen-activated protein kinases (MAPK) or janus 
kinase and signal transducer and activator of transcription (JAK-STAT) pathways, might also 
be inhibited. 
Materials and Methods 
Cell culture 
 RAW 264.7 mouse macrophage cells were cultured as previously described (Hammer 
et al., 2007).  Cells were grown in T-75 flasks until approximately 70-80% confluent, and 
plated in 150 x 25 mm tissue culture dishes and allowed to attach overnight.  The cells were 
treated with or without 1 µg/ml lipopolysaccharide (LPS) (Escherichia coli 02B:B6) (Sigma, 
St. Louis, MO) and solvent control [media + tissue culture grade dimethylsulfoxide (DMSO; 
Sigma, St. Louis, MO)], Hp sub-fraction at 10 µg/ml, or 4 component system composed of 
0.07 µM amentoflavone, 0.08 µM quercetin, 0.2 µM chlorogenic acid, and 0.03 µM 
pseudohypericin for 8 hours.  The Hp fraction was a third round sub-fraction derived from a 
bioactivity-guided fractionation of a Soxhlet ethanol Hp extract described previously 
(Hammer et al., 2008).  Each treatment was performed in triplicate.  Due to the light-
activated properties of pseudohypericin, treatments were performed in the dark with 
subsequent exposure for 30 minutes to ambient light (5.2 J/cm2) as previously described 
(Hammer et al., 2007).  Dark treatment conditions were not included in the assessment 
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because the 4 component system did not mimic the reduction of LPS-induced PGE2 of the 
Hp fraction in dark conditions (Hammer et al., 2008).  For the time course studies, treatments 
were performed as described above and samples were collected at 0.5, 1, 2, 4, 8, and 24 
hours after treatment was added. 
RNA isolation 
After the treatment period, the cells were washed twice with phosphate buffered 
saline on ice and the cells were collected in tubes.  RNA was extracted using the Trizol 
method (Invitrogen; Carlsbad, CA) followed by an RNeasy purification kit (Qiagen; 
Valencia, CA).  The RNA quality, integrity, and quantity were tested on an Agilent 
Bioanalyzer 2100 and RNA Nano 6000 Labchip kit (Agilent Technologies; Palo Alto, CA).   
Gene chip array 
Each replicated treatment was analyzed on an individual GeneChip Mouse 
Expression Set 430 representing 45,101 probesets and corresponding to 34,000 well-
substantiated genes (Affymetrix; Santa Clara, CA).  The chips were all from the same lot to 
eliminate variations among different lots.  The labeling of RNA was performed using the 
once-cycle target labeling and control reagent package according to manufacturer‟s 
instructions (Affymetrix; Santa Clara, CA).  A GeneChip fluidics station 450 and a 
GeneChip Scanner 3000 7G were used to process the chips (Affymetrix; Santa Clara, CA).  
All techniques for the gene chip array were performed according to the manufacturer‟s 
instructions by the Gene Chip Facility at Iowa State University.   
Quantitative real time-PCR 
Residual DNA was removed with an RNAse-free DNAse kit from Qiagen (Valencia, 
CA).  DNA-free RNA (200 ng) was reverse-transcribed using the iScript cDNA synthesis kit 
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(BioRad, Hercules, CA).  Genes that were selected for verification by quantitative real-time 
PCR analysis (qRT-PCR) were chosen based on their pattern of differential expression in 
treatments and their relationship to biological pathways of interest.  Nine genes in total and a 
minimum of one differentially expressed gene for each treatment group (4 component 
system, 4 component system +LPS, fraction, fraction +LPS) were verified using qRT-PCR.  
The primers used to confirm differentially expressed genes were designed using Primer3 
(Rosen and Skaletsky, 2000) and synthesized by Integrated DNA Technologies, Inc. 
(Coralville, IA).   Each primer was designed with an annealing temperature of 60° C.  
Sequences for each respective primer are shown in Table 1.  Conditions for the polymerase 
chain reaction (PCR) were: 94° C for 5 minutes, and 40 cycles of 94° C for 15 seconds, 60° 
C for 30 seconds, and 72° C for 30 seconds.   
PCR products were cloned into a pGEMT vector (Promega; Madison, WI).  Sequence 
confirmation of resulting PCR products from each respective plasmid was performed by 
submitting the PCR product to the Iowa State University Sequencing Facility for verification 
of the gene of interest.  Standard curves were generated for each target gene by serial dilution 
and expression level of transcript abundance was calculated by regression against each 
respective standard curve performed in the same plate.  The housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control because it was 
not differentially affected under any of the treatments.  Analysis of the gene expression data 
was performed according to the methods of Pfaffl (2001).  Gene expression profiles for the 
microarray confirmation are presented as expression changes in transcript abundance in 
comparison to respective control, either media +DMSO or media +LPS +DMSO.  Gene 
expression profiles for the time-course are presented as expression changes in transcript 
144 
 
 
abundance in comparison to media control at time 0.  Conditions for qRT-PCR were: 95° C 
for 5 minutes, 40 cycles of 95° C for 30 seconds, 60° C for 30 seconds, 72° C for 30 seconds, 
followed by 95° C for 1 minute, and 55° C for 1 minute.  An iCycler using the SYBR green 
supermix kit was used for the qRT-PCR according to manufacturer‟s instructions (Biorad; 
Hercules, CA). 
Statistical analysis 
The microarray experiment was designed as a randomized complete block design 
with 3 replications as fixed blocks and LPS (with, without) and treatment (DMSO, fraction, 4 
component system) as the factors.  The log signal was analyzed by each of the 45,101 
probesets using Proc Mixed analysis in SAS (SAS Institute; Cary, NC) to identify 
differentially expressed genes.  For each gene, t-tests were used for comparisons and 
corresponding p-values were converted into q-values using the method of Storey and 
Tibshirani (2003) to account for multiple comparisons.  Fraction +LPS and 4 component 
system +LPS were compared to media +LPS +DMSO and fraction and 4 component system 
were compared to media + DMSO.  In general, a p-value < 0.05 was used, with a q-value < 
0.01 for fraction, fraction +LPS and a q-value < 0.4 for 4 component system and 4 
component system +LPS.  Different q-values were used for the fraction and 4 component 
system to facilitate comparison of the intersection of differentially expressed genes, since the 
4 component system affected very few genes under more stringent q-values.  To identify 
LPS-responsive genes, media +DMSO was compared to media +LPS +DMSO.  
Additionally, treatment by LPS interactions were determined for DMSO, fraction, and 4 
component system treatments.  A q-value < 0.05 was used for LPS-responsive genes and 
treatment by LPS interactions.  For the time-course gene expression analysis, time point 0 
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was used to compare against the media +LPS +DMSO control to identify patterns of 
differential expression and a  p-value < 0.05 was used when media +LPS +DMSO was 
compared against fraction +LPS or 4 component system +LPS for each respective time-point. 
Analysis of microarray data 
DAVID 2007 was used to identify pathways with a significant representation of 
differentially expressed genes and prepare gene ontology functional classifications based on 
the differentially expressed gene lists (Dennis et al., 2003). The background used for the 
program was the mouse Affymetrix background.  Cluster and TreeView programs were used 
to cluster the data and develop heat maps (Eisen et al., 1998). 
Results 
 To analyze the effect of treatment with LPS for 8 hours on gene expression in RAW 
264.7 mouse macrophages, media +DMSO treatments were compared against media +LPS 
+DMSO treatments.  Analysis of these two treatments showed that 3,923 genes were 
differentially expressed by the addition of LPS to media +DMSO:  2,501 genes had increased 
expression levels (5.6% of total probe-sets) and 1,422 genes (3.2% of total probe-sets) had 
decreased expression levels (Table 2).  Further analysis of changes in expression levels of 
transcript abundance showed that 530 genes were decreased at least 50% below the 
expression level of the control and 1,228 genes were increased at least 50% above the 
expression level of control by LPS treatment, representing 1.2% and 2.7% of the total probe-
sets, respectively.  Additionally, the expression levels of 104 genes showed a significant 
treatment by LPS interaction when DMSO and fraction were compared, but 0 of the 104 
differentially expressed genes were significant for 4 component system and DMSO.  LPS 
treatment increased genes involved in cell proliferation, cell cycle, cell signaling, and 
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inflammatory response and LPS treatment decreased genes involved in response to stress, 
immune response, cell motility, and cell death (Table 2).    
To identify functional classes of genes that were differentially expressed due to the 
Hp fraction or 4 putative bioactive constituents combined to make a 4 component system, 
treatments (4 component system and fraction, 4 component system +LPS and fraction +LPS) 
were compared against appropriate controls (media +DMSO or media +LPS +DMSO, 
respectively). Table 3 shows the gene ontology classifications of differentially expressed 
genes by treatment group when compared against respective controls.  Biological classes that 
were significantly increased were apoptosis, cell cycle, and immune response and the class 
that was significantly decreased was cell proliferation (Table 3).  The 4 component system 
and 4 component system +LPS compared against media +DMSO and media + LPS +DMSO, 
respectively, affected fewer genes in these classifications and similar patterns of differential 
expression were observed within biological classes for fraction and fraction +LPS when 
compared against media +DMSO and media +LPS +DMSO, respectively. 
 Figure 1 shows the number of genes that were differentially expressed for each 
treatment (4 component system, fraction compared to media +DMSO; 4 component system 
+LPS, fraction +LPS compared to media +LPS +DMSO) and the overlap in differentially 
expressed genes for the treatments (4 component system and fraction, 4 component system 
+LPS and fraction +LPS).  Fraction and fraction +LPS affected the expression levels of many 
genes in comparison to their respective controls, 1,837 and 1,193 genes, respectively.  The 4 
component system without LPS affected the expression levels of only 6 genes significantly 
and the 4 component system +LPS affected the expression levels of 69 genes when compared 
to respective controls.  Forty-four genes were differentially expressed by fraction +LPS and 4 
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component system +LPS when compared to media +LPS +DMSO.  Additionally, 32 of the 
44 genes that were differentially expressed by fraction +LPS and 4 component system +LPS 
were also differentially expressed by the fraction when it was compared against the media 
+DMSO control.  
Table 4 shows the pathways that were significantly enriched by the treatments when 
treatments were compared against respective controls (4 component system, fraction versus 
media +DMSO; 4 component system +LPS, fraction +LPS versus media +LPS +DMSO).  
Pathways significantly affected only by the fraction and fraction +LPS included terpenoid, 
and steroid biosynthesis (p<0.05).  Additionally, pyrimidine biosynthesis was enriched with a 
p-value of <0.07.  Pathways that may be important for the activity of both the 4 component 
system and the fraction in LPS-stimulated conditions were eicosanoid biosynthesis and JAK-
STAT pathway (p<0.05), with an enrichment of the p38 MAPK pathway (p-value<0.07). 
 Table 5 lists the genes that were differentially expressed by both the 4 component 
system and fraction when compared to media +DMSO (Table 5a) or 4 component system + 
LPS and fraction +LPS when compared to media +LPS +DMSO (Table 5b), representing the 
intersection of key genes impacted by fraction and 4 component system under no LPS and 
LPS-stimulated conditions.  Also listed in Table 5b is the effect of the fraction, compared 
against the media +DMSO control, since the fraction affected 32 of the 44 genes that were 
affected by both fraction +LPS and 4 component system +LPS.   
Twelve of the 44 differentially expressed genes by fraction +LPS and 4 component 
system +LPS as compared to media +LPS +DMSO were not affected by the fraction as 
compared to media +DMSO, suggesting that these genes might be of particular interest in 
LPS-stimulated cells treated with the fraction and 4 component system.  Of the 12 genes 
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affected by both fraction +LPS and 4 component system +LPS , only 2 were not affected in 
the same direction by fraction and fraction +LPS when compared to media +DMSO and 
media +LPS +DMSO, respectively.  These were the cysteinyl leukotriene receptor 1 and 
granulocyte-macrophage colony stimulating factor 2.  Interestingly, no uncharacterized 
cDNAs or expressed sequence tags were identified in the intersection of the fraction +LPS or 
4 component system +LPS, suggesting that the pathways of particular importance for the 
activity are well-characterized.  The heat map shows the magnitude of differential expression 
of the 12 genes shared by the 4 component system +LPS and fraction +LPS (Figure 2).  
These differentially expressed genes can be divided into three main groups: eicosanoid 
biosynthesis, JAK-STAT pathway, and type 1 interferon response. 
 Table 6 represents quantitative real-time PCR (qRT-PCR) analysis of expression 
levels of genes differentially expressed under the different treatment conditions in the 
microarray experiment at 8 hours when compared against the appropriate control, either 
media +DMSO or media +LPS +DMSO. The expression levels of 9 genes were confirmed by 
qRT-PCR (COX-2, PLCβ1, SOCS3, JAK2, STAT3, STAT1, PIK3, ITK, COX-1) with 8 of 
the 9 directly confirming results from the microarray.  JAK2 gene expression levels were 
significantly decreased by 4 component system +LPS and fraction +LPS which confirmed 
the results from the microarray, but JAK2 expression levels were also significantly decreased 
by fraction in the qRT-PCR analysis, and this decrease was not observed in the microarray. 
 Since the microarray and qRT-PCR analysis was performed at only the 8 hour 
timepoint, a time-course experiment was performed to determine if the fraction and 4 
component system had similar effects on the expression levels of key genes over the course 
of LPS-induced inflammation in RAW 264.7 mouse macrophages (Figure 3).  Each of the 8 
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genes showed differential induction of gene expression by LPS at 0.5, 1, 2, 4, 8, or 24 hours 
when compared against the media control at time point 0.  Expression levels for fraction 
+LPS and 4 component system +LPS were compared against the expression levels of media 
+LPS +DMSO at each respective time point.  STAT3 gene expression was increased by both 
treatments when compared to media +LPS +DMSO at 0.5 and 8 hours, but STAT1 gene 
expression was decreased by both treatments at 0.5 hours and decreased by the fraction +LPS 
at 8 hours when compared to media +LPS +DMSO at the respective time-points.  JAK1 gene 
expression was increased by both treatments at 0.5 hours when compared to media +LPS 
+DMSO and conversely JAK2 gene expression was decreased by both treatments at 0.5 
hours and 8 hours when compared to media +LPS +DMSO at the respective time-points.  
SOCS3 gene expression was increased by fraction +LPS at 1 hour and by fraction +LPS and 
4 component system +LPS at 8 hours when compared to media +LPS +DMSO at the 
respective time-points.  COX-2 gene expression was decreased by both treatments at 1, 2, 
and 8 hours when compared to media +LPS +DMSO at the respective time-point.  PLCβ1 
gene expression was increased by both at 0.5, 2, 4, and 8 hours and increased by fraction 
+LPS at 1 hour and decreased by 4 component system +LPS at 1 hour when compared to 
media +LPS +DMSO at the respective time-points.    Finally, p38 MAPK gene expression 
was decreased by both treatments at 0.5 hours when compared to media +LPS +DMSO at 0.5 
hours. 
Discussion 
 LPS stimulation in macrophages has previously been shown to affect a large number 
of genes, and in particular, those genes involved in inflammation.  A study by Wells et al. 
(2003) identified LPS-inducible genes in primary bone marrow-derived macrophages treated 
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with LPS.  LPS-inducible genes represented functional classes such as endocytosis and 
phagocytosis, along with 18% of the differentially expressed genes involved in cell signaling, 
10% involved in antigen presentation, and 4% in cytokine or chemokine functions (179).  
Ravasi et al. (2002) examined LPS-inducible subclones of RAW 264.7 mouse macrophages 
cells treated with LPS using cDNA microarrays (180).  They found that not all genes that 
were putative LPS-inducible genes, like TNF, were induced by LPS in all subclones.  
Clustering revealed groups of genes that were likely to be co-expressed in subclones and 
ontology analysis showed that these genes were generally regulatory genes or genes involved 
in immune function.  Shen et al. (2006) found that LPS treatment in peritoneal macrophages 
for 3 hours up-regulated the expression levels of COX-2, SOCS, IκBα, JAK2, STAT1, and 
PLC. LPS treatment for 1 or 4 hours in THP-1 macrophages significantly affected the 
expression levels of 72 out of 465 genes (15.4%) including COX-2, IκBα, and TNF-α (Sharif 
et al., 2007).  Similarly, we found increases in the gene expression levels of COX-2, SOCS3, 
JAK2, STAT1, and PLCβ1 at early time points in RAW 264.7 cells treated with LPS.  
Bjorkbacka et al. (2004) studied LPS-induced gene expression in mouse macrophages treated 
for 2 hours.  They found that 1,055 of 13,000 probe-sets (8.1%) were LPS responsive.  
Finally, Huang et al. (2008) found that in RAW 264.7 mouse macrophages treated with LPS 
for 6 hours, there were 1,270 LPS responsive genes (3.9 %).    Similar to these studies, we 
found 3,923 genes were LPS responsive (8.7 %) in the RAW 264.7 macrophages treated with 
LPS for 8 hours and 1758 (2.9%) genes had expression levels of transcript abundance at least 
50% above or 50% below the control expression levels.   
 One biological activity that is relevant to this study is cytotoxicity.  The cytotoxicity 
of Hp extracts has been well-established in cell culture models (Hostanska et al., 2002; 
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Schmitt et al., 2006).  Although the Hp fraction and 4 component system did not significantly 
decrease cell viability in the RAW 264.7 macrophages at concentrations tested in the 
microarray experiment (Hammer et al., 2008), these treatments still may affect genes 
responsible for these bioactivities.   Fraction and fraction +LPS increased gene ontology 
classes such as cell cycle and apoptosis when compared against respective media +DMSO 
and media +LPS +DMSO controls, and the genes may be related to the previously 
documented toxicity associated with Hp.  Another bioactivity relevant for this study is anti-
viral activity, since one of the pathways that was discovered using the intersections of 
differentially expressed genes from fraction +LPS and 4 component system +LPS was a type 
I interferon response, which is important for recognition of double stranded RNA. 
The eicosanoid pathway is essential for PGE2 production, an endpoint used 
extensively in our laboratory to screen Hp extracts and fractions that may possess anti-
inflammatory activity (Hammer et al., 2007; Hammer et al., 2008).  Differentially expressed 
genes of importance in this pathway were COX-2, PLCβ1, TXAS1, and CYSLTR1.   COX-2 
gene expression was decreased by the 4 component system +LPS and fraction +LPS when 
compared to media +LPS +DMSO in the microarray.   Additionally, COX-2 gene expression 
was decreased by both the fraction +LPS and 4 component system +LPS at 1, 2, and 8 hours 
in the time-course experiment when compared against media +LPS +DMSO at each 
respective time-point.  This confirms previous data from our laboratory that showed similar 
inhibition of PGE2 production and COX-2 enzyme activity with fraction +LPS and 4 
component system +LPS (Hammer et al., 2008) and validates that the primary genes 
involved have been identified.  However, since the PGE2 screen had been set up to identify 
Hp extracts and fractions that inhibited this pathway when LPS was added, the results were 
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not surprising and perhaps there are still other anti-inflammatory targets of interest, such as 
cytokines, that have not been identified.   
Phospholipase C β1 (PLCβ1) gene expression was increased by the 4 component 
system +LPS and fraction +LPS when compared to media +LPS +DMSO in the microarray.  
Ribardo et al. (2001) showed that PGE2 levels in LPS-stimulated macrophages are controlled 
by activation of PLC in addition to PLA2, so it is intriguing that PLCβ1 gene expression was 
increased by both fraction +LPS and 4 component system +LPS, but COX-2 gene expression 
was decreased by both.  We previously showed that the fraction +LPS and 4 component 
system +LPS decreased phospholipase A2 enzyme activity (Hammer et al., 2008) and in the 
microarray, expression levels of phospholipase A2 were decreased by fraction and fraction 
+LPS when compared to respective controls.  Time-course qRT-PCR analysis found that 
PLCβ1 gene expression was increased by both the fraction +LPS and 4 component system 
+LPS at 0.5, 2, 4, and 8 hours.  Additionally, PLCβ1 is the only PLCβ isoform that possesses 
a MAPK phosporylation site (Cocco et al., 1996).  Interactions with MAPK pathways may 
help explain why PLCβ1 is increased at 8 hours or compensatory mechanisms may have 
increased PLCβ1 since PLA2 enzyme activity was reduced.   
The JAK-STAT pathway incorporates an important signaling mechanism for 
cytokines and growth factors in inflammation and can be linked to the eicosanoid pathway 
(Rawlings et al., 2004).  Genes in this pathway that were differentially expressed include 
STAT1, STAT3, JAK2, GM-CSF2, and SOCS3.  STAT1-responsive genes may promote 
inflammation and antagonize proliferation and Stat1 was necessary for the macrophage 
response to LPS (Kamekazi et al., 2004; Ohmori and Hamilton, 2001) whereas STAT3 target 
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genes may promote proliferation and antagonize inflammation (Schindler et al., 2007).   
STAT1 gene expression was significantly decreased by fraction +LPS and fraction when 
compared against media +LPS +DMSO and media +DMSO, respectively in the microarray.  
STAT3 gene expression was increased by the 4 component system +LPS and fraction +LPS 
when compared against media +LPS +DMSO in the microarray suggesting that the 4 
component system may act in the same way as the fraction to antagonize inflammation by 
increasing STAT3 expression.  In the time-course analysis, STAT1 gene expression was 
decreased by fraction +LPS and 4 component system +LPS at 0.5 hours and STAT3 gene 
expression was increased by both at 0.5 hours and 8 hours when compared  to media +LPS 
+DMSO at the respective time-points.  Both STAT1 and STAT3 expression levels were 
increased over time point 0 at early time points (0.5 and 1 hours), confirming data from Liu 
et al. (2005) in which gene expression levels of STAT1 and STAT3 were increased within 2 
hours of LPS treatment in peritoneal macrophages.   
Janus kinases (JAKs) are regulators of the JAK-STAT pathway and JAK2 was 
phosphorylated immediately after LPS stimulation in RAW 264.7 macrophages via TLR4 
(Okugawa et al., 2003).   SOCS proteins can antagonize STAT activation by feedback 
inhibition and ERK, JNK, and p38 pathways, in addition to STAT3, are involved in SOCS3 
gene expression (Qin et al., 2007).  JAK2 gene expression was decreased by the 4 component 
system +LPS and fraction +LPS when compared to media +LPS +DMSO in the microarray.  
SOCS3 gene expression was increased by the 4 component system +LPS and fraction +LPS  
when compared to media +LPS +DMSO in the microarray suggesting that the JAK-STAT 
pathway may be modulated by decreasing JAK2 transcript abundance and increasing 
feedback inhibition through increased SOCS3 gene expression.  In the time course, JAK1 
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expression levels were increased by fraction +LPS and 4 component system +LPS at 0.5 
hours and JAK2 expression levels were decreased by fraction +LPS and 4 component system 
+LPS at 0.5 and 8 hours when compared against media +LPS +DMSO at the respective time-
points.  Similarly, Liu et al. (2005) showed that JAK2 expression was increased at early time 
points (within 2 hours of stimulation) in peritoneal macrophages.  Additionally, LPS-induced 
SOCS3 gene expression was detected at 0.5 hours in macrophages, with maximum 
stimulation between 8 and 16 hours and expression levels returning to unstimulated levels by 
36 hours (Qin et al., 2007).  Time course results showed that SOCS3 gene expression was 
increased at 0.5, 1, 8, and 24 hours when compared to time point 0.  SOCS3 expression levels 
were increased by fraction +LPS and 4 component system +LPS at 8 hours and increased by 
fraction +LPS at 1 and 24 hours when compared against media +LPS +DMSO at the 
respective time-points.   
In the qRT-PCR time course analysis, fraction +LPS and 4 component system +LPS 
affected the expression levels of STAT1, JAK1, JAK2, COX-2, and p38 MAPK in similar 
ways throughout the time of treatment.  However, fraction +LPS appeared to increase the 
expression of some genes more than 4 component system +LPS in the time course ( STAT3 
at 0.5, 1, and 8 hours, PLCβ1 at 0.5, 1, and 8 hours, and SOCS3 at 0.5, 1, 8, and 24 hours).  
Optimal time points to observe a significant increase or decrease in the expression of the 
genes that were used in the time course seemed to be early (0.5 or 1 hours) and middle time 
points (8 hours).  Few effects were seen at the latest time point, 24 hours, with the exception 
of an increase in SOCS3 expression levels by treatment with fraction +LPS. 
There may be considerable cross-talk between the JAK-STAT and eicosanoid 
biosynthesis pathways at multiple levels, most likely mediated by MAPK-regulated pathways 
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(Rawlings et al., 2004).  Figure 4 highlights the potential interactions among pathways, 
namely JAK-STAT and MAPK signaling cascades, which may be important for the activity 
of both the 4 component system and fraction in the LPS-stimulated condition.  Kovarik et al. 
(1998) showed that LPS caused phosphorylation of STAT1 on serine 727 through a pathway 
requiring p38 MAPK, but not a downstream substrate, MAPKAP-2.  JAK2 was not 
necessary for the phosphorylation of STAT1 and activated JAK2 alone was not sufficient for 
phosphorylation.  Additionally, SOCS3 can bind to RasGAP, negative regulator of Ras, and 
reduce its activity, which would reduce the activity of the MAPK pathways.  Thus, SOCS3 
activation may also link JAK-STAT and MAPK pathways directly.   
In addition to Toll-like receptor 4 (TLR4), which recognizes LPS, Toll-like receptor 3 
(TLR3) appears to be not only important for the innate immune recognition of viral infection 
leading to a type 1 interferon response (Kawai and Akira, 2006), but also for eicosanoid 
production.  Knockdown of TLR3 in mice prevented PGE2 secretion and COX-2 expression 
in response to ligand; furthermore, TLR3 signaling involved cPLA2 activation (Pindado et 
al., 2007).  TLR3 gene expression was increased by the 4 component system +LPS and 
fraction +LPS when compared against media +LPS +DMSO suggesting that the treatments 
may increase LPS-induced TLR3 expression but downstream mediators, such as JAK-STAT 
and MAPK pathway genes, may be inhibited. 
Another gene that can be linked to PGE2 production is IκBα.  IκBα binds to NF-κB 
dimers and when IκBα is phosphorylated and subsequently degraded, NF-κB can localize in 
the nucleus and activate the transcription of genes important for inflammation (Karin and 
Greten, 2005).  Particularly, COX-2 expression in LPS-stimulated macrophages is dependent 
on NF-κB (Lo et al., 1993). IκBα gene expression was decreased by the 4 component system 
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+LPS and fraction +LPS when compared to media +LPS +DMSO.   It is also possible that 
cross-talk with MAPK pathways could affect the levels of IκBα expression. 
Since terpenoid, pyrimidine, and steroid biosynthesis pathways were increased by 
fraction and fraction +LPS but not the four component system or 4 component system +LPS 
when compared to respective controls, detrimental effects associated with the up-regulation 
of these pathways may be eliminated by using the 4 component system.  Terpenoid products 
are structurally similar to cholesterol and can serve as lipid attachments for signaling 
molecules suggesting that increased signaling could occur, at least in treatments with the Hp 
fraction (Liao et al., 2002).   
Both the 4 component system and fraction in LPS-stimulated conditions may have 
activities independent of inflammation.  Rab family members facilitate protein transport 
between the endoplasmic reticulum and Golgi complex (Tisdale et al., 1992) and Rab2 gene 
expression was decreased by fraction +LPS and 4 component system +LPS when compared 
against media +LPS +DMSO suggesting that protein transport may be decreased. Plexin B2 
associates with guanine exchange factors of Rho (Perrot et al., 2002) and rho proteins are 
largely involved in phagocytic activity, a role crucial to macrophages.  Plexin B2 gene 
expression was increased by the 4 component system +LPS and fraction +LPS when 
compared against media +LPS +DMSO suggesting that these treatments may increase genes 
important for phagocytosis.  
Conclusions 
It is clear that the expression levels of genes affected by the 4 component system can 
explain some of the fraction‟s activity with respect to PGE2 production.  In particular, it 
appears that COX-2 is a major target for both the fraction and 4 component system in LPS-
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stimulated conditions.  Additionally, upstream pathways leading to COX-2 expression are 
affected by both treatments, suggesting that these four putative bioactive constituents explain 
at least part of the activity.   
 The limitations of this study are that one cell line was used, RAW 264.7 mouse 
macrophages, and one time point was studied in the microarray experiment, 8 hours.  To 
complement this data, a time-course experiment was performed to help determine the role of 
the 4 component system in the activity of the fraction through the period of an inflammatory 
response by LPS.  Another limitation is that an increased q-value was used for the 4 
component system treatments because they did not affect the expression levels of very many 
genes.  Additional studies may look at other inflammatory endpoints or other key activities 
like bioavailability.   
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Table 1.  Primer sequences for differentially expressed genes verified by quantitative real 
time PCR 
Gene Primer 
Oligonucleotide Sequence 
 (5'-3') 
COX-1 S CCTCACCAGTCAATCCCTGT 
 
AS GTAGCCCGTGCGAGTACAAT 
COX-2 S TTGGGGAGACCATGGTAGAG 
 
AS GCTCGGCTTCCAGTATTGAG 
PLCβ1 S ACAACCAAGACATCCCAAGG 
 
AS CTCAAACAGGCCAGAGAAGG 
STAT1 S GTCAGGGCAAGACATCCACT 
 
AS GAAAATGCCATCCTCGTCAT 
STAT3 S TCCTTTCCCACTTGACCTTG 
 
AS CTGTAAGGCAATCCCTCTCG 
JAK1 S CATCCCAGTCTCTGTGCTGA 
 
AS AGCAGCCACACTCAGGTTCT 
JAK2 S GACCTGGCAACAAGGAACAT 
 
AS TCCCCTGGCTCCTTTACTTT 
SOCS3 S ATTCACCCAGGTGGCTACAG 
 
AS GCCAATGTCTTCCCAGTGTT 
PIK3 S ACCAAGAAGTCCTTCGAGCA 
 
AS GATGCCACCAGTGAGGAAAT 
ITK S AAACAAATGACAGCCCCAAG 
 
AS GAGTGACCAAACCTCCTCCA 
β-actin S GGCTATGCTCTCCCTCACG 
 
AS CACGCTCGGTCAGGATCTT 
GAPDH S CAATGTGTCCGTCGTGGAT 
 
AS AGCCCAAGATGCCCTTCAG 
S= sense, A= anti-sense.  Primers were designed for mouse gene sequences using Primer3 
(Rozen and Skaletzky, 2000). 
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Table 2.   Functional classes of genes that were significantly increased or decreased by 
adding LPS to the media +DMSO control 
 
pathway 
% genes 
differentially 
expressed in 
pathway 
enrichment 
score 
genes increased 
 by LPS 
(1,228 genes) 
Cell proliferation 6.9 4.5* 
Cell cycle 4.3 3.4* 
Cell-cell signaling 1.2 2.7* 
Inflammatory response 1.6 2.2* 
genes decreased  
by LPS  
(530 genes) 
Response to stress 1.4 2.2* 
Immune response 6.6 2.2* 
Cell motility 2.2 1.7* 
Cell death 4.0 1.5* 
Media +DMSO was compared against media + LPS +DMSO.  Enrichment score is the 
negative log of the p-value (* score >1.3 indicates p-value <0.05).  Number of genes per 
pathway in accordance with DAVID 2007.  2,501 genes were increased and 1,422 genes 
decreased with a q-value < 0.05.  1,228 genes were increased and 530 genes decreased with 
q-value < 0.05 and expression levels increased or decreased by 50% above or below the 
transcript abundance levels of the respective control. 
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Table 3.   Biological process gene ontology categorization of differentially expressed genes. 
  ontology class 
enrichment 
score 
# genes 
affected by 4 
component 
systema 
# genes 
affected 
by 
fractiona 
# genes 
affected by 4 
component 
system 
+LPSb 
# genes 
affected 
by 
fraction 
+LPSb 
classes 
increased by 
treatments 
apoptosis 3.4* 0 22 6 33 
cell cycle 4.5* 0 30 10 30 
immune response 4.2* 1 28 16 31 
cell differentiation 0.8 0 13 6 21 
immune cell activation 0.4 0 7 1 8 
classes 
decreased by 
treatments 
cell proliferation 1.6* 0 25 10 36 
inflammatory response 0.3 0 2 0 3 
innate immune response 0.1 1 0 0 0 
 
Media +DMSO was compared against media + LPS +DMSO.  Enrichment score is the negative log of the p-value (* score > 1.3 
indicates p-value <0.05).  Number of genes per pathway in accordance with DAVID 2007.  Categories were chosen based on 
significance and functional category of interest to inflammation, immune response, and other categories known to be affected by 
Hp.  aFraction and 4 component system compared to media + DMSO.  bFraction + LPS and 4 component system + LPS compared 
to media + LPS + DMSO.  Fraction and 4 component system were compared to media + DMSO.  Fraction +LPS and 4 component 
system +LPS were compared to media + LPS + DMSO.  q-value < 0.01 for fraction and fraction +LPS, or < 0.4 for 4 component 
system and 4 component system +LPS .  Different q-values were used for the fraction and 4 component system to facilitate 
comparison of the intersection of differentially expressed genes, since the 4 component system affected very few genes under 
more stringent q-values. 
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Table 4.  Analysis of pathways identified as having a significant proportion of differentially expressed genes under 4 component 
system or fraction when compared to media +DMSO and 4 component system +LPS and fraction +LPS when compared to media 
+LPS +DMSO 
  Pathway 
enrichment 
score 
% 
differentially 
expressed 
genes/pathway 
# genes 
affected by 
4 
component 
systema 
# genes 
affected 
by 
fractiona 
# genes 
affected by 4 
component 
system 
+LPSb 
# genes 
affected by 
fraction 
+LPSb 
pathways increased 
and decreased by 
fraction, fraction 
+LPS, and 4 
component system 
+LPS 
Eicosanoid biosynthesis 1.68* 37.5 0 4 6 6 
JAK-STAT 1.59* 16.7 0 8 8 13 
p38 MAPK 1.2 13.3 0 8 4 7 
B cell receptor 0.7 7.9 0 7 5 8 
T cell receptor 0.9 6.5 1 6 3 6 
pathways increased 
by fraction, fraction 
+LPS 
Terpenoid biosynthesis 5.42* 60 0 3 0 3 
Steroid biosynthesis 5.13* 43.8 0 7 0 7 
Pyrimidine biosynthesis 1.2 19 0 7 0 3 
Inositol phosphate metabolism 0.9 13.3 0 5 1 6 
 
Enrichment score is the negative log of the p-value (* score >1.3 indicates p-value <0.05).  Enrichment scores for eicosanoid 
biosynthesis, JAK-STAT, p38 MAPK, B cell receptor, and T cell receptor represent increased and decreased genes combined.  
Gene expression levels for terpenoid biosynthesis, steroid biosynthesis, pyrimidine biosynthesis, and inositol phosphate 
metabolism were only increased except for a single gene that was decreased with fraction.  aFraction and 4 component system 
compared to media + DMSO.  bFraction + LPS and 4 component system + LPS compared to media + LPS + DMSO.  Total 
number of differentially expressed genes were as shown in Figure 1: 4 component system=6, fraction=1,837, 4 component system 
+LPS=69, and fraction +LPS=1,193.  q-value < 0.01 for fraction and fraction +LPS or < 0.4 for 4 component system and 4 
component system +LPS.  Different q-values were used for the fraction and 4 component system to facilitate comparison of the 
intersection of differentially expressed genes, since the 4 component system affected very few genes under more stringent q-
values.  Number of genes per pathway in accordance with DAVID 2007.  
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Table 5.  Intersection of genes differentially expressed by 4 component system and fraction when compared to media +DMSO 
(Table 5a) or intersection of genes differentially expressed by 4 component system + LPS, fraction +LPS, and fraction (Table 5b) 
  
Change in expression level compared to control 
Gene 
Gene  
Symbol 4 Component Systema,c Fractiona,d 
IL-2 inducible T cell kinase  Itk 1.8 1.4 
Calcium/calmodulin dependent protein kinase II inhibitor I  Camk2n1 -0.1 -0.2 
Hephaestin-like I Heph1 -0.1 -0.4 
   
 
 
 
Change in expression level compared to control 
Gene Gene Symbol 
4 Component System 
+LPSb,d 
Fraction 
+LPSb,d Fractiona,d 
Cyclooxygenase-2 Cox-2 -0.6 -0.6 0 
Thromboxane A synthase 1 Txas1 1.2 1.1 0.1 
Cysteinyl leukotriene receptor 1 Cysltr1 -1.2 1.6 0 
Phospholipase C beta, 1 Plcb1 2.6 5.6 0.08 
Suppressor of cytokine signaling 3 Socs3 1.8 2.6 0 
Janus kinase 2 Jak2 -0.6 -0.7 -0.05 
Signal transducer and activator of transcription 3 Stat3 1.5 1.2 0.05 
Colony stimulating factor 2 (macrophage-granulocyte) Csf2 2.0 -0.9 -0.01 
Toll-like receptor 3 Tlr3 2.6 2.4 0.04 
Nuclear factor κ light chain gene enhancer in b-cells inhibitor α Nfkbia -0.7 -0.6 -1.5 
RAB2, member Ras oncogenes Rab2 -0.5 -0.6 0.09 
plexin B2 Plxnb2 1.3 1.9 0.04 
Prostaglandin I receptor Ptgir 2.1 -0.7 -0.8 
Prostaglandin E receptor 2 Ptger2 1.9 -0.8 -0.9 
Microtubule-associated protein 1S e Mtap1s 1.5 1.1 1.2 
Mannosidase, endo-alpha e Manea -0.2 -0.6 -0.5 
Sorting nexin 13 e Snx13 -0.2 -0.7 -0.7 
Shroom family member 3 e Shroom3 -0.2 -0.4 -0.2 
5a 
5b 
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Table 5b (continued) 
    Phosphatidylinositol glycan anchor biosynthesis, class A e Piga 1.4 1.2 1.2 
Heterogeneous nuclear ribonucleoprotein D-like Hnrpdl 1.2 -0.8 -0.8 
Makorin, ring finger protein, 1  Mkrn1 1.2 -0.4 -0.2 
Chromatin licensing and DNA replication factor 1 Cdt1 1.4 -0.3 -0.6 
Cyclin D binding myb-like transcription factor 1 e Dmtf1 1.3 1.4 1.2 
Pantothenate kinase 2 e Pank2 -0.3 -0.3 -0.3 
RIKEN cDNA 2610203E10 e 2610203E10 -0.2 -0.2 -0.2 
Leuckine rich repeat & sterile alpha motif containing 1 Lrsam1 -0.3 -0.6 -0.8 
Deltex 4 homolog Dtx4 -0.6 1.6 -0.7 
Amyloid beta precursor protein (cytoplasmic tail) binding protein 2 Appbp2 10.1 -0.7 -0.8 
Programmed cell death 6 interacting protein e Pcd6ip 1.9 1.4 1.2 
Cystathionase (cystathionine gamma-lyase) Cth 1.5 -0.1 -0.1 
Netrin 1 Ntn1 7.9 -0.7 -0.6 
Spermatid perinuclear RNA binding protein e Strbp  -0.6 -0.8 -0.8 
Braf transforming gene f Braf -0.7 -0.2 1.1 
Tropomodulin 2 e Tmod2 5.1 1.6 1.6 
Zinc finger binding protein 296 Zfp296 -0.6 1.2 1.2 
Reticulon 4 receptor-like 2 f Rtn4rl2 2.7 -0.6 1.3 
Solute carrier family 43, member 2 Slc43a2 3.8 -0.3 1.3 
Brain expressed myelocytomatosis oncogene e Bmyc -0.3 -0.3 -0.1 
Ubiquilin 2 Ubqln2 -0.9 1.3 1.1 
GTPase activating protein (SH3 domain) binding protein 2 G3bp2 -0.9 1.3 1.4 
Transmembrane protein 85 f Tmem85 -0.8 3.1 1.0 
Heat shock protein 90kDa alpha (cytosolic), class A member 1 Hsp90aa1 1.3 -0.6 -0.4 
Activating transcription factor 5 e Atf5 -0.7 -0.6 -0.7 
TNF-α receptor-interacting serine threonine kinase 2 Ripk2 1.4 -0.7 -0.7 
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Table 5b. (continued) 
a Fraction and 4 component system compared to media + DMSO as in Figure 2.  b Fraction + LPS and 4 component system + LPS 
compared to media + LPS + DMSO as in Figure 2.  c q-value <0.4 for 4 component system with and without LPS.   d q-value < 
0.01 for fraction and fraction +LPS.   Different q-values were used for the fraction and 4 component system to facilitate 
comparison of the intersection of differentially expressed genes, since the 4 component system affected very few genes under 
more stringent q-values.  32 of the 44 genes were affected by 4 component system +LPS and fraction +LPS when compared to 
media +LPS +DMSO and fraction when compared to media +DMSO.  e 14 of the 32 genes were affected in the same direction 
(either increased or decreased) by all treatments (fraction, fraction +LPS, 4 component system +LPS compared to respective 
controls).  f Of the 38 genes, 4 were not affected in the same direction by fraction and fraction +LPS when compared to media 
+DMSO and media +LPS +DMSO, respectively.  Bolded rows indicate 12 genes that were significantly affected by fraction +LPS 
and 4 component system +LPS when compared to media +LPS +DMSO but not fraction when compared to media +DMSO.   
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Table 6.  Quantitative real-time PCR analysis of the expression levels of 9 genes at the 8 hour 
timepoint to confirm microarray results 
Gene 
4 Component 
System Fraction 
4 Component 
System  
+LPS 
Fraction        
+LPS 
Confirmed 
Microarray 
Results 
COX-2 0.2 ± 0.2 0.2 ± 0.1 -0.8 ± 0.06* -0.9 ± 0.1* yes 
PLCβ1 0.2 ± 0.2 0.2 ± 0.2 2.7 ± 0.5* 5.5 ± 0.2* yes 
SOCS3 0.05 ± 0.3 0.01 ± 0.3 1.7 ± 0.3* 2.6 ± 0.2* yes 
JAK2 0.01 ± 0.06 -1.6 ± 0.2*  -1.8 ± 0.2* -1.8 ± 0.1* yesa 
STAT3 0.09 ± 0.4 -0.04 ± 0.4  1.5 ± 0.07* 1.8 ± 0.08* yes 
STAT1 0.03 ± 0.2 -0.9 ± 0.2* -0.09 ± 0.3 -0.9 ± 0.06* yes 
PIK3 0.1 ± 0.1 2.0 ± 0.1* 0.08 ± 0.1 2.8 ± 0.05* yes 
ITK 0.4 ± 0.05* 0.4 ± 0.1* -0.07 ± 0.3 0.2 ± 0.2 yes 
COX-1 0.06 ± 0.08 -0.07 ± 0.09 -0.04 ± 0.08 0.05 ± 0.09 yes 
Data represented as change in expression level over respective control, media +DMSO or 
media +LPS +DMSO, for direct comparison with data from the microarray.  * Data with an 
asterisk indicates that the gene expression was significantly different than control in the 
microarray analysis.   aconfirmed microarray data with decreases in Jak2 gene expression by 
fraction +LPS and 4 component system +LPS but qRT-PCR analysis also detected a decrease 
in JAK2 gene expression by the fraction that was not detected in the microarray.  N=3 for 
each.  Expression levels for COX-2, PLCβ1, SOCS3, JAK2, and STAT3 can be found in 
Table 5b.  For comparison, microarray data expression levels of transcript abundance 
compared to respective controls for COX-1, PIK3, and STAT1 are: COX-1: no significant 
increase or decrease for any treatment, PIK3: 1.6 for fraction, 2.7 for fraction +LPS, STAT1: 
-0.6 for fraction, -0.9 for with fraction +LPS. * p-value <0.05 as compared to respective 
control, either media +DMSO or media +LPS +DMSO. 
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Figure Legends 
 
Figure 1.  Diagram highlighting the number and intersection of differentially expressed genes 
for fraction and 4 component system compared against media +DMSO and fraction +LPS 
and 4 component system +LPS compared against media +LPS +DMSO.  q-value < 0.05 for 
fraction and fraction +LPS or q-value < 0.2 for 4 component system and 4 component system 
+LPS, all treatments with p-value < 0.05.  Numbers in common represent genes that were 
differentially expressed under each respective treatment group when compared to respective 
control. Genes from each treatment group (fraction, fraction +LPS, 4 component system, and 
4 component system +LPS) that were associated with pathways are shown in Table 4.   a2 of 
the 6 genes that were differentially expressed by both fraction and 4 component system when 
compared against media +DMSO were also differentially expressed by 4 component system 
+LPS when compared against media +LPS +DMSO.  b32 of the 44 genes that were 
differentially expressed by fraction +LPS and 4 component system +LPS when compared 
against media +LPS +DMSO were also differentially expressed by fraction when compared 
to media +DMSO (shown in Table 5b). 
 
Figure 2.  Heat map showing the magnitude of differential expression of the genes impacted 
by only the 4 component system +LPs and fraction +LPS.  Cluster and TreeView programs 
were used to create the heat map.  Fraction and 4 component system compared to media 
+DMSO.  Fraction + LPS and 4 component system +LPS compared to media +LPS +DMSO.  
Black represents no change, red represents an increase as compared to respective control, and 
green represents a decrease as compared to respective control.  4 Comp Sys= 4 component 
system.  All gene names can be found in Table 5b. 
 
Figure 3.  Time-course gene expression analysis (0.5, 1, 2, 4, 8, and 24 hours after treatment) 
using real-time quantitative PCR of 8 genes involved in inflammation.   Data represented as 
change in expression level of transcript abundance compared to media control at time point 
0.  Media +LPS +DMSO treatment time-points that do not share common italicized letters 
are significantly different with a <b <c (p-value <0.05) as compared to time point 0 media 
control expression level of the respective gene.  * Data with an asterisk indicates that the 
gene expression level for the treatment (fraction +LPS or 4 component system +LPS) was 
significantly different than media +LPS +DMSO control for the respective time-point with a 
p-value <0.05.   N=3 for each. 
 
Figure 4.  Relationship among the 12 genes differentially expressed in 4 component system 
+LPS and fraction +LPS but not fraction treatments.  Colors represent change in expression 
levels of respective genes from the microarray data at the 8 hour timepoint.  Black represents 
no change in expression level, green represents decreased expression level, and red 
represents increased expression level of the respective gene.
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Figure 2. 
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CHAPTER 6: GENERAL CONCLUSIONS 
 
Hypericum perforatum (Hp) is a botanical herb that has been used extensively for 
centuries to treat conditions ranging from snake bites to malaria (1).  Recent research 
supports the use of Hp preparations for the treatment of mild-to-moderate depression (2).  In 
addition to anti-depressant properties, Hp preparations also have anti-viral and cytotoxic 
bioactivities (3-5).  Biological properties can be associated with distinct classes of chemicals 
that are present in Hp, two of which are unique to certain species of the Hypericum genus (1).  
In particular, the napthodianthrones and phloroglucinols play a role in well-established 
bioactivities.  However, it is probable that the interactions of the constituents are also 
important (6). 
The naphthodianthrones hypericin and pseudohypericin play a particularly important 
role in anti-viral and cytotoxic properties of Hp preparations (7, 8).  They are lipophilic 
compounds that are able to damage cellular components upon activation by absorption of 
light energy (9).  Upon light activation, these compounds can use distinct mechanisms to 
produce reactive oxygen species, which can damage cell membranes (9).  Hypericin has been 
well-studied in anti-viral and cytotoxicity models and is currently undergoing testing in phase 
I clinical trials for cancer therapy (10).   
Other compounds have previously been explored for anti-inflammatory activity.  For 
example, the flavonoid quercetin has been widely studied and found to possess significant 
anti-inflammatory activity in in vitro, cell culture, and in vivo models of inflammation (11-
18).  Other constituents that are also present in many species of plants have also been 
relatively well-characterized.  Chlorogenic acid has been shown to possess anti-inflammatory 
activity in some model systems (19).  However, compounds that are unknown and/or 
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unidentified in Hp extracts may also possess activity and it is essential to relate the activity of 
individual constituents to the activity of the Hp extracts and begin to identify constituents 
that may be responsible for the activity.  Additionally, research on other bioactivities of Hp 
suggests that interactions of constituents in Hp extracts may be especially important for 
effective bioactivities of the extract (20, 21). 
The anti-inflammatory activity, as characterized by a reduction in lipopolysaccharide 
(LPS)- induced prostaglandin E2 (PGE2) production in RAW 264.7 mouse macrophages, of 
Hp extracts prepared in solvents ranging in hydrophobicity by either Soxhlet extraction or 
room temperature shaking were assessed under light-activated and dark conditions.  In 
general, Soxhlet extracts tended to display greater reduction in PGE2 than room temperature 
extracts.   Although high performance liquid chromatography (HPLC) analysis suggested that 
the Soxhlet and room temperature extracts had similar chemical profiles, the Soxhlet method 
extracted more plant material than the room temperature shaking method.  The Soxhlet 
hexane extract caused the greatest reduction in LPS-induced PGE2 levels at the lowest 
concentration tested, however hexane extracts were not used in later studies because ethanol 
extracts are used primarily in the supplement industry and chloroform extracts do not contain 
the light-activated hypericin and pseudohypericin constituents. 
Next, different populations of Hp extracted with either Soxhlet ethanol or Soxhlet 
chloroform were assessed in the same model.  Hp extracts prepared by ethanol extraction 
contained many of the constituents known to be present in Hp.  In contrast, the chloroform 
extracts had very few known constituents present in them (amentoflavone, hyperforin, or 
hypericin detected in some extracts).   The light-dependence of the Hp extracts was assessed 
and interestingly, the anti-inflammatory activity of the Hp extracts was light-independent.  
176 
 
 
One population of Hp, accession Elixir™, displayed superior anti-inflammatory activity to 
the other 5 accessions tested.  Interestingly, the ethanol and chloroform extracts of accession 
Elixir™ displayed strikingly similar reductions in PGE2; although the constituents present in 
them differed dramatically (hypericin was the only constituent detected in the chloroform 
ElixirTm extract).  While most of the known constituents were present in the ethanol extract, 
very few constituents were detected in the chloroform extract suggesting that either 
unidentified compounds may be responsible for the activity of both, or different constituents 
were responsible for the activities in each of the respective extracts. 
The results from this study supported that pure constituents also needed to be 
assessed using the PGE2 screen to determine whether an individual constituent could be 
responsible for the activity seen with the Hp extracts.  Constituents from the major classes of 
compounds present in Hp were assessed using the PGE2 screen: flavonoids and biflavonoids 
(quercetin, quercetrin, isoquercetrin, rutin, hyperoside, and amentoflavone), caffeic acid 
derivatives (chlorogenic acid), phloroglucinols (hyperforin), and naphthodianthrones 
(pseudohypericin, hypericin).  Light-activation was not required for the anti-inflammatory 
activity of the flavonoids, bi-flavonoids, and phloroglucinols and no anti-inflammatory 
activity was detected with chlorogenic acid.  Cytotoxicity was not a major concern with these 
constituents at concentrations that were present in the Hp extracts.  The naphthodianthrones 
hypericin and pseudohypericin exhibited light-activated activity.  Pseudohypericin 
significantly decreased LPS-induced PGE2 production and hypericin significantly increased 
LPS-induced PGE2 only in light-activated conditions.  Cytotoxicity was a concern with light-
activated pseudohypericin, even at low concentrations (1 µM) where pseudohypericin also 
significantly reduced PGE2.  However, the reduction in PGE2 could not fully be explained by 
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the reduction in cell viability.  In general, the levels of constituents in the Hp extracts could 
not account for the reductions in PGE2 seen with the extracts.  Therefore, we postulated that 
the interactions of constituents may be important for the anti-inflammatory activity.   
To assess the impact of classes of constituents on anti-inflammatory activity, we 
employed an anti-inflammatory-guided fractionation of a Soxhlet ethanol Hp extract 
(accession Common) through four rounds of iterative fractionation.  An ethanol Hp extract 
was used since known constituents were detected in the Hp ethanol extracts and the 
fractionation was aimed at identifying known constituents that were responsible for the anti-
inflammatory activity.  Bioactivity testing from each round indicated that one fraction from 
each round had significant activity.  
 A third round subfraction, fraction 3A, was the most active fraction from all four 
rounds of fractionation.  The constituents detected in fraction 3A included quercetin, 
amentoflavone, chlorogenic acid, and pseudohypericin.  The levels of these 4 constituents 
(0.08 µM quercetin, 0.07 µM amentoflavone, 0.2 µM chlorogenic acid, and 0.03 µM 
pseudohypericin) alone could not explain the reductions in PGE2 associated with the fraction.  
The structures of these constituents are shown in appendix Figure 1.  These 4 constituents 
were combined at the concentration detected in 10 µg/ml of the Hp sub-fraction and called a 
4 component system.  The 4 component system displayed similar PGE2-reducing activity to 
the Hp fraction in light-activated but not dark conditions.  Combination experiments 
determined that the combination of all 4 constituents displayed the greatest activity in light-
activated conditions, and that 2 and 3 way combinations could not fully explain the activity.  
Further, pseudohypericin appeared to be necessary, but not sufficient for the light-activated 
reduction of PGE2 in combination experiments.  To further compare the anti-inflammatory 
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activity of the fraction and 4 component system, we assessed other inflammatory endpoints.  
The 4 component system and fraction displayed similar reductions in COX-2, LO, and 
cPLA2 enzyme activity, but not in the reduction of the pro-inflammatory cytokine tumor 
necrosis factor-α or the increase in the anti-inflammatory cytokine interleukin-10.  Data from 
the Kohut laboratory using mouse spleen cells found that Hp in general does not increase IL-
10 but may decrease TNF-α.  The cytokine data using the Hp fraction and 4 component 
system suggested that the eicosanoid pathway may be of particular importance for the anti-
inflammatory activity.  Since the signaling pathways leading to activation of the eicosanoid 
pathway can be complex, we employed microarray technology to assess gene targets of both 
the 4 component system and Hp fraction and identify pathways that may be responsible for a 
reduction in eicosanoid pathway intermediates like PGE2 production.  
Interestingly, the fraction affected far more genes than the combined putative 
bioactive constituents, suggesting that while the combined constituents may explain some of 
the activity; they certainly cannot explain all the activity of the fraction.  Therefore, it is 
likely that unknown or unidentified compounds in the fraction may provide some activity as 
well.  Twelve genes were identified that may be particularly important targets for both the 
fraction and identified compounds, and 8 of those genes correlated with two pathways 
important in inflammation, prostaglandin biosynthesis JAK-STAT pathways.  Additionally, 
pathway analysis identified distinct pathways important for the fraction‟s activity but not the 
putative bioactive constituents, namely effects on cell cycle and cell death as well as effects 
on biological classes such as steroid, pyrimidine, and terpenoid biosynthesis.  It is clear that 
the constituents in the 4 component system achieved the reduction in PGE2 by impacting 
known signaling pathways and that is likely how these 4 constituents are acting within the 
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fraction.  However, the fraction possessed considerable activity alone suggesting that 
unknown or unidentified compounds are responsible for additional activities identified 
through gene expression analysis.   
The microarray analysis identified 44 genes that were affected by fraction +LPS and 
4 component system +LPS when compared to media +DMSO +LPS.  However, 32 of these 
genes were also affected by the fraction when compared to media +DMSO.  While these 
genes were not extensively characterized in Chapter 5, they may also provide additional 
insight into the anti-inflammatory activity of Hp (Table 1 of appendix).  Therefore, these 
genes may further explain why PGE2 was reduced and identify other potential gene targets to 
explore in future studies. 
To further assess the impact of constituents that could be responsible for anti-
inflammatory activity seen with chloroform extracts, we employed an anti-inflammatory 
guided fractionation of a Soxhlet chloroform Hp extract.  The original Hp Soxhlet 
chloroform extract (accession PI 371528) was assayed with the PGE2 system and results 
shown in Figure 2 (in the appendix) support that this extract reduced LPS-induced PGE2 at 
all doses tested.  No cytotoxicity was observed with any of the doses used in the PGE2 
screen.  Analysis of the fractions from a preparative column fractionation using the PGE2 
screen found that many of the fractions significantly reduced PGE2 (Figures 3a and 3b in the 
appendix).  The fractions were analyzed using gas chromatography-mass spectrometry.  All 
of the active fractions had many compounds in them and three of the 4 most active fractions 
had dehydroabietic acid.  All four of the most active fractions had hexadecanoic acid in them.  
However, the levels of dehydroabietic acid and hexadecanoic acid did not appear to correlate 
with reductions in PGE2.  Since so many compounds were present in the active fractions and 
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since the most active fractions had the least amount of material to work with, this analysis 
was not extended beyond the initial round of fractionation, although further fractionation was 
used for testing in anti-viral bioassays.  
There are several limitations with using bioactivity-guided fractionation.  For the 
Soxhlet ethanol Hp fractionation, silica gel was chosen as a support for column 
chromatography to maximize the separation efficiency.  One limitation of using silica gel is 
that non-reversible adsorption to the column may occur.  However, we were able to detect 
chlorogenic acid, rutin, hyperoside, isoquercitrin, quercitrin, quercetin, amentoflavone, 
pseudohypericin, hypericin, and hyperforin in the original Soxhlet ethanol extract and also in 
the active fractions from the first two rounds of fractionation, suggesting that adsorption did 
not completely abolish the presence of one particular constituent that we looked for in the 
chemical analysis.  Although compounds such as hypericin may have non-reversibly 
adsorbed to the silica gel column, results from the PGE2 assays with the fraction and 
subfractions showed that at least one fraction reduced LPS-induced PGE2 from each round. 
In previous studies, hypericin was shown to increase LPS-induced PGE2 production in the 
RAW 264.7 mouse macrophages.  Another limitation of using this type of fractionation 
strategy for separating compounds is that compounds that need to be together to produce 
activity may be separated into different fractions and thus, subsequent fractionation may 
cause a loss of activity.  At least one fraction reduced LPS-induced PGE2 from each round 
and the third round subfraction had four compounds that were at least partially responsible 
for the light-activated activity of the fraction, so loss of activity was not a significant factor in 
the analysis, at least in the Soxhlet ethanol fractionation. 
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One of the biggest limitations with using the 4 component system as a model is that 
the ratio of constituents that were shown to have synergy may not be the optimal ratios 
needed to produce effective anti-inflammatory activity by interactions.  Table 2 (in the 
appendix) outlines the estimated ratios of chlorogenic acid: quercetin: amentoflavone: 
pseudohypericin in the Soxhlet ethanol Hp accession extracts, the Soxhlet ethanol Common 
extract used in the fractionation, and the 4 active fractions from the ethanol fractionation.  
Interestingly, the chlorogenic acid levels in all of the extracts and fractions except for 
fraction 3A were much higher than the rest of the constituents.  Chlorogenic acid had no 
effect on LPS-induced PGE2 production up to 40 µM so chlorogenic acid may need to be 
diminished to observe synergy.  However, others have found that chlorogenic acid does have 
anti-inflammatory activity in different inflammatory models (19), so there still may be 
evidence to support the role of chlorogenic acid in anti-inflammatory activity and the lack of 
anti-inflammatory activity seen with chlorogenic acid in the PGE2 screen may not be seen in 
other models.  The accession extracts significantly reduced PGE2 and the ratios of 
constituents in the extracts do not seem to explain the greater anti-inflammatory activity of 
Elixir™ or the effectiveness of all the ethanol accession extracts, although many more 
compounds were present in the Hp accession extracts than were present in the later round 
fractions.  Thus, the optimal ratios of these 4 constituents may not have been found for the 
model system used in these studies, LPS-induced production of inflammatory mediators in 
RAW 264.7 mouse macrophage cells.   
Although the results shown in this dissertation support that Hp extracts have anti-
inflammatory activities and that four putative bioactive constituents can explain the light-
activated anti-inflammatory activity of an Hp subfraction, further work highlighting the role 
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of the individual constituents in bioavailability models is needed.  Based on literature about 
interactions of constituents, it is plausible that one constituent could aid in the absorption of 
another key constituent in the Hp fraction.  One such scenario would be if the flavonoids 
quercetin or amentoflavone could increase the bioavailability of pseudohypericin, since the 
flavonoids are generally absorbed to a greater extent than pseudohypericin.  Alternately, 
flavonoids or chlorogenic acid may reduce phototoxicity produced by light-activated 
pseudohypericin by decreasing ROS or free radical quenching.  However, until combinations 
of the four putative bioactive constituents have been tested in bioavailability models, it is 
unclear if one of the constituents can enhance the bioavailability of another.  In the Hp 
subfraction, there may be other undetected or unidentified compounds that may either 
influence these four putative bioactive constituents or be influenced by them in terms of 
bioavailability of active constituents. 
One limitation of these series of studies is that PGE2 was the primary inflammatory 
endpoint used for screening the Hp extracts, fractions, and constituents.  Alternate results 
may have been seen if using other endpoints alone or in combination with the PGE2 
screening.  In the case of the 4 component system and fraction, LPS-induced TNF-α and IL-
10 production differed for the 4 component system and fraction (Chapter 4).  Follow-up 
analysis included some enzyme activity and gene expression analysis, but this was only for 
the 4 component system and Hp subfraction 3A.  A preliminary examination of the effect of 
some treatments on expression levels of phosphorylated: total p38, COX-1, and COX-2 
protein levels were performed for an Hp extract (appendix Figure 4), three doses of quercetin 
(appendix Figure 5), and three doses of amentoflavone (appendix Figure 6).  Additionally, 
COX-1 and COX-2 protein levels were assessed for two doses of light-activated hypericin 
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and pseudohypericin (appendix Figure 7) and phosphorylated: total p38 levels were assessed 
for fraction 3A and the 4 component system (appendix Figure 8).  COX-1 and COX-2 protein 
levels for fraction and 4 component system were published in Chapter 4.  Phosphorylated: 
total p38 protein levels were assessed because one of the original hypotheses was that Hp 
extracts were reducing inflammation by reducing activity in the p38 pathway, which may 
lead to reduced COX-2 activity.  The Hp Elixir™ extract significantly decreased 
phosphorylated: total p38 protein levels and COX-2 protein levels only at the highest 
concentration tested, which was 120 µg/ml.  Quercetin inhibited phosphorylated: total p38 
protein levels and Cox-2 at 100 µM and amentoflavone inhibited Cox-2 protein levels at 1 
and 10 µM but did not affect phosphorylated: total p38 protein levels.  Hypericin did not 
inhibit COX-1 or COX-2 protein levels at either 0.5 or 2 µM in light-activated conditions but 
pseudohypericin significantly inhibited COX-2 protein levels at 2 µM in light-activated 
conditions.  Finally, fraction 3A and the 4 component system did not affect phosphorylated: 
total p38 protein levels in light-activated conditions.  However, because of inconsistent 
results and the complexity of the Hp mixtures, phosphorylated: total p38 protein levels were 
not pursued further.  Additionally, our focus was to identify active constituents and the PGE2 
screen allowed for an efficient way to screen all the constituents and extracts in the same 
model system.   
This work was performed in one cell line, RAW 264.7 mouse macrophages.  While 
this model was beneficial to begin to identify active constituents, further work may support 
the role of these putative bioactive constituents in the anti-inflammatory activity of animal 
models, and eventually human studies.  Additional data on bioactivities in other cell lines 
may help to more accurately describe the role of constituents in the complex Hp mixtures. 
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 Although Hypericum perforatum has been studied extensively for some bioactivities 
such as in the treatment of mild-to-moderate depression and for anti-viral and cytotoxic 
activities, research exploring its‟ potential for treating inflammatory conditions has been 
relatively limited.  Because this herb exhibits diverse bioactivities, a variety of constituents 
may be responsible for different bioactivities.  In addition, the unique compounds in Hp pose 
a challenge in interpretation of existing data because light conditions need to be adequately 
described.  Since Hp is routinely used by consumers and since the complexity of chemicals is 
so great, there is dire need to identify active constituents and the molecular targets associated 
with them and, in particular, to identify interactions of constituents that may account for 
activities associated with whole extracts.  Additionally, inflammation plays a role in many 
different diseases and botanical herbs that can modulate inflammatory targets may provide 
benefit for consumers taking the supplements.  
 Although the data presented in this dissertation is of substantial benefit to research on 
Hp, this research is only a first step to provide scientific evidence for using Hp to treat 
inflammation.   Additional work highlighting the anti-inflammatory activity of Hp needs to 
be performed in multiple cell lines and eventually in animal models of inflammation.  Work 
with constituents needs to identify active constituents and potential synergies among 
constituents in Hp extracts or fractions and explore the role of synergies in supplements that 
consumers may be taking.  Additionally, bioavailability data is necessary to show that the 
constituents that are active are actually getting to the tissues in the body where they may be 
effective.  An ultimate goal for this type of Hp research is to produce a standardized extract 
that has documented anti-inflammatory activity with little toxicity or stimulation of 
cytochrome p450 enzymes.  This will maximize the effectiveness of the extract or fraction 
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and eliminate detrimental side effects that may cause consumers to report adverse reactions.    
Consumers that are prescribed other drugs often are discouraged from taking Hp preparations 
due to the well-known interactions of Hp with cytochrome p450 enzymes.  If an Hp 
preparation, such as a fraction with defined, active constituents could still have potent anti-
inflammatory activity with no stimulation of the cytochrome p450 enzymes, perhaps this 
type of Hp preparation could be used by consumers who are taking other drugs.   
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APPENDIX 
 
Table 1.  Genes that were significantly affected by fraction, fraction +LPS, and 4 component 
system +LPS in the microarray analysis. 
Increased by fraction, fraction +LPS, and 4 component system +LPS 
Microtubule-associated protein 1S 
Cyclin D binding myb-like transcription factor 1 
Tropomodulin 2 
Programmed cell death 6 interacting protein 
Phosphatidylinositol glycan anchor biosynthesis, class A 
Decreased by fraction, fraction +LPS, and 4 component system +LPS 
Shroom family member 3 
Sorting nexin 13 
Activating transcription factor 5 
Pantothenate kinase 1 
Mannosidase, endo-alpha 
RIKEN cDNA 2610203E10 
Spermatid perinuclear RNA binding protein 
Leucine rich repeat and sterile alpha motif containing 1 
Brain expressed myelocytomatosis oncogene 
Increased by 4 component system +LPS,  decreased by fraction and fraction +LPS 
Prostaglandin E receptor 2 
Heterogeneous nuclear ribonucleoprotein D-like 
Makorin, ring finger protein 1 
Cystathionase 
Heat shock protein 30kDa alpha, class A member 1 
Netrin 1 
Prostaglandin I receptor 
TNF-α receptor-interacting serine threonine kinase 2 
Amyloid beta precursor protein binding protein 2 
Reticulon 4 receptor-like 2 
Chromatin licensing and DNA replication factor 1 
Decreased by 4 component system +LPS and fraction, increased by fraction +LPS 
Deltex 4 homolog 
 
Fraction compared to media + DMSO.  Fraction + LPS and 4 component system + LPS 
compared to media + LPS + DMSO.  q-value < 0.01 for fraction and fraction +LPS, and q-
value <0.4 for  4 component system +LPS.   
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Table 1. (continued) 
Decreased by 4 component system +LPS, increased by fraction and fraction +LPS 
Zinc finger binding protein 296 
Ubiquilin 2 
GTPase activating protein binding protein 2 
Transmembrane protein 85 
Decreased by 4 component system +LPS and fraction +LPS, increased by fraction 
Braf transforming gene 
Increased by 4 component system +LPS and fraction, decreased by fraction +LPS 
Solute carrier family 43, member 2 
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Table 2.  Ratios of chlorogenic acid: quercetin: amentoflavone: pseudohypericin present in 
Soxhlet ethanol Hp accession extracts, Soxhlet ethanol Hp Common extract used for 
fractionation, and the 4 active fractions from the bioactivity-guided ethanol fractionation. 
 
 
Chlorogenic Acid Quercetin Amentoflavone Pseudohypericin 
Common 25.0 1.0 0.5 1.0 
PI 325351 26.0 1.0 0.4 1.0 
PI 371528 36.7 0.7 0.7 1.0 
'Helos' 28.0 0.8 2.0 1.0 
Elixir™ 35.7 0.7 1.0 1.0 
'Topas' 50.0 1.0 0.1 1.0 
Commona 30.5 1.0 1.0 1.0 
Fraction 1C 25.0 2.5 2.3 1.0 
Fraction 2C 300.0 20.0 20.0 1.0 
Fraction 3A 3.3 2.3 2.7 1.0 
Fraction 4F 140.0 0.0 0.0 1.0 
 
These ratios represent an estimate of the levels of chlorogenic acid, quercetin, amentoflavone 
and pseudohypericin in the extracts and fractions as the chemical analysis for the accession 
Hp extracts and the fractions were performed using two different methods by Matthew 
Hillwig in Dr. Eve Wurtele‟s laboratory (HPLC and liquid chromatography-mass 
spectrometry).  Information about Soxhlet ethanol Hp extracts of accessions Common, PI 
325351, PI 371528, „Helos‟, Elixir™, and „Topas‟ can be found in Chapter 3.  Ratios for 
these extracts are based on the highest amoung of plant material extracted and dissolved in a 
set amount of DMSO.  a Common Soxhlet ethanol extract used for fractionation.  Information 
about the Soxhlet ethanol Hp extract (accession Common) used for fractionation can be 
found in Chapter 3, along with information about fractions 1C, 2C, 3A, and 4F.  Ratios for 
these extracts are based on a common concentration (10 µg/ml).  
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Figure 1.  Structures of the four putative bioactive constituents that make up the 4 component 
system 
 
compound 1              compound 2              compound 3                compound 4
pseudohypericin quercetin amentoflavone chlorogenic acid
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Figure 2.  PGE2 levels showing the effect of the Hp Soxhlet chloroform extract (accession 
Common) that was used for preparative column fractionation in RAW 264.7 mouse 
macrophages 
 
Mean PGE2 level as compared to either media +DMSO or media + LPS + DMSO control (± 
standard error) of the extract.  n=4 for all treatments. Quercetin was used as the positive 
control.   * p-value ˂ 0.05 as compared to media +LPS +DMSO.  No cytotoxicity was 
observed at the doses tested. 
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Figure 3.  PGE2 levels showing the effect of the fractions tested at 5 µg/ml from the 
preparative fractionation of an Hp Soxhlet chloroform extract in RAW 264.7 mouse 
macrophages 
 
 
 
Mean PGE2 levels as compared to media + LPS + DMSO control (± standard error) of 
fractions.  n=4 for all treatments. Quercetin was used as the positive control.  * p-value ˂ 
0.05 as compared to media +LPS +DMSO.  No cytotoxicity was observed at the 
concentrations tested. 
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Figure 4.  Semi-quantitative representation of the effect of light-activated Hp Elixir™ 
Soxhlet ethanol extract on phosphorylated: total p38, COX-1, and COX-2 protein levels in 
RAW 264.7 mouse macrophages 
 
Data is represented as mean percent of media + DMSO + LPS control ± standard error.  n=4 
for each.  Treatments without LPS did not significantly affect p38, COX-1, or COX-2 protein 
as compared to media + DMSO control (average 98 ± 12% of control).  LPS increased the 
expression of COX-2 protein (29 ± 16 % of control for media + DMSO, 100 ± 17 for media 
+ LPS + DMSO) but not COX-1 protein (100 ± 15 % of control for media + DMSO).  Dark 
treatments did not significantly affect LPS-induced COX-1 or COX-2 protein levels (average 
99 ±15% of control).  Quercetin (100 µM) used as a positive control for reduction in LPS-
induced COX-2 protein (27 ± 22 % of control).  Quercetin did not affect LPS-induced COX-
1 protein (103 ± 18% of control).  * p-value ˂ 0.05 as compared to media + LPS + DMSO 
control.   
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Figure 5.  Semi-quantitative representation of the effect of quercetin on phosphorylated: total 
p38, COX-1, and COX-2 protein levels in RAW 264.7 mouse macrophages 
 
 
Data is represented as mean percent of media + DMSO + LPS control ± standard error.  n=4 
for each.  Treatments without LPS did not significantly affect phosphorylated: total p38, 
COX-1, or COX-2 protein as compared to media + DMSO control (average 98 ± 12% of 
control).  LPS increased the expression of COX-2 protein (29 ± 16 % of control for media + 
DMSO, 100 ± 17 for media + LPS + DMSO) but not COX-1 protein (100 ± 15 % of control 
for media + DMSO).  Dark treatments did not significantly affect LPS-induced COX-1 or 
COX-2 protein levels (average 95 ±15% of control).  * p-value ˂ 0.05 as compared to media 
+ LPS + DMSO control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
media +DMSO 
+LPS
1 µM       
Quercetin
10 µM    
Quercetin
100 µM 
Quercetin
P
e
rc
e
n
t 
o
f 
C
o
n
tr
o
l
Phospho: Total p38 Cox-1 Cox-2
*
*
196 
 
 
Figure 6.  Semi-quantitative representation of the effect of amentoflavone on phosphorylated: 
total p38, COX-1, and COX-2 protein levels in RAW 264.7 mouse macrophages 
 
 
Data is represented as mean percent of media + DMSO + LPS control ± standard error.  n=2 
for each.  Treatments without LPS did not significantly affect phosphorylated: total p38, 
COX-1, or COX-2 protein as compared to media + DMSO control (average 98 ± 12% of 
control).  LPS increased the expression of COX-2 protein (29 ± 16 % of control for media + 
DMSO, 100 ± 17 for media + LPS + DMSO) but not COX-1 protein (100 ± 15 % of control 
for media + DMSO).  Dark treatments did not significantly affect LPS-induced COX-1 or 
COX-2 protein levels (average 102 ±9% of control).  Quercetin (100 µM) used as a positive 
control for reduction in LPS-induced COX-2 protein (27 ± 22 % of control).  Quercetin did 
not affect LPS-induced COX-1 protein (103 ± 18% of control).  * p-value ˂ 0.05 as 
compared to media + LPS + DMSO control.   
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Figure 7.  Semi-quantitative representation of the effect of light-activated hypericin and 
pseudohypericin on COX-1 and COX-2 protein levels in RAW 264.7 mouse macrophages 
 
 
Data is represented as mean percent of media + DMSO + LPS control ± standard error.  n=3 
for each.  Treatments without LPS did not significantly affect COX-1 or COX-2 protein as 
compared to media + DMSO control (average 98 ± 12% of control).  LPS increased the 
expression of COX-2 protein (29 ± 16 % of control for media + DMSO, 100 ± 17 for media 
+ LPS + DMSO) but not COX-1 protein (100 ± 15 % of control for media + DMSO).  Dark 
treatments did not significantly affect LPS-induced COX-1 or COX-2 protein levels (average 
96 ±11% of control).  Quercetin (100 µM) used as a positive control for reduction in LPS-
induced COX-2 protein (27 ± 22 % of control).  Quercetin did not affect LPS-induced COX-
1 protein (103 ± 18% of control).  * p-value ˂ 0.05 as compared to media + LPS + DMSO 
control.   
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Figure 8.  Semi-quantitative representation of the effect of light-activated 4 component 
system and 10x and 100x 4 component system on phosphorylated: total p38 protein levels in 
RAW 264.7 mouse macrophages 
 
 
Data is represented as mean percent of media + DMSO + LPS control ± standard error.  n=2 
for each.  Treatments without LPS did not significantly affect phospho: total p38 as 
compared to media + DMSO control (average 98 ± 12% of control).  Dark treatments did not 
significantly affect LPS-induced p38 protein levels (average 97 ±18% of control).  Quercetin 
(100 µM) was used as a positive control for reduction in LPS-induced levels of 
phosphorylated:total p38 protein (see appendix Figure 5). 
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